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Jingxian Chen:  The Application of Nonlinear Mixed-Effects Modeling to the Optimization 
of HIV Treatment in Special Populations 
(Under the direction of Julie B. Dumond) 
 
The HIV-infected population is heterogeneous in terms of drug disposition and drug 
response to HIV treatment. Identifying subgroups of patients at risk of suboptimal therapeutic 
effects or toxicity is critical to maintain drug efficacy and safety. The objectives of this dissertation 
were to apply nonlinear mixed-effects modeling (NLME) methods to investigate the potential 
discrepancies in the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of two special 
populations, pregnant women and older patients, compared to the general HIV-infected 
population, and inform appropriate HIV treatment for these patients. 
In the investigation of lopinavir/ritonavir (LPV/RTV) unbound drug PK in twelve HIV-
infected pregnant women, clearances of LPV and RTV during pregnancy demonstrated an 
exponential increase between 20-32 weeks of gestation. The unbound fractions of LPV/RTV were 
not significantly different between pregnancy and postpartum. Despite the increased LPV/RTV 
elimination in pregnancy, >90% effective LPV inhibitory quotient (IQ) values were predicted under 
the standard dosing (400/100 mg B.I.D.) with ≤4-fold increase in viral half inhibitory concentration 
(IC50), supporting the use of standard dosing in pregnant women with low-resistance virus. As 
viral susceptibility decreases (>10-fold increase in viral IC50), higher doses or alternative regimens 
should be considered.  
The effects of aging on ART PK were studied in the context of different aging surrogates 
and pharmacogenetics in ninety-one HIV-infected patients aged 18-72 years receiving either 
efavirenz (EFV)- or atazanavir/ritonavir (ATV/RTV)- containing regimens. A cellular aging 
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biomarker, the expression of p16INK4a, was shown to be negatively associated with the unbound 
drug clearance of EFV, implying that cellular aging might predict slower EFV metabolism. No 
alterations in drug clearance or unbound fraction with aging were observed for ATV or RTV. 
Regarding the recovery of CD4+ T-cells, analyses of long-term data (up to 15 years on 
treatment) of 102 patients and short-term data (within 2 years) of 20 patients indicated that 
advanced age was significantly associated with a greater apparent elimination rate constant of 
CD4+ naïve T-cells. Simulation showed that the differences of median total CD4+ T-cell counts 
between younger (18-35 years) and older (≥50 years) age groups were 93, 137 and 145 cells/μL 
at year 1, 4 years and steady state after treatment, respectively, suggesting that advanced age 
may have a greater negative effect on the long-term CD4+ T-cell recovery.    
In summary, this dissertation demonstrates the power of NLME approaches in studying 
antiretroviral PK and PD, and provides insights for the optimization of HIV intervention in pregnant 
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 Antiretroviral therapy (ART) has achieved tremendous success in turning HIV infection 
into a controllable chronic condition, though HIV infection remains a significant concern in public 
health. According to 2017 UNAIDS statistics, approximately 36.7 million people globally were 
living with HIV, with 1.8 million new infections and 1 million deaths. 20.9 million people had access 
to antiretroviral therapy up to June 20171. 
HIV treatment is life-long. The currently available ARTs include 25 drugs from six classes 
acting on different stages of HIV replication, including entry inhibitor, fusion inhibitor, nucleotide 
reverse transcriptase inhibitor (NRTI), non-Nucleoside reverse transcriptase inhibitor (NNRTI), 
integrase strand transfer inhibitor (INSTI) and protease inhibitor (PI)2. To ensure sufficient 
treatment efficacy, ARTs are generally used in combination regimens consisting of drugs from 
more than one class2.  
The US HIV/AIDS treatment guidelines for adults and adolescents has been changed over 
time3. By 2014, the guidelines recommended a PI (boosted), NRTI or INSTI with two NRTI 
backbones as preferred initial therapy. In the following two years, NRTI- and most PI-based 
regimens were removed from the preferred regimens as more INSTIs with better efficacy and 
safety profiles became available. Current US guidelines recommend INSTI with two NRTIs 
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combinations as initial therapy for most HIV-infected patients. NNRTI- and PI-based regimens are 
recommended in certain clinical conditions3.  
ARTs have various disposition routes. NNRTIs are generally eliminated by the kidney, 
while other drugs are metabolized by liver enzymes, mainly CYP3A, 2B6, 2C9, 2C19 and UGT 
enzymes. The latter ones can exhibit high protein binding4. These processes may vary in different 
populations, leading to different PK profiles. Some ARTs have well-characterized 
pharmacokinetic-pharmacogenetic (PK-PGx) relationships. For example, patients with a 
CYP2B6*6 phenotype demonstrate a slower metabolism of EFV5. In different populations, this 
relationship may be altered, but it is less studied. For example, for drugs with impaired metabolism 
in older population, the decrease in the clearance of a poor metabolizer may be attenuated 
compared to younger patients6.  
Taken together, the variation in physiology of different populations may lead to different 
PK, which is typically linked to the efficacy and toxicity of ART. Finding the right ART dose for 
different populations is critical to ensure viral suppression and safety. Quantifying PK variability 
of antiretroviral regimens in different populations and identifying relevant influential factors is 
essential to guide appropriate dosing. This dissertation is focused on two HIV-infected 
populations, pregnant women and older patients. In addition to PK, whether there is a sub-optimal 
immune recovery under successful ART treatment in older patients is also investigated, since 
aging is considered a risk factor for blunted immune responses7. Identifying the influence of aging 
on immune recovery is of importance to inform the proper intervention for the older HIV-infected 
population. 
NLME modeling is a rigorous statistical tool to understand the factors leading to variability 
as well as the underlying system in drug PK and PD8. This dissertation applies NLME methods to 
investigate 1) the changes in PK of lopinavir/ritonavir (LPV/RTV) in HIV-infected pregnant women, 
2) the effect of aging on unbound drug disposition of atazanavir/ritonavir (ATV/RTV) and efavirenz 
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(EFV) and 3) the impact of aging on longitudinal CD4+ T-cell recovery. The chapter will review 
the background and rationales of the above three projects.   
 
 
Alteration of Antiretroviral Pharmacokinetics in Pregnancy 
 
The use of antiretroviral treatment has reduced the rate of mother-to-child transmission 
(MTCT) from 15%-45% to less than 5%9. Worldwide, it is estimated that 1.5 million HIV-infected 
women give birth annually, and 77% of pregnant women received ART1. The perinatal ART 
treatments goals are not only to provide sufficient viral suppression and prevent MTCT, but also 
to minimize the side effects of ARTs for mothers and fetus or newborns9. This section will review 
the concerns in the use of approved antiretroviral drugs during pregnancy from a pharmacokinetic 
standpoint.    
Pregnancy causes a series of physiological and biochemical changes that could alter drug 
PK in terms of absorption, distribution, metabolism and excretion10,11. The elevated sex steroids, 
mainly progesterone and estrogen, could reduce gastric emptying and intestine motility, leading 
to delayed absorption10. They also alter (induce or inhibit) cytochrome P450 enzymes which 
impact drug elimination12. Substrates of CYP3A (such as many NNRTIs and PIs) and UGT1A 
(such as raltegravir (RAL) and dolutegravir (DTG)) are shown to have increased metabolism in 
pregnancy11,13,14. On the other hand, etravirine (ETR), a substrate of CYP2C19, is shown to have 
decreased clearance15. In addition, the biliary clearance of drugs may reduce owing to estrogen-
induced cholestasis10. During pregnancy, total body water expands by up to 8 liters and body fat 
by approximately 4 kilograms16, which could lead to the increase in volume of distribution of both 
hydrophilic and lipophilic drugs. The decreased levels of drug binding proteins, mainly acid-1-aicd 
glycoprotein (AAG) and albumin, and drug replacement on albumin by steroid and placental 
hormones could potentially increase unbound drug fraction10,16. In pregnancy, renal blood flow 
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can elevate by 60-80% and glomerular filtration rate can increase by 50%16, leading to raised 
clearance of renally-eliminated drugs, such as tenofovir (TFV) and emtricitabine (FTC). Figure 1 
summarizes the key alterations and their associations with PK changes10,11.  
Combined, these effects can result in different extents of alteration in total drug exposure 
of ARTs in pregnant women, which has led some to recommend increased dosing in pregnancy17. 
In this context, the unbound concentrations are pharmacologically relevant. As the levels of the 
main drug-binding proteins significantly decrease during pregnancy, thereby potentially leading 
to increased unbound drug fraction, the decrease in the unbound drug concentrations could not 
be simply projected by the decrease in total drug concentrations, and cannot inform the strategies 
for dose adjustment. To illustrate this, we simulated the unbound and total concentration versus 
time profiles, as conceptualized by Schoen et al4,  for two hypothetical scenarios, non-pregnancy 
and pregnancy, where the intrinsic clearance and the unbound fraction were assumed to increase 
by ~20% during pregnancy, respectively (Figure 2). Simulation showed that the total trough 
concentration at steady state (Ctrough,ss) decreased by 34% in pregnancy, while unbound Ctrough,ss 
Figure 1. Physiological and Potential Pharmacokinetic Alterations during Pregnancy. 
GI: gastrointestinal, Cmax: maximal concentration, Tmax: time to maximal concentration, F: 
bioavailability, V: volume of distribution, fu: unbound fraction, CLint: intrinsic clearance, 
CLblie: biliary clearance, CLrenal: renal clearance 
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only by 20%. When the dose was raised by 50%, total Ctrough,ss in pregnancy could match those 
in non-pregnancy, however, the unbound Ctrough,ss was increased by 20%, which potentially lead 
to toxicity.    
 
Figure 2. Hypothetical Alterations of Total and Unbound Drug Pharmacokinetics in Non-
pregnancy and Pregnancy, Given Standard and Increased Dose. 
The intrinsic clearance (CLint) and unbound fraction (fu) are assumed to increase by 20% during 
pregnancy. Modified dose is 50% increased from standard dose. Black and colored lines 
represent drug concentration profiles in non-pregnancy and pregnancy, respectively. Solid and 
dotdash lines represent drug concentration profiles given standard and increased dose 
respectively. The percent changes in steady state trough concentrations in pregnancy from non-
pregnancy are indicated. 
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Therefore, appropriate dose adjustment in pregnancy should be based on the 
measurement of unbound drug concentrations, especially those with high protein binding fraction. 
Table 1 is a summary of the protein binding properties of the approved ARTs according to the 
FDA drug labels18. Drugs undergoing extensive hepatic clearance and exhibiting high protein 
binding, such as rilpivirine (RPV), darunavir (DRV), lopinavir (LPV), Dolutegravir (DTG) and 
elvitegravir (EVG), might be especially relevant to be addressed. Unfortunately, unbound 
concentrations are not routinely measured in the clinic or PK studies, therefore, dose adjustment 
based on unbound drugs is uncommon. Beyond that, the small sample size of studies involving 
pregnant women has limited the ability to explore dosing for patients with viral resistance, which 
is always absent in the dosing recommendations. Maintaining sufficient drug efficacy for pregnant 












Non- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor 
Efavirenz >99.9% Albumin CYP2B6 and CYP3A4 
Etravirine 99.9% Albumin, AAG 
CYP3A4, CYP2C9 and 
CYP2C19 
Nevirapine 60% Albumin CYP3A4 and CYP2B6 
Rilpivirine >99% Albumin CYP3A4 
Protease Inhibitor 
Atazanavir 86% AAG, albumin CYP3A4 
Darunavir 95% AAG CYP3A4 
Fosamprenavir 90% AAG 
Prodrug is hydrolyzed to 
active form, then 
metabolized by CYP3A4 
Lopinavir(/Ritonavir) 98-99% AAG, albumin CYP3A4 and CYP3A5 
Integrase Inhibitor 
Dolutegravir 98% Albumin, AAG CYP3A4 and UGT1A1 
Elvitegravir(/Cobicistat)  97-99% Albumin, AAG CYP3A4 and UGTs 
Raltegravir 83% Albumin UGT1A1 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitor 




Emtricitabine <4% - Renal 
Lamivudine <36% - Renal 
Tenofovir <0.7% - Renal 
Zidovudine <38% - UGT2B7 (primary) 
Entry Inhibitor 




Below is a review of the current U.S. Perinatal HIV Guidelines providing suggestions for 
dosing adjustment of ARTs in pregnancy17. To note, most of the suggestions are based on total 
drug PK, but not unbound concentrations. The guidelines suggest the standard dose for drugs 
demonstrating minimal changes in drug exposure, including abacavir (ABC), lamivudine (3TC), 
zidovudine (ZDV), efavirenz (EFV) and nevirapine (NPV), or pharmacological irrelevant changes 
in drug exposure, including tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), raltegravir 
(RAL) and maraviroc (MVC). The guidelines do not have suggestions on dose adjustment for 
drugs with insufficient PK data, including tenofovir alafenamide (TAF), etravirine (ETR), rilpivirine 
(RPV), fosamprenavir (FPV), dolutegravir (DTG) and elvitergravir(/cobicistat) (EVG/COBI). 
Adequate antiviral efficacy is demonstrated in the available studies of these drugs, regardless of 
decreased drug exposure during pregnancy (ETR has increased drug exposure), though more 
studied subjects are needed to validate these findings.  
In the guidelines, dose increase in pregnancy has been suggested for two protease 
inhibitors, ATV and LPV(/RTV). For ATV, the drug exposure could decrease by 25-34% and 
trough concentration by 14-42% during pregnancy given standard dose of 300/100 mg of 
ATV/RTV once daily19. Regardless, viral suppression was reported in most studies when the 
standard dose was administered in pregnancy. Therefore, FDA-approved ATV package label 
recommends the standard dose in pregnancy for both treatment-naive and treatment-experienced 
women, and the increased dose (400/100 mg once daily)  in patients receiving TFV or a 
histamine2-receptor antagonist (known to reduce ATV exposure). Some experts, however, 
recommended the increased dose in 2nd and 3rd trimester for all women17. The use LPV in 
pregnancy is faced with a similar situation, where a 50% dose increase during the 2nd and 3rd 
trimesters was suggested by some experts, particularly for pregnant women with undocumented 
or known viral resistance mutations. A systemic PK studies for LPV/RTV, the regimen which will 
serve as a model regimen to study the necessity of dose increase in pregnancy, will be reviewed 
in Chapter II with more detail. For RTV boosted darunavir (DRV/RTV), only 17-26% reduction in 
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DRV AUC and 8-16% decrease in DRV Ctrough were observed with standard twice daily dosing 
(600/100 mg) in pregnancy20–22, supporting the use of standard dosing in pregnancy; however, 
the increased twice daily dosing (800/100 mg) is not recommended since it does not lead to 
increased DRV exposure21. Table 2-5 summarizes the pharmacokinetic studies of the approved 







Table 2. Pharmacokinetic Profiles and Dosing Recommendations for Nucleoside Reverse 



















Drug exposure and trough 
concentrations are lower during 
pregnancy, but drug levels are 
above therapeutic targets. 25–29 
No dose adjustment 
Lamivudine 
(3TC) 




No sufficient PK data for 
tenofovir alafenamide (TAF); 
Higher apparent clearance33, 
lower drug exposure (AUC, 
peak, trough)34 given tenofovir 
disoproxil fumarate (TDF) are 
shown in pregnancy, but 
decreased exposure is not 
correlated with virologic 
failure28. 
No suggestions for 
TAF on dose 
adjustment; No dose 





Not significantly altered35,36. 









Table 3. Pharmacokinetic Profiles and Dosing Recommendations for Non-Nucleoside 













Slightly or non-significant lower 
concentrations are shown in 
pregnancy. 37,38 






AUC, Cmin and Cmax are shown 
1.2-1.4 fold increase in 
pregnancy in two studies15,39. 
One study with four subjects 
shows similar PK in pregnancy 
to non-pregnancy40. 
No suggestions on 






Two studies show unchanged 
PK in pregnant women41,42, 
while one shows higher 
clearance, lower AUC and Cmax 
during pregnancy43. 




AUCs are reduced by 20-43% 
during pregnancy compared to 
postpartum44,45. 90% women 
have trough concentration 
above protein adjusted EC5045. 
No suggestions on 



















AUCs reduce during pregnancy 
compared to postpartum, 
but >97% women have sufficient 
trough concentration with 
300/100 mg ATV/RTV19. 
Some experts 
recommend increased 
dosing in 2nd and 3rd 




increased ATV only 
for ART-experienced 





17%-33% decrease in plasma 
concentrations is shown in the 
3rd trimester than postpartum 
receiving 600/100 mg twice daily 
or 800/100mg once daily20–22. 
Protein binding results are 
inconclusive20,21. 800/100 mg 
twice daily does not increase 
drug exposure46. 
600/100 mg DRV/RTV 
is recommended, but 
increased twice-daily 










Limited data. One study shows 
slight decrease in AUC and 
trough concentration during 
pregnancy than postpartum 
given 700/100 mg FPV/RTV, but 
the exposures are adequate for 
patients with susceptible virus47. 
No suggestions on 







Substantial decreased total drug 
exposure is observed given 
400/100 LPV/RTV48. Increased 
dose 600/150mg can provide 
similar drug exposure compared 
to non-pregnancy49. However, 
unbound concentrations are not 
changed given a higher dose 
during pregnancy50,51. 
Increased dose of 
600/150 mg twice 
daily in 2nd and 3rd 
trimesters are 
suggested by some 
experts, particularly 
among pregnant 
women with viral 
resistance mutations. 
500/125 mg is an 
alternative approach 




Table 5. Pharmacokinetic Profiles and Dosing Recommendations for Integrase Inhibitors 














Limited data. Drug exposures 
are lower in pregnancy, but 
effective14,52,53. 
No suggestions on 







Limited data. AUCs are similar 
in pregnancy to postpartum, but 
Cmin is significantly lower and 
below the therapeutic target. 
Cobicistat AUCs are reduced in 
pregnancy. Viral load is 
undetectable regardless of the 
decreased PK54. 
No suggestions on 





Drug exposures are similar or 
lower in pregnancy than 
postpartum, but concentrations 
provide adequate viral 
suppression13,55,56. 





30% decrease in drug 
exposure and 15% in trough 
concentration are shown during 
pregnancy; however, trough 
concentrations are above the 
therapeutic target57. 
No suggestions on 





Clinical Pharmacokinetic and Pharmacodynamic Considerations in Older HIV-
Infected Patients 
 
Aging is a trend in HIV infection as a result of increased life span of HIV-infected patients 
receiving highly effective and well-tolerated ARTs. In the field of HIV treatment, the age of 50 
years is a documented cutoff for the older population based on various immunologic and 
physiologic considerations58. Worldwide, an estimated 3.6 million people aged 50 years and older 
were living with HIV in 201359. In 2014, people over 50 years older accounted for 45% of HIV-
infected patients in the US, with the age distribution concentrated between 50 and 65 years of 
age (Figure 3a)60. This trend is predicted to continue (Figure 3b), with the portion of people aged 




Figure 3. Aging in HIV Infection. 
a) Statistics of people living with diagnosed HIV by age in the United 
States from HIV Surveillance Report, 2015. Red bars represent data from 
patients aged 50 years or over. b) Predicted age distribution of HIV-
infected patients. The prediction is performed based on the model for the 
Netherlands using data from the ATHENA cohort. Red arrows highlight 
the proportion of people aged 50 years or over, with the corresponding 
percentages indicated.    
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The Effect of Aging in Antiretroviral Pharmacokinetics 
Aging could alter ART drug disposition in multiple ways4,62. In terms of absorption, older 
patients may have delayed gastrointestinal motility and reduced splanchnic blood flow, which may 
delay absorption4. Potential downregulation of intestinal enzymes (e.g. CYP3A4) and efflux 
transporters (e.g. P-glycoprotein) could increase the bioavailability of their substrates, such as 
PIs, some NNRTIs and maraviroc63. Increased gastric pH may be relevant to the reduction in 
absorption of drugs that require acidic environment to dissolve, such as ATV64. As body water 
decreases with age, and body fat increases, lipophilic drugs may display increased volumes of 
distribution, while polar drugs (such as NRTIs) may show the opposite4. Also, drugs bound to 
albumin could exhibit an increased volume of distribution of total drug in the elderly as albumin 
level typically decreases with age, whereas drugs bound to AAG may display unchanged or 
decreased volume of distribution62.  
Aging may decrease drug metabolism due to reduced liver mass and decreased hepatic 
blood flow in elderly. With aging, cytochrome P450 enzyme metabolism may decrease up to 
25%65,66. The hepatic clearance of unbound drugs is determined by liver function, while the total 
drug apparent clearance is associated with both intrinsic clearance and protein binding, as 
denoted by CL/F ~ CLint x fu. For these drugs bound to albumin, the aging effects on their total 
drug exposure could be concealed by the opposing effects of decreased liver function and 
increased drug protein binding4. Figure 4 shows the work done by Schoen et al4 where total and 
unbound EFV concentrations were simulated in younger adults and older adults, assuming 50% 
lower intrinsic clearance and 50% higher unbound fraction in the older group. The simulations 
show that even though the total EFV exposures overlap in the two groups, the unbound drug 
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concentration is two-fold higher in the older group compared to the younger group. This could be 
one reason why the effect of age on clearance of total drug was not found in some studies. 
In most patients, renal function declines predictably with age, with a reduction in 
glomerular filtration rate of about 1% per year67, which is particularly relevant to NRITs. Up to 20% 















Increased unbound drug exposure 
Unchanged total drug exposure 
Total EFV concentration 
Unbound EFV concentration 
Unbound EFV concentration 
The inset presents the unbound drug exposure in the scale accommodating the range of 
simulated unbound concentrations. Black and red lines represent concentrations in younger an 
older individuals, respectively. Intrinsic clearance in older individuals is assumed 50% of that in 
younger adults, but unbound fraction is also assumed to 50% higher in older adults. This figure 
is adapted from Schoen et al’s work (cited in the text).  




increased risk of TFV renal toxicity in older patients and therefore require dose adjustment. Table 
6 summarizes the potential impacts of age-related changes on ART PK. 
 
Table 6. Potential Influences of Age-related Alterations in Antiretroviral Pharmacokinetics. 
Adapted from Schoen et al4. AAG: α-1-acid-glycoprotein, CL/F: apparent oral clearance, CLint: 
intrinsic clearance, CYP: cytochrome P450 enzymes, F: bioavailability, INSTI: integrase strand 
transfer inhibitor, Ka: absorption constant, NNRTI: non-nucleoside reverse transcriptase inhibitor, 
NRTI: nucleoside reverse transcriptase inhibitor, P-gp: permeability glycoprotein, PI: protease 
inhibitor, PK: pharmacokinetic, Vd: volume of distribution 
 




↑ Gastric pH 
↓ Gastric emptying 
↓ Splanchnic blood flow 
↓ Intestinal CYP3A 
↓ Intestinal P-gp 
↓ Ka 
↑ ↔ ↓F 
Atazanavir  
Rilpivirine  
Other PIs  
Maraviroc 
Distribution 
↓ Albumin  
↑ ↔ AAG  
↑ Body fat composition  
↓ Lean muscle  
↓ Total body water 
↑ Vd (lipophilic) 
↓ Vd (hydrophilic) 
↓ ↔ fu (AAG bound) 





↓ Albumin  
↑ ↔ AAG 
↓ Liver mass  
↓ Hepatic blood flow 
↓ CLint 






↓ Renal function 
↓Transport processes 




The absence of dosing recommendations for this population requires PK studies to guide 
appropriate treatment. There have been a few prospective studies investigating ART PK in older 
HIV-infected patients. Crawford et al compared the LPV total trough concentrations in treatment-
naïve HIV-infected patients aged 45-79 years (n=40) versus 18-30 years (n=37). Higher LPV 
concentrations were seen in the older patients at week 24, and age was shown to negatively 
associate with LPV clearance in a population PK model69. Dumond et al conducted a pilot study 
involving twelve HIV-infected patients aged 55 years or older (mean age 59.7 ± 3.9 years) 
receiving ATV/RTV (n=6) or efavirenz (n=6) with TFV/FTC backbone70. Compared to historical 
data, modest changes (<30%) in AUC0-24h and Cmax in these drugs were observed in these elderly 
subjects, although these alterations were not statistically significant probably due to the small 
sample size. Avihingsanon et al investigated the effect of age and gender on ATV exposure in 
twenty-two HIV-infected subjects receiving ATV/RTV/TFV/FTC. The older group (≥42 years, 
n=11) had 34-55% higher ATV AUC0-24, Cmax and Cmin, compared to the younger group, and 27% 
slower apparent clearance71. Although these relationships were not statistically significant, older 
age was found to be a significant predictor for higher ATV concentrations after adjusting for other 
covariates. Vera et al evaluated the PK profiles of RAL in nineteen HIV-infected patients over 60 
years, but no significant difference in RAL apparent oral clearance in the studied population was 
observed compared to the younger HIV-infected populations72. Recently, Calze et al found higher 
mean plasma Ctrough of DRV and RTV in older patients (≥60 years) than in younger patients (≤40 
years) with HIV infection, while RAL exposures were similar in the two groups73. In this study, 
DRV Ctrough was significantly higher by 18% in the 21 older patients than in the 25 younger 
patients.  
In the above studies, the unbound concentrations were not measured, although most of 
the studied drugs are moderately to highly protein bound. Also, the relevant PGx factors were not 
investigated. In addition to chronological age, other factors reflecting the functional declines in 
older patients were not assessed. HIV-infected patients can exhibit accelerated aging process 
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compared to the general population and may develop age-related symptoms discordant from 
chronological age74. Therefore, including additional functional and cellular surrogates may allow 
a more accurate assessment of the association between aging and ART PK. Frailty is a symptom 
of aging leading to increased morbidity and mortality, and is associated with elevated cytokine 
levels such as IL-6, CRP and TNF-α75. A phenotype characterizing frailty has been described in 
the HIV population, and often manifests itself 10 years earlier than in the uninfected population. 
Previous studies have demonstrated the association between frailty and decreased drug 
clearance76–78. At the cellular level, tumor suppressor gene p16INK4a expression, which induces 
cell replicative senescence, can serve as a biomarker of cellular aging79. Its expression in 
peripheral blood mononuclear cells (PBMCs) is indicated to correlate with both chronologic age 
and inflammation in healthy subjects and HIV-suppressed patients80,81. Due to the discordant 
aging process in HIV-infected patients from their chronological age, additional studies are needed 
to systematically evaluate the effect of aging on unbound ART PK with considerations of these 
surrogates.  
 
The Effects of Aging on Immunological System and Its Relevance to Immune Recovery 
on HIV Treatment 
Although older HIV-infected adults typically demonstrate excellent virologic response, 
immunologic responses can be poorer compared to younger patients due to a decline in immune 
functoin82. An aging immune system can lead to more vulnerability to environmental insults and 
less efficiency in responding to vaccination in elderly. Below is an outline summarizing how aging 
impairs immune function7,83–85. 
1) Innate immunity. Neutrophils and macrophages display impaired phagocytosis with 
aging86,87. Decreased cytotoxicity and capacity to produce immunoregulatory cytokines are 
observed in natural killer cells in older subjects88,89. These changes could damage the innate 
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immune function and render the elderly at higher risk of infection. Impaired antigen presentation 
function of dendritic cells with aging could hamper their efficiency to activate the adaptive immune 
response90.  
2) T cells. Decreased naïve T-cells numbers resulting from thymus involution and T-cell 
oligoclonal expansions with aging could lead to reduced T-cell repertoire diversity91. Weakened 
T-cell receptor (TCR)-mediated signaling and impaired T-cell proliferative capacity can result in 
reduced capacity to generate effector T-cells92,93. Both alterations consequent to blunted T-cell 
responses to antigens. Expression of inhibitory receptors, e.g. PD-1, LAG-3 and TIM-3, is 
indicative of T-cell exhaustion and an insufficient response to infectious agents and 
vaccination94,95.  
3) B cells. Older subjects have impaired B-cell activation, proliferation and reduced 
antibody production, which can cause insufficient humoral immunity96,97. The quality of antibodies 
in elderly is lower, as characterized by reduced diversity and efficacy98,99.  
4) Cytokines. Aging is associated with chronic inflammation which results in the increase 
of pro-inflammatory cytokines, such as IL-6, TNF-α and C-reactive protein. The imbalance in 
cytokine profiles in elderly could lead to increase adverse health events100. 
The CD4+ T-cell, or T helper cell, plays an important role in coordinating the activity in the 
immune system, especially the adaptive immune system. By releasing T-cell cytokines, these 
cells help activate cytotoxic T cells to kill infected target cells, B cells to produce antibodies and 
macrophages to attack ingested microbes101. In HIV infection, the number of CD4+ T-cells 
declines, leading to progressive deficiency of immune function and increased risk of opportunistic 
infections102. Therefore, the recovery of CD4+ T-cells under HIV suppression with ART is one 
essential clinical endpoint in HIV treatment103. Clinicians use CD4+ T-cell counts to monitor 
disease progression and diagnose AIDS, defined as CD4+ T-cells under 200 cells/µL102. From 
the therapeutic standpoint, clinicians use CD4+ T-cell counts to monitor therapeutic response and 
guide HIV treatment. Although nowadays it’s recommended that ART should be initiated 
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regardless of CD4+ T-cell counts, clinicians use this measurement to guide initiating and 
discontinuing opportunistic infection prophylaxis103.  
The CD4+ T-cell recovery can be described as a three-phase process, as shown in Figure 
5104. In the first six months after ART initiation, the cell count increase is about 20-30 cells/µL per 
month, followed by the second phase up to 2 years with the rate of 5-10 cells/µL per month, 
resulting 200-250 cells/µL increase from the baseline. In the third phase, the rate may slow down 
to 2-10 cells/µL per month. By the end of the fourth year of treatment, the increase of cell count 
from the baseline is about 300-350 cells/µL.  
Several mechanisms are proposed to account for the CD4+ T-cell recovery104,105. The first 
mechanism is de novo production of T cells from the thymus. Even though the thymus is thought 
to be most active in childhood and involute as one ages, in HIV infection condition, the thymus in 
Bright blue line represents the trajectory of CD4+ T-cell recovery over time on ART. Yellow 
arrows represent the increase of CD4+ T-cell count from baseline. CD4+ T-cell counts are 
presented on the Y axis. Years after ART initiation are presented on the X axis. The rate and 
extent of CD4+ T-cell increase are indicated in the corresponding positions. This figure is 
adapted from Corbeau et al’s review paper. 
Figure 5. Average CD4+ T-Cell Recovery on Antiretroviral Therapy in HIV-Infected Patients. 
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adults could be re-activated and release new T cells in the blood stream106. The second 
mechanism is the homeostatic proliferation of the residual T-cells under the regulation of a series 
of cytokines, such as IL-7107. The third mechanism is the extension of CD4+ T-cell half-life which 
allows the cells to stay longer in the blood stream108. 
Aging could impact the above dynamic processes in a complex manner, as summarized 
in Figure 6. Aging is known to decrease thymus output; The biomarker of thymus output, the T-
cell receptor excision circles (TRECs), is known to decrease with age109. As a potential off-setting 
effect, aging could extend the half-life of naïve T-cells, at least in a mouse model108. In addition, 
age can be associated with pathways known to interfere with T-cell recovery, such as immune 
activation and immune exhaustion. Immune activation increase with antigen exposure and age110. 
In HIV-infected patients, 5% increase in the level of its biomarkers, CD38+/HLA-DR+, has been 
related to 30 cells/μL decrease in the CD4+ T-cell gain111,112. Immune exhaustion is a state of T-
cell dysfunction in many chronic infections113, and its occurrence with aging is believed to cause 
increased comorbidity in elderly114. Elevated expression of PD-1, one of the biomarkers of 
immune exhaustion, has been observed in HIV-infected patients with poor immune recovery115. 
Red and green colors represent destructive and beneficial effects, respectively. Plus and minus 
signs indicate positive and negative associations between the pathway and aging, respectively.    
Figure 6. The Hypothetical Effects of Aging on CD4+ T-Cell Turnover. 
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Although it seems intuitive that age is a risk factor of suboptimal CD4+ T-cell recovery, the 
findings in the literature are not consistent. Several prospective studies compared the CD4+ T-
cell reconstitution in younger and older HIV-infected patients, but yield conflicting results. Viard et 
al studied a prospective cohort of 1956 HIV-infected patients initiating PI- or NNRTI-based 
treatment between 1996 and 2000116. Patients were divided into four groups based on age at ART 
initiation: <32.7 years, 32.7–37.1 years, 37.2–44.4 years, and >44.5 years. Within the ~31-month 
study period, younger patients had significantly greater median CD4+ T-cell increase (251, 246, 
212, and 213 cells/µL, respectively) and maximum CD4+ T-cell counts (500, 448, 430, and 
419 cells/µL, respectively) than the older patients. Grabar et al’s prospective cohort study based 
on 3015 HIV-infected patients from a French Hospital Database on HIV compared immunologic 
and clinical responses up to 30 months of ART in patients aged <50 years and ≥50 years117. Using 
a longitudinal model, age was found to be a significant predictor of the mean increase in CD4+ T-
cell count during the first 6 months when adjusted for baseline HIV levels. In contrast, other 
studies did not identify age as an important factor to CD4+ T-cell recovery. A prospective case-
control study conducted by Tumbarello et al compared CD4+ increase in 120 patients aged ≥50 
years and 476 patients aged 20-35 years118. In the 6-year follow-up period, there was no 
statistically significant difference between younger and older patient groups in CD4+ T-cell count 
enhancement, regardless of the significantly lower mean CD4+ T-cell baseline in the older group. 
Another prospective cohort study conducted by Cuzin et al followed up 639 HIV-infected patients 
aged ≥50 years and 540 aged <50 years for 51 months. No significant association between age 
and the immunologic response, defined as CD4+ T-cell count ≥350 cell/µL, after 6 months of 
treatment was found in this study 119. A summary of these studied is shown in Table 7. 





Table 7. Prospective Studies Comparing CD4+ T-Cell Recovery in Younger and Older HIV-
infected Patients on Antiretroviral Treatment. 
Patients from these studies received ARTs which were defined as a combination of two NRTIs 
plus either an NNRTI or PI. ART in Cuzin et al’s study also contained 3 NRTIs. NNRTI: non-
nucleoside reverse transcriptase inhibitor, NRTI: nucleoside reverse transcriptase inhibitor, PI: 
protease inhibitor, IQR: Inter-quantile range. Age distribution is presented as either median 
(IQR) or mean ± standard deviation.  
Author Follow up Sample Size Findings Age Distribution 
JP Viard et 




1956 (1996 – 
Feb 2000) 
Older age leads to 
smaller maximum CD4+ 
T-cell count and longer 
time to max 
37.2 in median (IQR 
32.7 – 44.5) 
Grabar et al, 
AIDS, 2004117 




When adjusted for HIV 
baseline, age is 
significant predictor of 
mean increase in CD4+ 
T-cell count during the 
first 6 months 
<50 years:  
35.7 (IQR 31.1-40.6); 
>=50 years: 57.2 (IQR 
52.6-60.3) 
Tumbarello 






<50 years  
Nonsignificant 
difference in CD4+ T-
cell increase between 
>50 years vs. 20-35 
years 
>=50 years: 58 ± 5.1 
<50 years:  
31 ± 13.2 (20-35 years) 





in median  
639 >=50 
years; 
540 <50 years  
(1996-2006) 
Age is not associate 
with CD4+ T-cell count 
>350 cells/µL after 6 
months of treatment 
<50 years:  
35.9 (IQR 29.9-41.7) 
>=50 years: 




The conflicting findings may be partially explained by the inconsistency in the 
measurement endpoints regarding CD4+ T-cell recovery, age cutoffs for patient grouping, and 
the timing for statistical comparisons. As mentioned above, since aging influences on different 
CD4+ T-cell recovery mechanisms differently and sometimes in opposing ways, the overall effect 
of aging may not be reflective of an individual pathway. Given these complications, 
mechanistically investigating this problem involving important immune biomarkers would allow 
better understanding of the effects of aging on CD4+ T-cell kinetics. Also, CD4+ T-cell counts are 
highly variable among tests103 and subjects (~30% coefficient of variance)120; accounting for the 
large variability is critical to reveal important associations. From a therapeutic standpoint, 
identifying the influence of aging on CD4+ T-cell recovery in a quantitative manner is important to 
inform appropriate treatment in the older HIV-infected population. Using modeling and simulation 
methods, long-term CD4+ T-cell reconstitution profiles could be predicted the using information 




Nonlinear Mixed-Effects Modeling 
 
Due to its capability to integrate information from different sources and project new 
scenarios, population PKPD modeling and simulation methods have been widely used to inform 
rationale dosage design and optimized treatment in academia, pharmaceutical industry and 
regulatory agencies121. Compared to traditional PKPD analyses, population PKPD approaches 
are able to analyze sparsely-sampled data, single large study or pooled data with diverse patient 
populations8. It provides an efficient way to investigate multiple factors in one analysis, including 
demographics, pathophysiological conditions, multiple drug interactions, food effects and the 
combination of these factors122.   
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NLME modeling is a powerful tool in population PKPD analyses to understand factors 
leading to variability in PK and PD response. A NLME model consists of a general structure of 
the underlying system and a set of hierarchical variability components (Figure 7). Its nonlinearity 
allows the description of repeated measures data or response–time relationship commonly seen 
in health science. By using a series of biologically-related parameters, NLME models allow to 
describe the system more mechanistically than traditional statistical methods.   
Simultaneously with the system structure, NLME models can describe both fixed effects 
and random effects, namely, mixed effects. The fixed effects are those effects that can be related 
to observable or measurable variables, such as age, body weight, creatinine clearance and 
disease state. The random effects are the unexplained random variability, which include inter-
occasion variability (IOV), inter-individual variability (IIV) and intra-individual variability (or residual 
variability), accounting for multiple variability sources from different trials, experimental conditions, 
subjects and measurements. NLME models typically describe at least two levels of random effects 
(IIV and residual variability) with a nested (hierarchical) model.  
In this dissertation, NLME models are developed to describe PK or PD profiles of several 
antiretroviral drugs, to quantify the variability in the drug exposure and response and to determine 
the relevance of pregnancy and aging in varying PK or PD, with the goal to devise optimal 





Unexplained random variability 
• Inter-individual variability 
• Intra-individual variability 
• Inter-occasional variability  
Structural model parameters and 
relationships could be related to 
observable variables 
• Age 
• Body weight 
• Creatinine clearance 




Concentrations versus time profiles are hypothetical. a) Fixed effects, which consist of 
structural parameters describing the system and covariate effects related to observable or 
measurable variables. The concentrations can be described as a function of time in a nonlinear 
manner with a set of physiologically relevant parameters. Examples of covariates are listed in 
bullet points. The concentration versus time profile on the left shows that drug exposure 
increases with decreased creatinine clearance, and the fixed effect modeling is able to quantify 
this relationship. b) Different types of random variability. The inset shows two types of random 
effects, inter-individual variability, which is the variability among individuals, and intra-individual 
variability, which is the difference between the model prediction and observation. C: 
concentration, t: time, Ka: absorption rate constant, V: volume of distribution, CL: clearance. 
CrCL: creatinine clearance.  




AIM 1. To investigate the need to increase lopinavir/ritonavir (LPV/RTV) dosing or to switch 
therapies for HIV-infected pregnant women with different viral resistance levels, by 
analyzing longitudinal unbound concentrations during pregnancy. (Chapter II) 
1a. Develop models describing longitudinal unbound LPV/RTV PK in pregnancy 
1b. Evaluate the drug-drug interaction between LPV and RTV 
1c. Evaluate the effect of physiological and biochemical changes on unbound LPV/RTV 
1d. Predict unbound LPV concentrations under different dosing strategies, and provide treatment 
recommendations for pregnant women with different viral resistance 
AIM 2. To investigate the effect of aging, including chronological, functional and cellular, 
on the unbound drug disposition of efavirenz (EFV) and atazanavir/ritonavir (ATV/RTV), 
taking into account of the gene polymorphisms of drug metabolic enzymes and transporters. 
(Chapter III) 
2a. Construct population PK models to describe the studied drugs 
2b. Evaluate the effects of aging and other factors on PK parameters 
2c. Explore the association of gene polymorphisms with PK parameters and their impact on the 
aging effects 
AIM 3. To investigate the aging effects on longitudinal CD4+ T-cell recovery in HIV-
suppressed subjects. A semi-mechanistic population model will be constructed to explore the 
effect of chronological age on CD4+ T-cell dynamics, with adjustment for multiple age-related 
immune processes. (Chapter IV) 
3a. Construct a NLME model to describe longitudinal CD4+ T-cell recovery 
3b. Evaluate the effects of age and age-related immune processes, including thymus output, 
immune activation, immune exhaustion, on CD4+ T-cell trajectory 








Chapter II:  Analysis of Unbound Lopinavir/Ritonavir (LPV/RTV) 
Concentrations in HIV-Infected Pregnant Women: Implication for Dosing 




Physiological changes during pregnancy can affect drug pharmacokinetics. In this chapter, 
we present a population pharmacokinetic model to describe the longitudinal change of unbound 
lopinavir/ritonavir (LPV/RTV) PK parameters with gestational age, and to predict unbound LPV 
concentrations and effectiveness under different dosing regimens. The changes in apparent 
intrinsic clearances of LPV and RTV during pregnancy were described using an exponential 
function of gestational age. The unbound fractions of LPV/RTV were not significantly different 
between pregnancy and postpartum. Simulation reveals that despite increased in LPV intrinsic 
clearance, effective LPV inhibitory quotient (IQ) values were predicted with the standard dosing 
(400/100 mg B.I.D.) in >90% of simulations, with ≤4‐fold increase in viral IC50. As viral 
susceptibility decreases, higher doses increased the likelihood of efficacy. With ≥40‐fold 
increases in IC50, IQs suggested alternate regimens be considered. This approach refines 
previous LPV PK reports, and supports that standard dosing is effective with susceptible virus.    
  
                                               
1 This chapter was taken from an article previously published. The original citation is as follows: 
Chen J, Malone S, Prince HM, Patterson KB, Dumond JB. Model-Based Analysis of Unbound 
Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the 






Fully suppressive combination antiretroviral (ARV) regimens, in combination with other 
interventions, have reduced the risk of mother-to-child-transmission (MTCT) of HIV to less than 
2% in the developed world17. Lopinavir/ritonavir (LPV/RTV) is a widely used component of 
perinatal regimens. Pregnancy induces a host of variable changes in physiology throughout its 
course that can affect the pharmacokinetic (PK) properties of ARVs123. LPV/RTV are highly 
protein-bound substrates, inducers, and inhibitors of the CYP450 enzyme system and drug 
transporters124,125, and total drug exposures decrease substantially during the second and third 
trimesters. Table 8-9 provides a brief overview of the clinical studies documenting this effect51,126–
133. In 2005, LPV/RTV was reformulated from a soft-gel capsule to a Meltrex tablet134, with 
improved bioavailability and less impact of pregnancy on PK133, although guidelines and some 
experts recommended increased doses of LPV/RTV from 400/100mg to 600/150mg twice daily 
with the tablet formulation17.  
Despite decreases in total LPV concentrations, most investigations into the unbound, 
virologically active concentrations of LPV have demonstrated that they remain well above wild-
type IC50 values, and do not significantly increase with increased LPV/RTV dosing50,51,134–136. This 
might be due to the decreased drug-binding protein levels and the resultant elevated unbound 
drug fraction during pregnancy. It was shown that in pregnancy, the levels of alpha-1-acid 
glycoprotein (AAG) and human serum albumin, the major drug-binding proteins, decreased by 
20%- 50%16. LPV unbound fraction was shown to increase by 18% during third trimester135, 
though how this impacts unbound LPV efficacy has not been well described.  
In 2015, the US Food and Drug Administration (FDA) approved a change to the labeling 
of the Kaletra® (AbbVie Inc., North Chicago, IL) tablet, indicating a dosage increase in pregnancy 
is not needed in women with susceptible virus137. However, no clinical data exist to make 
recommendations regarding dosage requirements for women who may have reduced 
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susceptibility to LPV. About 25% of the PI-experienced patients were shown to carry clinically 
importance viral mutations resistant to LPV124. Moreover, reduced adherence due to LPV-induced 
side effects (nausea, diarrhea and vomiting) in pregnant women, in addition to lower drug 
exposures, could lead to a higher risk of resistance17. Using data from a study of 12 HIV-infected 
pregnancy women who underwent an empiric dosage adjustment in the 3rd trimester from 
400/100mg to 500/125mg twice daily where unbound LPV/RTV concentrations were measured51, 
a population PK model was developed. Simulations of unbound concentrations under 3 dosing 
scenarios and 5 viral resistance patterns were then undertaken to inform dosing 





















Table 8. Literature review of pharmacokinetics alteration of LPV/RTV in pregnancy (2006-
2011) 
LPV: lopinavir; LPV/RTV: lopinavir/ritonavir; AUC: area under the curve; C12: concentration 12 




















AUC decreased 28%, C12 
decreased 56% in the 3rd 
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2nd and 3rd 
trimester, 2 
weeks PP 
41% decreases in 3rd trimester 
LPV AUC and 31% decrease in 
LPV C12 compared to post-
partum 2nd vs 3rd trimesters: 30% 
decrease in AUC 
2nd trimester vs pp: 52% 
decrease in AUC 















2nd and 3rd 
trimester, and 
2 weeks PP 
27% decrease in AUC and 28% 
decrease in C12 in 3rd trimester 
compared to PP  
2nd vs 3rd trimesters:  23% 
decrease in AUC, 44% decrease 
in C12hr 
2nd trimester vs. pp: 49% 
decrease in AUC, 55% decrease 
in C12 
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12 weeks PP 
Mean LPV AUC was 24% lower 




Table 9. Literature review of pharmacokinetics alteration of LPV/RTV in pregnancy (2012-
present) 
LPV: lopinavir; LPV/RTV: lopinavir/ritonavir; AUC: area under the curve; C12: concentration 12 





















2nd and 3rd 
trimesters, 4-
6 weeks PP 
Cohort 1: 2nd vs 3rd trimester: 
35% decrease in AUC 
Cohort 2: 2nd vs 3rd trimesters: 
28% decrease in AUC; 3rd 
trimester vs PP: 35% decrease in 
AUC 
Troughs decreased between 2nd 
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500/125 mg 
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25% dose increase resulted in 
~10% increase in total LPV 
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significantly lower than PP before 
dose increase 













13% decrease in trough LPV 
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non-pregnant controls was not 
















tablets for 6 
weeks PP 
2nd and 3rd 
trimester, PP 
400/100 mg arm: minimum LPV 
concentrations of 4.4, 4.3, and 
6.1 μg/ml in 2nd and 3rd trimesters 
and PP, respectively, compared 
to 7.9, 6.9, and 9.2 μg/ml in the 
600/150 mg arm. 
The mean values of LPV Cmax, 
AUC0–12, C12 were significantly 






Clinical Study Conduct 
A detailed description of study conduct has been previously published51. Briefly, twelve HIV‐
infected pregnant women receiving LPV/RTV in combination with nucleoside agents were 
enrolled at the University of North Carolina at Chapel Hill and Northwestern University. Subjects 
underwent intensive PK sampling at four visits over the course of pregnancy: 20–24 weeks' 
gestation at a dose of 400/100 mg B.I.D.; 30 weeks' gestation at 400/100 mg B.I.D., followed by 
a dose increase to 500/125 mg B.I.D.; 32 weeks' gestation at 500/125 mg B.I.D.; about 8 weeks 
postpartum and at steady state of the 400/100 mg B.I.D. dosing. Albumin and alpha‐1 acid 
glycoprotein (AAG) concentrations were measured at each visit. The UNC Biomedical Institutional 
Review Board approved this study (NCT00766818). The dosing and sampling schemes of the 
study are shown in Figure 8.     
Drug Concentrations  
 
Figure 8. Clinical Study Design.  
a) PK visits and dosing. b) PK sampling scheme at each visit. Total and unbound 




Total LPV/RTV concentrations were measured in plasma using validated high‐
performance liquid chromatography/ultraviolet (HPLC/UV) methods138. Unbound LPV/RTV 
concentrations were measured using rapid equilibrium dialysis and liquid chromatography/mass 
spectrometry (LC/MS) methods as previously described51,139. 
 
Table 10. Characteristics of the Studied Patient at Baseline, Pregnancy and Postpartum. 
Continuous data are presented in median (range). Count data are presented in frequency 
(percentage). Wks: weeks, BMI: body mass index, ART: antiretroviral therapy, AAG: alpha-1-acid 
glycoprotein. This table is adapted from the original paper51.  






    












9 (75%)     
Caucasian 3 (25%)     
ART 
Exposure 
Naïve 8 (67%)     
Experienced 4 (33%)     
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Population Pharmacokinetic Modeling and Simulation 
Population PK analysis was performed using NONMEM 7.3 (ICON Development 
Solutions, Hanover, MD). R (version 3.1.0, r-project.org) was used for data management, 
statistical analysis and graphical analysis. Pirana (version 2.9.2) was used for model management 
and output visualization. The ADVAN13 subroutine and First-order conditional estimation (FOCE) 
method with interaction was used for model development. Non-compartmental analysis (NCA) 
was performed using Phoenix WinNonlin 6.3 (Pharsight, A Certara Company, St. Louis, MO) to 
calculate the areas under the concentration time curve (AUC). Repeated measures ANOVA was 
used to compare the unbound fraction of LPV and RTV, AAG levels and albumin levels across 
study visits. Data were log-transformed to achieve a normal distribution. A p-value <0.05 was 
considered statistically significant.  
LPV and RTV Structural Model  
LPV and RTV were initially modeled separately. Unbound and total concentrations were 
co-modeled with unbound drug as the central compartment. To select the protein binding model, 
bound concentrations were plotted against unbound concentrations for each subject by each 
study visit to examine the protein binding behavior. One-compartment and two-compartment 
models were tested for both drugs. Zero-order, sequential first- and zero-order, first-order with or 
without a lag time and transit compartment model were tested for each drug for its absorption 
model. Inter-individual variability (IIV) and inter-occasion variability (IOV) were assumed 
exponential and were presented as following: 
θ𝑖𝑗 =  θ ×  𝑒
𝑖+ 𝑖𝑗                                                                                               (Eqn 1) 
where θ𝑖𝑗 denotes individual parameter of the ith subject in the jth occasion, θ denotes population 
parameter, i represents the deviation from the population parameter of the ith subject, and ij 
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represents the random variable of the ith subject in the jth occasion. Both IIV and IOV were 
assumed to be normally distributed. Correlations between IIVs were examined by post hoc 
random variable plots and their correlation coefficients (R) from the correlation matrices for 
random effects in the NONMEM output. Proportional, additive and combined proportional-additive 
error models were tested for residual variability. The effect of total body weight and lean body 
mass21, 22, 23 on apparent intrinsic clearance (CLu/F) and apparent volume of distribution (V/F) 
were examined in both models using the empirical allometric scaling factors, 0.75 and 1, 
respectively. Model discrimination was determined by objective function values (OFV), using the 
likelihood ratio test (α = 0.05), and diagnostic plots.  
Covariate Evaluation  
Forward addition/backward elimination was perform for this analysis (α = 0.05/0.01). The 
effects of study visit, gestational week and race were tested for CLu/F, Vu/F and absorption 
parameter(s). The postpartum study visit and the African American population were set as the 
references. Week of gestation was coded as zero for the postpartum visit. Parameter-covariate 
pairs were selected by examining the individual predicted PK parameters versus covariate plots. 
Race, body mass index (BMI), pregnancy and the concentrations of AAG and albumin were 
examined on fu. In addition to total body weight, we also explored the effect of lean body mass 
(LBM), as calculated by the following two methods: 
1) Convert the measured body weight and height to LBM using the below two formulas, 
respectively140,141: 
The James Formula (Women): 
LMB = 1.07 × weight (kg) − 148 × (weight (kg) height (cm))⁄
2
                               (Eqn 2) 
The Hume Formula (Women): 
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LBW = 0.29569 × weight (kg) + 0.41813 × height (cm) − 43.2933                         (Eqn 3) 
2) Adjust LBM at the specific gestational weeks using the formula in Abduljalil’s paper16, 
which was developed to describe the change of the lean body mass in terms of gestational age 
(GA):    
Total Fat − free Mass = 44.5 − 0.0474 × GA (week) + 0.0034 × GA (week)2            (Eqn 4) 
 
Categorical variables were incorporated in the model as below; 
 =  0  ×  1
𝑋1 × 2
𝑋2 × … × 𝑖
𝑋𝑖                  (Eqn 5) 
where 0  is the population parameter of the reference population, 𝑖  is the fold change of 
parameter in the ith category from the reference, X is the tested covariate, and Xi is assigned to 
1 when the observation is within the ith category and otherwise 0. 
Continuous variables were tested with proportional linear model, power model or 
exponential model, as shown below. 
 =  1 × [1 + 2 × (𝑋 − 𝑚𝑒𝑑𝑖𝑎𝑛(𝑋)]                                (Eqn 6) 
 =  1 × (𝑋/𝑚𝑒𝑑𝑖𝑎𝑛(𝑋)
2                              (Eqn 7) 
 =  1 × 𝑒
2 ×[𝑋−𝑚𝑒𝑑𝑖𝑎𝑛(𝑋)]                              (Eqn 8) 
where  is the population PK parameter, 1 is the parameter of the population with the median X 
value, and 2 is the covariate effect coefficient. 
LPV-RTV Interaction Modeling  
Several approaches to test the effect of RTV exposure on LPV PK were explored: 
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As part of the covariate evaluation, post hoc RTV AUCs were tested for the LPV CLu/F 
using exponential model, power model and IMAX model as described below: 
CL𝑢,𝐿𝑃𝑉 = 1 × 𝑒
−𝑐𝑜𝑒𝑓×[𝐴𝑈𝐶𝑢,𝑅𝑇𝑉−𝑚𝑒𝑑𝑖𝑎𝑛(𝐴𝑈𝐶𝑢,𝑅𝑇𝑉)]                            (Eqn 9) 
CL𝑢,𝐿𝑃𝑉 = 1 ×  [𝐴𝑈𝐶𝑢,𝑅𝑉𝑇/𝑚𝑒𝑑𝑖𝑎𝑛(𝐴𝑈𝐶𝑢,𝑅𝑇𝑉)]
−𝑐𝑜𝑒𝑓             (Eqn 10) 
CL𝑢,𝐿𝑃𝑉 =  2 × (1 −
𝐼𝑀𝐴𝑋×𝐴𝑈𝐶𝑢,𝑅𝑇𝑉
𝐴𝑈𝐶50+𝐴𝑈𝐶𝑢,𝑅𝑇𝑉
)               (Eqn 11) 
where CL𝑢,𝐿𝑃𝑉 represents the population LPV intrinsic clearance. 1 and 2 denote the intrinsic 
LPV clearance with median unbound RTV AUC and without RTV respectively. Coef presents the 
RTV inhibition coefficient. IMAX is the maximum inhibitory effect and is fixed to 1. AUC50 is the 
unbound RTV exposure resulting in 50% inhibition, and AUCu,RTV represents area under the 
unbound RTV concentration versus time curve.  
In an alternative approach, the interaction of LPV and RTV was evaluated based on the 
two individual models, and was described as the influence of unbound RTV concentrations (Cu,RTV) 
or AUCs on LPV intrinsic clearance. In terms of Cu,RTV, an exponential model, a power model and 
a simple IMAX model were used to characterize the interaction, as follows: 
CL𝑢,𝐿𝑃𝑉 = 1 × 𝑒
−𝑐𝑜𝑒𝑓×[𝐶𝑢,𝑅𝑉𝑇−𝑚𝑒𝑑𝑖𝑎𝑛(𝐶𝑢,𝑅𝑇𝑉)]                                (Eqn 12) 
CL𝑢,𝐿𝑃𝑉 = 1 ×  [𝐶𝑢,𝑅𝑉𝑇/𝑚𝑒𝑑𝑖𝑎𝑛(𝐶𝑢,𝑅𝑇𝑉)]
−𝑐𝑜𝑒𝑓                         (Eqn 13) 
CL𝑢,𝐿𝑃𝑉 =  2 × (1 −
𝐼𝑀𝐴𝑋×𝐶𝑢,𝑅𝑇𝑉
𝐼𝐶50+𝐶𝑢,𝑅𝑇𝑉
)                (Eqn 14) 
where CL𝑢,𝐿𝑃𝑉 represents the population LPV intrinsic clearance. 1 and 2 denote the intrinsic 
LPV clearance with median unbound RTV concentration and without RTV respectively. Coef 
presents the RTV inhibition coefficient. IMAX is the maximum inhibitory effect and is fixed to 1. IC50 
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is the unbound RTV concentration resulting in 50% inhibition, and Cu,RTV represents unbound RTV 
concentration.  
In terms of RTV AUCs, the same model types as described in Eqn 9-11 were evaluated. 




                     (Eqn 15) 
The interaction was tested with and without the covariate effects on LPV intrinsic clearance. 
Model discrimination was based on OFV, and a decrease of 3.84 in OFV (α = 0.05) was 
considered to be significant. 
Model Validation  
The goodness of fit of all models was evaluated by observation versus individual prediction 
(IPRED) and population prediction (PRED) plots, and conditional weighted residuals (CWRES) 
versus PRED and time plots. Visual predictive checks were performed after 1000 simulations with 
the final parameter estimates. Bootstrap estimates were obtained from 500 replicates and 
compared to model estimates to evaluate parameter precision.  
Outlier Determination and Data Exclusion 
Since the sample size in this study is relatively small, excluding data points from analysis 
was approached conservatively to include as many subjects and samples as possible. In this 
analysis, outliners were determined in the conditional residual plots and those observations 
yielding a |CWRES| > 6 were excluded for further analysis142.  
Simulation of Different LPV/RTV Dosing Regimens  
Unbound LPV concentrations of 1000 subjects were simulated at LPV/RTV dosing of 
400/100mg, 500/125mg and 600/150mg twice daily at 32 weeks of gestation and postpartum. 
42 
 
Unbound inhibitory quotient (IQ) were calculated from unbound trough concentrations (Cu,trough) 
as below: 
IQ = C𝑢,𝑡𝑟𝑜𝑢𝑔ℎ/𝐼𝐶50                             (Eqn 16) 
and were compared to the pharmacological effectiveness thresholds, as show below. The 
percentages of IQs showing effectiveness or ineffectiveness at each dosing level and each viral 
resistance were calculated.   
 
Virologic Parameters and Simulations 
Although viral susceptibility was not determined in the clinical study, previous work has 
suggested cut-offs for LPV efficacy based on calculation of the unbound Inhibitory Quotient (IQ) 
from virtual viral phenotypes (reported as fold-change decreases in susceptibility, rather than 
individual genetic mutations)143. Based on data in PI-experienced patients144,145, protein-free IC50 
increases of 4-, 10-, 20-, and 40-fold from wild-type virus were considered in the 3rd trimester at 
the increased and standard dosing. For each simulated subject (n=1000), the unbound LPV 
trough concentration (at 12 hours post-dose) in the third trimester was used to calculate the IQ 
(unbound LPV trough/viral IC50) under 5 viral resistance scenarios146, using 0.69 ng/mL as the 
wild-type IC50147. IQs greater than 15 were considered to be effective, while those <4 were 
considered to be ineffective143. The same simulations and calculations were performed using final 







Demographics of the twelve enrolled women have been published, as summarized in 
Table 1051. Briefly, the subjects ranged in age from 18-35 years old with a median age of 28 
years. Median weight at screening was 87.4 kg, range of 45.3-142.6 kg. Most of the subjects were 
African American (75%) and antiretroviral-treatment naive (67%). Plasma protein albumin and 
AAG levels (median, 25th - 75th percentile) were 4.2 (4.1-4.4) g/dL and 82 (72-116) mg/dL at 8 
weeks postpartum, respectively, and were significantly decreased (p < 0.001 for albumin and p = 
0.011 for AAG) during pregnancy. CD4+ T-cell counts were >400 cells/µL throughout study. 
Suppressed viral load (<48 copies/mL) was observed in all subjects in the latter part of the study. 
Concentration versus time profiles of all the subjects across four study visits are presented in 
Figure 9. In total, 330 plasma samples were available for analysis. No BLQ data were present, 
and the truncated concentration versus time profiles in three subjects were due to either missing 





a) unbound lopinavir (LPV), b) total LPV, c) unbound ritonavir (RTV) and d) total RTV. 
The blue lines are the medians for the observed data.  
Figure 9. Spaghetti Plot of the Observed Concentration versus Time Profiles. 
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LPV Individual Model 
The LPV model structural is presented in Figure 10. Unbound LPV concentrations were 
well described using a one-compartment model with first-order absorption and elimination. A lag 
time was included in the absorption phase. Zero-order, sequential zero- and first-order absorption 
and transit compartment models did not significantly improve the model. A linear protein binding 
model was chosen to describe the relationship between the unbound and total concentrations, as 
only one subject in the 4th visit showed a minimal trend of saturable binding (data not shown). 
Inter-individual variability (IIV) was included on the apparent intrinsic clearance (CLu/F) and 
unbound fraction (fu). Incorporating an inter-occasion variability (IOV) in CLu/F, absorption rate 
a) Lopinavir and b) Ritonavir. X
a
: amount of drug in the absorption compartment; K
a
: 
first-order absorption rate constant; T
lag
: absorption lag time; f
u
: unbound fraction; C
u
: 
unbound concentration; C: total concentration; V
u
/F: apparent volume of distribution of 
unbound drug; V/F: apparent volume of distribution of total drug; CL
u
/F: apparent unbound 
drug clearance or intrinsic clearance; F: bioavailability; LPV: lopinavir; RTV: ritonavir. 
* and † denote the inter-individual variability and inter-occasional variability on the 
parameters in the final model, respectively. 
Figure 10. Schematic Illustrations of the Pharmacokinetic Model Structure. 
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constant (ka) and fu decreased the OFV by 313.3, 17.3 and 29.3 sequentially. The empirical 
allometric effect of body weight or lean body mass on CLu/F and apparent unbound volume of 
distribution (Vu/F) was not justified in the model, as determined by likelihood ratio test. The 
residual variability of both total and unbound LPV was described using a proportional model. The 




Table 11. Parameter Estimates of Final Lopinavir and Ritonavir Models.  
CLu/F: apparent intrinsic clearance; CL/F: apparent total body clearance; Vu/F: apparent volume 
of distribution of unbound drug; V/F: apparent volume of distribution of total drug; Ka: first-order 
absorption rate constant; fu: unbound fraction; IIV: inter-individual variability; CV: coefficient of 
variation; CI: 95% confidence interval; r: correlation coefficient. 

















157         
(120, 202) 




Vu/F (L) 3430 
3325        
(2655, 4256) 
1560 
1630       
(1040, 2100) 
V/F (L)  † 88.5 - 232 - 
Ka (h-1) 1.07 
0.906               
(0.582, 1.78) 
1.01 
1.01      
(0.340, 2.00) 
fu (%) 2.58 
2.58                   
(2.48, 2.71) 
14.9 
14.8        
(12.1, 18.1) 
Lag time (h) 1.77 
1.75               
(1.25, 1.93) 
1.86 




impact on CLu/F 
0.0148 
0.0148   
(0.00835, 0.0223) 
0.0184 
0.0188    
(0.0129, 0.0262) 
Inter-individual variability (%CV) 












IIV correlation (r) 
ηCL -ηfu - - -0.95 - 
Inter-occasional variability (%CV) 
































Residual correlation (r) 




In the covariate analysis, while study visit and the week of gestation were both significant 
covariates on CLu/F, the latter could describe the change of the apparent intrinsic clearance 
across the study period in a more parsimonious manner, and this relationship was well described 
by an exponential function as below: 
𝐶𝐿𝑢/𝐹𝐿𝑃𝑉 =  𝜃 × 𝑒
𝑐𝑜𝑒𝑓×𝑊𝐸𝐸𝐾                  (Eqn 17) 
where θ is the population parameter estimate of LPV apparent intrinsic clearance at week zero of 
gestation, coef is the week effect coefficient and WEEK denotes the gestational week. Post hoc 
estimates of CLu/F and the back-calculated total body clearance for the four study visits are 
summarized in Table 12. Compared to 8 weeks postpartum, the median CLu/F of LPV increased 
by 38%, 56% and 61% at 20-24 weeks, 30 weeks and 32 weeks of gestation, respectively. 
For LPV fu, none of the tested covariates, including AAG, albumin levels, BMI, race, study 
visit and pregnancy, were significant (Table 13). This result was consistent with the nonsignificant 
difference of the unbound AUC fractions across study visits analyzed by repeated measures 
ANOVA (Figure 11).  
Table 12. Post Hoc Clearance Estimates Across Visits. 
The clearance estimates are presented as median (range). CLu,LPV/F: lopinavir apparent intrinsic 
clearance, CLLPV/F: lopinavir total body clearance, CLu,RTV/F: ritonavir apparent intrinsic 
clearance, CLRTV/F: ritonavir total body clearance.  
* Total body clearance = intrinsic clearance × lopinavir unbound fraction.  
 
Visit 1 













































RTV Individual Model 
The structural model of RTV, as presented in Figure 10, was similar to that of LPV, except 
that in the RTV model: 
1) Both CLu/F and Vu/F were adjusted for total body weight using empirical allometric 
rule; 
2) IIV were included on CLu/F  and fu, with an estimated off-diagonal relationship; 
3) In addition to IOVs on ka and fu, including IOV on bioavailability (F) significantly 
improved the model fit, while IOV on CLu/F was not significant after IOV on F was 
incorporated.  
Again, week of gestation was the most significant covariate for CLu/F, and the effect size 
of gestation week for RTV apparent intrinsic clearance was larger than that for LPV, with the 





a) lopinavir (LPV) and b) ritonavir (RTV) and spaghetti plots for c) LPV and d) RTV.  
Black dots represent the observed unbound fraction of the area under the concentration 
versus time curve (fuAUC). In a) and b), repeated measurements ANOVA was 
performed to examine the difference of log-transformed fuAUCs across visits. In c) and 
d), fuAUCs within the same subject were connected by solid lines.  
P = 0.804 P = 0.522 
Figure 11. Boxplots of Unbound Fraction Across Visits. 
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Including lean body mass in the structural model did not perform better than total body 
weight. IIVs on the coefficient were not justified for either LPV or RTV, implying the similar change 
of the clearance among the studied subjects. Covariate analysis of RTV fu found no significant 
effects of the tested variables (Table 13), and this was confirmed with the repeated measure 
ANOVA on unbound RTV AUC fraction (Figure 11).  
 
LPV-RTV Interaction Modeling 
When tested as a covariate, unbound RTV AUC did not have significant influence on LPV 
PK (Table 9). When the interaction was tested in the joint model, the PK parameters of RTV were 
fixed to reduce the complexity of the modeling process. The basic model for this analysis was the 
combination of the LPV and RTV final model from the above analysis, with the correlations of their 
residual errors estimated. Similar values were obtained for LPV CLu/F (167 L/h versus 167 L/h) 
and gestational week coefficients (0.149 versus 0.148) from this basic model and the individual 
model. Among the six tested models, the exponential model in expression of unbound RTV 
concentrations provided the lowest OFV; however, incorporating the interaction did not improve 
the model fit significantly (Table 14). The coefficient value of the interaction was 0.0028, 
corresponding to -3% to +11% of inhibition on LPV clearance, given the 5th and 95th percentile of 
unbound RTV concentration. When the interaction was evaluated without the gestational age 
effect, the OFV increased by 13.0, indicating the RTV concentrations could not sufficiently explain 
the longitudinal change of LPV clearance, even though a slight decrease of gestational week 
effect on LPV clearance compared to the basic model was observed. Therefore, the interaction 
model was not adopted in subsequent analysis. NONMEM control streams for individual and 




Table 13. Covariate Evaluation. 
RTV: ritonavir; AUC: area under the concentration-time curve; IC50: half maximum inhibitory 
concentration; AUC50: half maximum inhibitory AUC; AAG: Alpha 1-acid glycoprotein; BMI: body 
mass index; OFV: objective function value; : covariate coefficient; DF: degree of freedom  
* The model was compared to the one with gestational week on LPV CLu/F 
 
Parameters Covariate Function Form DF ΔOFV p value 
Lopinavir 
CLu/F Weight (WT/70)**0.75 0 7.677 - 
Vu/F Weight  WT/70 0 9.566 - 
CLu/F Study visit 1**VISIT1*2**VISIT2*3**VISIT3 3 -19.529 0.0002 
CLu/F RTV AUCs 1-AUCRTV/(AUCRTV+AUC50) 1 -6.153 0.013 
CLu/F RTV AUCs (AUCRTV/median(AUCRTV)** 1 -6.47 0.011 
CLu/F RTV AUCs 
exp*(*(AUCRTV-
median(AUCRTV)) 




exp(*WEEK) 1 -19.086 <0.0001 




1-*(ALBUMIN-median(ALBUMIN)) 1 0.067 - 
CLu/F RTV AUCs 1-AUCRTV/(AUCRTV+AUC50) 1 -3.83* 0.050 
CLu/F RTV AUCs (AUCRTV/median(AUCRTV)** 1 -3.82* 0.051 
CLu/F RTV AUCs 
exp*(*(AUCRTV-
median(AUCRTV)) 
1 -1.91* 0.17 
Ritonavir 
CLu/F Weight (WT/70)**0.75 0 -13.536 - 
Vu/F Weight WT/70 0 -6.066 - 
CLu/F Study visit 1**VISIT1*2**VISIT2*3**VISIT3 3 -30.696 <0.0001 
Vu/F Study visit 1**VISIT1*2**VISIT2*3**VISIT3 3 -9.199 0.0268 




exp(*WEEK) 1 -28.356 <0.0001 




1-*(albumin-median(albumin)) 1 -0.092 0.762 
fu BMI 1-*(BMI-median(BMI)) 1 7.883 - 
fu Race **RACE 1 -4.554 0.0328 




Table 14. LPV-RTV Interaction Model Selection. 
Model names: 
Basic model: LPV and RTV individual final models without interactions. 
1. AUCRTV maximum inhibition model 
2. AUCRTV power model 
3. AUCRTV exponential model 
4. CRTV maximum inhibition model 
5. CRTV power model 
6. CRTV exponential model 
7. CRTV exponential model without the pregnancy effect on LPV clearance 
LPV: lopinavir; RTV: ritonavir; AUCRTV: area under the ritonavir concentration-time curve; AUC50: 
half maximal inhibitory drug exposure (AUC); CRTV: ritonavir concentration; IC50: half maximal 
inhibitory concentration; coef: coefficient; IIV: inter-individual variability; OFV: objective function 
value. 
All the ritonavir concentrations and exposures are in terms of unbound ritonavir. AUCRTV,median is 
360 ng/(mL*h). CRTV,median is 28.8 ng/mL. 
Model 
Name 






Basic - -  - 0.0149 








-2.521 0.11 4.45E-4 0.0133 
4 1-CRTV/(CRTV+IC50) -3.185 0.074 188 ng/mL 0.0124 
5 (CRTV/CRTV,median)-coef -2.227 0.14 0.167 0.0133 
6 exp(-coef * (CRTV-CRTV,median)) -3.375 0.066 0.00277 0.0122 
7 exp(-coef * (CRTV-CRTV,median)) 12.927 - 0.00481 - 
 





The diagnostic plots for LPV and RTV (Figure 12) and individual goodness of fit plots 
(data not shown) showed that the observed data were fairly well predicted, with no obvious bias 
in the model. The visual predictive check demonstrated a good performance of the model in 
predicting both LPV and RTV (Figure 13) concentrations, with the observed percentiles well 




a-d: unbound lopinavir (LPV), e-h: total LPV, i-l: unbound ritonavir (RTV) and m-p: total 
RTV. From the left to the right are observation (DV) versus individual prediction (IPRED), 
observation verse population prediction (PRED), conditional weighted residual 
(CWRES) versus time and conditional weighted residual with interaction versus 
population prediction plots, respectively. The solid lines in the left two columns represent 
the lines of unity. The blue dashed lines are loess regression lines. The red dashed lines 
in right columns are loess regression lines of the absolute residual values. Values from 
different visits are denoted in different shapes.  





a-d: unbound lopinavir (LPV), e-h: total LPV, i-l: unbound ritonavir (RTV) and m-p: 
total RTV. The colored lines represent the prediction percentiles: red solid line for 
median and blue dashed lines for 5th and 95th percentile of prediction. The black lines 
represent the observation percentiles: solid line for median and dot-dash lines for 5th 
and 95th percentile of observation. The black dots represent the observation data. 
The colored shades are the 95% confidence intervals (CI) of the prediction 
percentile: red shades for 50% percentile and blue shades for 5th and 95th percentile. 











































































Figure 13. Visual Predictive Checks. 
57 
 
Simulated Unbound LPV Inhibitory Quotients (IQs) 
The unbound LPV IQs at 32 weeks gestation and postpartum, under three different dosing 
strategies are summarized in Table 15. The percentage of IQs showing effectiveness (>15) were 
calculated for each scenario. Overall, the percentage of effective IQs in the 3rd trimester were no 
greater than those in postpartum. With up to 4-fold increase in unbound IC50, over 90% of the 
simulated subjects were predicted to have effective IQs, and the difference between the 3rd 
trimester and postpartum was minimal. When unbound IC50 was increased 10-fold, the 
percentage of effective IQs significantly decreased to less than 50% in the 3rd trimester, with the 
standard dose of 400/100mg. With dose increased by 25% and 50%, this percentage could be 
brought up to 60% and 77%, respectively. Postpartum, the effect of increasing the dose was less 
than that in the 3rd trimester, with 89% - 98% effective IQs predicted. When unbound IC50 was 
increased 20-fold, less than 20% of the effective IQs were predicted for the 3rd trimester, 
regardless of an increase dose. For subjects in the postpartum period, increasing the dose could 
bring this percentage from 30% to 70%. When unbound IC50 increased 40-fold, 90% of more of 




Table 15. Simulated Inhibitory Quotients (IQs) at Different dosing Strategies at 32 Weeks 
of Gestation (3rd trimester) and Postpartum, at Five States of Viral Resistance. 
* Wild-type IC50: 0.69 ng/mL. 
IC50: half maximal inhibitory concentration; SD: standard deviation; %IQ>15 or %IQ<4 
represents the percentage of the simulated subjects with inhibitory quotients that is greater than 
15 or less than 4. 
Viral Resistance 
Pattern 
400/100mg Twice Daily 
Third Trimester Postpartum 
IQ (Mean±SD) %IQ<4 %IQ>15 IQ (Mean±SD) %IQ<4 %IQ>15 
Wild-type IC50 * 146.3 ± 60.4 0 100 257.9 ± 98.9 0 100 
4-fold IC50 increase 36.6 ± 15.1 0.1 95.4 64.5 ± 24.7 0 99.7 
10-fold IC50 increase 14.6 ± 6 0.5 40.9 25.8 ± 9.9 0.1 88.9 
20-fold IC50 increase 7.3 ± 3 11 1.9 12.9 ± 4.9 0.5 30.4 
40-fold IC50 increase 3.7 ± 1.5 64.1 0 6.4 ± 2.5 13.9 0.3 
Viral Resistance 
Pattern 
500/150mg Twice Daily 
Third Trimester Postpartum 
IQ (Mean±SD) %IQ<4 %IQ>15 IQ (Mean±SD) %IQ<4 %IQ>15 
Wild-type IC50 * 182.7 ± 79.3 0 100 321.7 ± 129.3 0 100 
4-fold IC50 increase 45.7 ± 19.8 0 98.7 80.4 ± 32.3 0 100 
10-fold IC50 increase 18.3 ± 7.9 0.1 59.8 32.2 ± 12.9 0 95 
20-fold IC50 increase 9.1 ± 4 5.4 8 16.1 ± 6.5 0.1 51.1 
40-fold IC50 increase 4.6 ± 2 44.6 0 8 ± 3.2 6.9 3.7 
Viral Resistance 
Pattern 
600/150mg Twice Daily 
Third Trimester Postpartum 
IQ (Mean±SD) %IQ<4 %IQ>15 IQ (Mean±SD) %IQ<4 %IQ>15 
Wild-type IC50 * 223.9 ± 93.6 0 100 394.2 ± 152.5 0 100 
4-fold IC50 increase 56 ± 23.4 0 99.7 98.6 ± 38.1 0 100 
10-fold IC50 increase 22.4 ± 9.4 0 77.3 39.4 ± 15.2 0 98.4 
20-fold IC50 increase 11.2 ± 4.7 1.6 18.3 19.7 ± 7.6 0 69.9 
40-fold IC50 increase 5.6 ± 2.3 27.1 0.3 9.9 ± 3.8 1.8 9.9 






A population pharmacokinetic model describing longitudinal PK and intrinsic unbound 
clearance of LPV and RTV in HIV-infected pregnant women was developed. Distinct from other 
analyses that have examined the pregnancy effect at a single point, this secondary analysis of 
the unbound and total LPV and RTV profiles from four study visits was able to quantify the 
trajectory of clearance changes for these two drugs during pregnancy and post-partum. The post 
hoc PK estimates showed that the LPV apparent intrinsic clearance increased by 61% at 32 
weeks of gestation compared to postpartum. The unbound fractions of neither LPV nor RTV were 
significantly affected by the physiological alterations of pregnancy, e.g. decreased AAG and 
albumin concentrations or increased BMI. Based on 1000 simulated subjects, the current 
standard LPV/RTV dose of 400/100 mg was predicted to produce effective unbound LPV IQs in 
over 90% of subjects with ≤4-fold increase in viral IC50, lending further support to the recent 
recommendations for maintaining Kaletra dosing at the standard dose in pregnancy134.  
           To our knowledge, this is the first model to use an exponential function to describe the 
longitudinal change of the apparent intrinsic clearance for LPV and RTV in pregnant women. The 
model indicates that gestational age has a more profound effect on the elimination of RTV than 
LPV, implying RTV is more sensitive to physiologic changes, including the alteration of metabolic 
enzyme activity148. The increase in CLu,LPV/F is 38%, 56% and 61% at 22 weeks, 30 weeks and 
32 weeks of gestation compared to post-partum in terms of the median post hoc PK estimates. 
Decreases in the drug bioavailability, increase in metabolic enzyme activity, or both could explain 
this increase, however, our model could not quantitatively differentiate the effect of these two 
factors due to lack of intravenous-administration PK or a direct assessment of metabolic activity.  
          It has been theorized that the decrease in AAG during pregnancy might result in increased 
unbound fraction51, but this assumption was made based on saturation of protein binding in 
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plasma. According to the protein binding analysis for each individual at each visit in this study, 
most of the subjects did not exhibit a noticeable saturation in protein binding, even with very high 
concentrations. Therefore, a linear protein binding model was sufficient to describe the unbound 
and total concentrations. The concentrations of AAG and albumin did not have a significant effect 
on the unbound fractions of either LPV or RTV in the covariate analysis. In vivo, even though 
binding to AAG is subject to capability limiting, albumin is unlikely to be saturated149, thus the 
subtle alteration in protein binding due to decreases in AAG and albumin concentrations might 
not be detected in this analysis, with limited sample size. The post hoc repeated measures 
ANOVA testing of the difference among the unbound AUC fractions across the four study visits 
showed no significant findings (p>0.05) for LPV and RTV, which is consistent with the results in 
the population PK analysis. 
The known interaction between LPV and RTV is not well characterized in this analysis. 
Neither unbound RTV AUCs nor its concentrations could further improve the LPV model while 
accounting for the gestational age effect. The interaction analysis in terms of AUC is consistent 
with insignificance of the post hoc unbound RTV AUCs in the covariate analysis. This is probably 
because the clinical study was not designed to detect the interaction, therefore the data are not 
ideal for quantifying this, given the small sample size and time-varying pharmacokinetics inherent 
in the study design. Nevertheless, our analysis reports an interaction coefficient of 0.0028, or 
0.00041 in terms of total RTV concentration, which is consistent with the interaction value of 
0.00064 reported by Wang et al150, using the same interaction function form.  
            Several studies (published in 2008-2013) have investigated the HIV-1 drug resistance in 
pregnant women, though with limited information on the prevalence of LPV resistance in HIV-
infected pregnant women receiving LPV-containing regimens. In Baroncelli et al’s study involving 
68 HIV-infected pregnancy women (week 26-38) mainly from Africa and Eastern Europe, one viral 
isolate sample out of 24 (4%) from patient receiving LPV/RTV (400/100 mg twice daily co-
administrated with two other NNRTIs) showed resistance to LPV151. Gingelmaier et al’s study 
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showed no clinically significant mutation to LPV in 33 women (mainly from Africa and German) in 
pregnancy receiving short-term (mean 29.5 weeks) fixed-dose LPV/RTV with two NNRTIs152. The 
OCTANE trial (745 women at 10 sites in seven African countries) reported a rate of 2.84% viral 
failure in HIV-infected pregnant women in the LPV/RTV arm with previous exposure to single-
dose nevirapine153. Van Dyke et al’s study comparing three regimens in 169 HIV-infected 
pregnant Thai women (28-38 weeks of gestation) receiving single-dose nevirapine showed that 
no major LPV resistance mutations in PI-based treatment arms (n=113)154. Souda et al’s study 
conducted in Botswana showed that eight out of 25 HIV-infected pregnant women (32%) receiving 
LPV/RTV/ZDV/3TC developed one or more protease mutations at 7 months postpartum after 1 
month of ART discontinuation, though those mutations were considered not to be clinically 
significant155. Vario et al reported a 76.1% prevalence of L89M (potentially related to resistance 
to fosamprenavir, and to a lesser extent to darunavir and lopinavir) in 97 treatment naïve HIV-
infected pregnant women from Tanzania, even though no major PI mutations were observed156.  
In summary of the above studies, the prevalence of viral resistance to LPV during 
pregnancy seems to be low; however, studies involving pregnant women usually have limited 
samples size. Moreover, resistance to LPV is shown to be more frequent when LPV/RTV is given 
to those have been treated with other PIs134. Therefore, the prevalence of treatment-experienced 
women with LPV-resisting virus might be more relevant to our study. No study has specifically 
investigate this for women; however, since gender does not seem to affect the LPV resistance 
mutation prevalence157, the prevalence of LPV resistance in the general population can be used 
as a reference. According to the Kaletra drug label, the prevalence of <10, 10 - 40, and ≥ 40 fold 
change in susceptibility at the baselines of three clinical studies involving PI-experienced subjects 
is 54%, 30% and 16%, respectively134. Based on these data, patients with ≥10 fold change in 
susceptibility account for 46% of the population, suggesting that LPV resistance is clinically 
relevant. The current analysis extends the perspective on the use of the standard dose in HIV-
infected women in the context of viral resistance. While the standard dose is sufficient for pregnant 
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women with susceptible virus, higher efficacy with increased doses is indicated with 10-fold 
increases in IC50. When IC50 increases by ≥20 fold, an alternative regimen to LPV/RTV should be 
considered for pregnant women, especially in the 3rd trimester.  
 While useful, this work does have some limitations. First, the viral susceptibility to LPV 
was not measured in these women, and thus this work is based on the literature and simulations 
and not clinical data. Additionally, the clinical data available to us did not include dosing at the 
600/150 mg regimen, and the population model was used to predict these concentrations. Our 
simulated total concentrations are consistent with the literature129,132, we believe this approach is 
reasonable. For the protein binding model, we assume that the protein binding behavior of LPV 
at this dose does not differ substantially from the observed behavior at the lower doses, supported 
by data that LPV protein binding is constant over a wide range of concentrations134. As with most 
studies in pregnancy, the sample size is small, potentially limiting model robustness and 
generalizability. These women, however, were intensively studied longitudinally, and contributed 
to one of the most comprehensive characterizations of LPV PK in pregnancy. 
Compared to using pre-pregnancy as the baseline, measuring PK profiles at post-partum 
as a control is more commonly seen due to feasibility of the clinical trial conduct. In this study, we 
assumed the drug exposures at 8 weeks postpartum as the “baseline” when modeling the PK 
trajectory as a function of gestational week, and we consider this is a reasonable procedure. The 
timing of using postpartum PK curves as the reference has been investigated in a European 
clinical pharmacology network (PANNA, the Pharmacokinetics of newly developed ANtiretroviral 
agents in HIV-infected pregNAnt women), where the trajectory of AUC and Cmax ratios during 
postpartum relative to the non-pregnant population means of several antiretroviral drugs (FTC, 
TFV, ATV/RTV, DRV/RTV, RAL and MVC) were described. Among the studied drugs, the PK 
properties of DRV/RTV are similar to those of LPV/RTV. It was shown that the postpartum PK 
parameters from at least 3 weeks post-delivery were not different from non-pregnant population 
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means158. For total LPV, our observed PK data at 8 weeks postpartum were comparable to those 
in non-pregnancy150.   
            In summary, this model-based approach extends and refines the previously reported PK 
results for LPV, and supports the standard dosing regimen of LPV/RTV in pregnancy. These 
results are consistent with the observations that despite lower plasma LPV concentrations in 











Chapter III: Evaluation of the Effect of Aging on Unbound Drug Disposition 
of Atazanavir/Ritonavir and Efavirenz: Highlighting Different Aging 




Aging may cause alterations relevant to antiretroviral pharmacokinetics. This study aimed 
to determine if chronologic age or markers of biologic aging, such as the frailty phenotype and 
p16INK4a gene expression, altered unbound pharmacokinetics (PKs) of efavirenz (EFV) and 
atazanavir/ritonavir (ATV/RTV). Sixty human immunodeficiency virus (HIV)-infected participants 
receiving EFV and thirty-one receiving ATV/RTV provided 1 to 11 samples to quantify total and 
unbound plasma concentrations. Population PK models with total and unbound concentrations 
simultaneously described were developed for each drug. The unbound fractions for EFV, ATV, 
and RTV were 0.65%, 5.67%, and 0.63%, respectively. Covariate analysis suggests RTV 
unbound PK was sensitive to body size. Pharmacogenetic analyses associated unbound ATV 
disposition with MRP4, RTV with P-gp and EFV with CYP2B6 and MRP4 genetic variants. 
Notably, p16INK4a expression, the cellular aging marker predicted EFV PK when genetic factors 
were adjusted. Both age and p16INK4a expression interacted with PGx on ATV disposition, implying 
potential dose adjustment based on aging may depend on genetic background. 
                                               
2 This chapter was taken from two articles previously published. The original citations are as 
follows: Dumond JB, Chen J, Cottrell ML, Trezza CR, Prince H, Sykes C, Torrice C, White N, 
Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A. Population Pharmacokinetics 
Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging 
Biomarkers. CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):128-135; Chen J, Akhtari FS, 
Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, Dumond JB. Pharmacogenetic Analysis of 
the Model-based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect 






As humans age, declines in renal and hepatic function are well‐described159. Less 
straightforward, however, are the impacts of these changes in physiology on drug metabolism, 
transport, and elimination. For drugs that undergo mainly renal elimination, dosing can be guided 
by changes in serum creatinine, an easily assessed marker of renal function. For drugs with 
hepatic elimination, the effects of aging on phase I and phase II metabolism and transport are not 
easily quantified in order to guide drug therapy. Potential changes in protein binding are not 
thought to be of major clinical significance in most cases160, but changes in the intrinsic clearance 
of unbound drug can further complicate pharmacotherapy in the elderly161. To probe potential 
changes in disposition, three ARVs used in two different regimens with key disposition 
characteristics (Table 16) were selected for study: efavirenz (EFV) and atazanavir/ritonavir 
(ATV/RTV; co‐administered with tenofovir and emtricitabine, reported separately). 
ATV (coadministered with RTV) was chosen to probe absorption, as its absorption 
requires an acidic gastric environment64, and older patients may have changes in gastric pH. As 
body water decreases with age, and body fat increases, lipophilic drugs display increased 
volumes of distribution162, whereas polar drugs display decreased volumes of distribution163. As 
ATV, RTV, and EFV are all lipophilic64,164,165, volume of distribution may increase with aging.  
Altered drug metabolism may occur with aging, as liver mass and blood flow decrease by 
20–50%, and cytochrome P450 enzyme metabolism may decrease up to 25%65,66,166,167. As laid 
out in Schoen et al.4, it is hypothesized that off‐setting changes in intrinsic clearance due to 
altered metabolism and unbound fraction of a drug highly bound to albumin could result in 
unchanged total oral clearance and similar total plasma concentrations in older patients, but with 
significant increases in unbound concentrations. EFV, ATV, and RTV are >99.5%165, 86%64  and 
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98–99%164 bound to plasma proteins, respectively. EFV is mainly bound to albumin, whereas ATV 
and RTV are mainly bound to alpha‐1 acid glycoprotein (AAG), and were chosen to test the 
hypothesis presented in the Schoen et al review4. Others have also proposed that for highly 
protein‐bound, capacity‐limited drugs, measuring total drug alone may mask important changes 
in intrinsic, unbound drug clearance in the elderly; this has been demonstrated for valproic acid, 
and suggested for phenytoin and diazepam161. 
 
Table 16. Pharmacokinetic Characteristics of the Studied Drugs.  
EFV: efavirenz; ATV: atazanavir; RTV: ritonavir; NNRTI: non-nucleoside reverse transcriptase 
inhibitor; PI: protease inhibitor; CYP: cytochrome P450 
 EFV ATV RTV 





Distribution  Lipophilic  
Protein Binding >99.5% 86% 98-99% 
Metabolism CYP2B6/CYP3A CYP3A CYP3A 
Excretion Minimally eliminated by kidney 
 
 
In addition, our studied drugs also serve as reasonable models for PGx-PK investigation, 
since their disposition profiles cover a broad spectrum of metabolic enzymes and drug 
transporters. ATV and RTV are CYP3A substrates64,164. Also, the upstream CYP3A expression 
regulator, pregnane X receptor (PXR), affects ATV clearance168,169. UGT1A is responsible for ATV 
glucuronidation, and is inhibited by ATV64. EFV has a complex metabolic profile which involves 
CYP2B, CYP2A, CYP3A, CYP1A and UGT165,170. It is also an inducer or inhibitor of CYP2B, 
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CYP3A and CYP2C165,170. Transporters in the gut, such as P-gp and MRPs, are presumably 
important globally to ARVs which are mostly orally administrated171. OATPs which are enriched 
in the liver could be relevant to ATV, RTV and EFV172. 
Gene polymorphisms play an important role in drug disposition and individualized therapy. 
Their roles in some special populations, such as pregnancy173 and pediatrics174, have been 
investigated. However, the PGx of ARVs in the older HIV-infected population has not been well 
studied. Gene polymorphisms can modify the effect of aging on PK, and evidence for such 
interactions has been demonstrated in some non-ARV drugs. For example, less profound 
changes in system clearance of omeprazole between younger and older patients were observed 
in CYP2C19 poor metabolizers than in extensive metabolizers175. This implies that dose 
adjustment in older patients might be less important given the dysfunctional CYP2C19 genotype. 
In another example, an 8-fold increase in the mean dose-adjusted plasma concentration of 
venlafaxine was seen in older compared to younger patients among the CYP2D6 poor 
metabolizers, but not in the other genotype groups175. This suggests that dose adjustment might 
be necessary in the presence of CYP2D6 dysfunction. This aging-PGx interaction can also be 
expected for ARV PK, though not adequately studied. Additionally, identification of influential gene 
polymorphisms can assist better statistical analysis of aging by reducing variability in PK. 
Syndromes of aging and the heterogeneity of the aging process itself can complicate the 
quantification of the effects of physiologic processes on PK in HIV-infected patients. The geriatric 
field has developed several means to capture this heterogeneity. Frailty is one surrogate of 
interest in this study. Significant decreases in drug clearance of 50% or greater have been 
demonstrated in the frail HIV‐negative elderly for acetaminophen76, metoclopramide176, and 
antipyrine177 compared with younger, healthier, HIV‐negative subjects. This increase in exposure 
is likely due to a combination of decreased renal clearance and cytokine‐induced downregulation 
of metabolic enzymes178. 
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Another surrogate is the p16INK4a tumor suppressor‐gene expression in peripheral blood T 
lymphocyte. This is a marker of cellular senescence that correlates with both chronologic age and 
inflammatory state, validated in both healthy volunteers80 and HIV‐infected patients81. In 
untreated, viremic HIV‐infected patients this correlation was not seen, suggesting that the 
inflammatory state induced by viremia alters p16INK4aexpression patterns. In treated patients with 
suppressed virus, p16INK4a expression were similar to uninfected controls and correlated with 
chronologic age, demonstrating that it can be used as a marker of cellular aging and senescence 
in this population. 
As HIV‐infected patients may develop frailty discordant from their chronological age, 
functional and biochemical surrogates of an aging immune system are critical to describe 
interactions between the aging process and ARV PK. Also, investigating aging in the context of 
PGx, or aging-PGx interaction is essential to provide precise treatment for older patients. Here, 
nonlinear mixed effects modeling, conjugated with other statistical approaches, was used to 
assess unbound drug PKs in HIV‐infected subjects ranging in age from 20 to 73 years who 






The detail of the study conduct has been describe in the previous publication179,180. Briefly, 
HIV-infected patients were enrolled from UNC HealthCare Infectious Diseases Clinic (Chapel Hill, 
NC) and the Cone Health Regional Center for Infectious Diseases (Greensboro, NC). All the 
subject received steady state tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) 300/200 mg 
with either efavirenz 600mg or atazanavir/ritonavir (ATV/RTV) 300/200 mg daily. Blood samples 
were collected either sparsely at four time points (pre-dose, and then 2 hours, 4-6 hours, and 10-
14 hours post-dose) or intensively at 11 time points for pharmacokinetic analysis (Figure 14). At 
one visit, subjects underwent frailty phenotyping and provided additional blood for 
pharmacogenomics, cytokine concentrations, and p16INK4a expression analysis. For intensive 
sampling group, frailty phenotyping was performed at screening, and cytokine and p16INK4a 
samples were not collected. The study protocol was approved by the Institutional Review Boards 
of both institutions (Clinicaltrials.gov NCT01180075).   
 
The arrows are the time course of one dosing interval, with the yellow bars representing 
the dosing time. 
Figure 14. Pharmacokinetic Sampling Scheme. 
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Measurement of Aging Surrogates 
Different measurements of aging in this analysis are shown in Figure 15. 
Frailty Phenotyping  
Frailty was evaluated using Fried frailty phenotyping181. The measurement consisted of 
questions regarding unintentional weight loss, perceived effort of daily living, grip strength, walk 
time for 15 feet, and the Minnesota Leisure Activity Questionnaire. Each component has defined 
cutoff values, and if a subject's result for a component falls into the range defined as frail, this is 
a positive component. Components are not weighted; the final result of this phenotyping is the 
sum of the positive components, and can range from 0–5. Frailty was defined as having three or 
more positive components of the phenotype; prefrail was defined as having one to two positive 
components; nonfrail was defined as having no positive components. Testing was conducted by 










Fried Frailty Phenotype 
p16
INKA4a
 is a cellular aging biomarker; the activation of this tumor 
suppression gene induces cell senescence. 
Figure 15. Different Measurements of Aging. 
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or older were enrolled in the intensive sampling group (i.e., only older, nonfrail subjects were 
included in this group).  
Cytokine Measurement 
Measurement of 39 cytokine concentrations was performed in the Duke Regional 
Biocontainment Laboratory (RBL) Immunology Unit (Durham, NC) using MILLIPLEX® MAP 
Human Cytokine/Chemokine Premixed 39 Plex bead-based assay kit (EMD Millipore Corporation, 
Billerica, Massachusetts). 
p16INK4a Expression 
The p16 expression was measured from whole blood using previously published validated 
PCR-based methods81. Briefly, Cellular RNA was extracted from isolated CD3+ cells. TaqMan 
qPCR (Applied Biosystems) was run with p16INK4A- and p14ARF-specific primers on total RNA, as 
well as a housekeeping transcript (18S). Expression of p14ARF, a related transcript from the cyclin-
dependent kinase inhibitor 2a (CKN2a) locus which correlates with p16INK4a expression (r2 >0.7), 
was measured contemporaneously to identify poor quality RNA. 
 
Drug Concentrations 
Total EFV, ATV, and RTV concentrations were analyzed using a validated liquid 
chromatography/ultraviolet detection method.182 Complete assay range for EFV was 10–10,000 
ng/mL, and 25–10,000 ng/mL for ATV and RTV, with inter‐ and intra‐day coefficient of variation 
(CV)% ranged from 2.3–8.3%. Unbound EFV, ATV, and RTV concentrations were analyzed using 
rapid equilibrium dialysis and liquid chromatography tandem mass spectrometry. Complete assay 
range for EFV was 0.25–5,000 ng/mL and 0.5–5,000 ng/mL for ATV and RTV. Overall assay 
precision and accuracy statistics met 15% acceptance criteria. All drug concentrations were 
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determined in the UNC Center for AIDS Research Clinical Pharmacology and Analytical 
Chemistry Laboratory. The laboratory participates in national and international proficiency testing 
of its methods, and consistently achieves >95% accuracy in this testing. 
 
Genotyping 
Genome DNA was extracted from whole blood using QIAamp DNA Blood Mini Kit 
(QIAGEN). Genotyping was conducted for selected metabolic enzymes and drug transporters 
using DMET Plus microarray (Affymetrix, CA). Samples with a call rate <95% were excluded from 
analysis. Single nucleotide polymorphisms (SNPs) were excluded if its minor allele frequency was 
<4% and its missing genotype was >30%. Deviations from expected proportions based on Hardy-
Weinberg equilibrium (exact test, α > 0.05) and linkage disequilibrium (R2 > 0.2) analysis were 
performed in PLINK 1.07183. 
 
Population Pharmacokinetic Analysis 
Population Pharmacokinetic Modeling  
 Population PK analyses of the drug concentration data were performed using NONMEM 
7.3 (ICON Development Solutions, Hanover, MD). Data management, graphical analysis and 
standard statistical analysis were conducted in R (version 3.1.0, r-project.org). Pirana (version 
2.9.2) was used for model management and NONMEM output visualization. The ADVAN13 
subroutine and stochastic approximation expectation maximization (SAEM) method were used 
for model development. For each drug, total and unbound concentrations were simultaneously 
described in one model, with the unbound concentration as the central compartment. The total 
drug concentrations were related to unbound drug with the unbound fraction, fu. 
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For basic model selection, one-compartment and two-compartment models were tested 
for each drug. First-order input with or without a lag time and a mixture model were tested for the 
absorption. The effects of body weight (WT) and body mass index (BMI) on apparent unbound 
clearance (CLu/F) and apparent volume of distribution of unbound drugs (Vu/F) were investigated 
as part of the structural model, using a power model and the empirical scaling factor, 0.75 and 1, 
respectively. WT was centered on 70kg and BMI on 30 kg/m2. Those effects which decreased the 
objective function value (OFV) by 3.84 (α = 0.05) were kept in the model. Inter-individual variability 
(IIV) and inter-occasional variability (IOV) were assumed to be normally distributed and 
exponentially related to the population parameters. Proportional, additive and combined 
proportional-additive error models were tested for residual variability, using the L2 data item to 
estimate correlation of this error for each drug. Model discrimination was determined by change 
in OFV, using the likelihood ratio test (α = 0.05), and diagnostic plots.  
Covariate evaluation  
The relationships of chronological age, p16INK4a expression, gender, race, WT, BMI, the 
extent of frailty and cytokines concentrations with PK parameter estimates were explored by 
graphical and standard statistical analysis. Continuous covariates were tested using correlation 
analysis and categorical variables using Wilcoxon rank sum tests (α = 0.05). Potential covariates 
were determined by their physiological possibilities and their relationships with the post hoc IIV 
estimates. Covariate analysis was performed using forward addition/backward elimination (α = 
0.05/0.01). Besides the original continuous value, BMI was also converted to 0 or 1 split by 30 
kg/m2. Categorical variables were incorporated using an exponential model, as shown below: 
 =  0  ×  1
𝐶𝑂𝑉1 × 2
𝐶𝑂𝑉2 × … × 𝑖
𝐶𝑂𝑉𝑖                                                             (Eqn 18) 
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Where 0 is the population parameter of the reference population, 𝑖 is the fold change of 
parameter in the ith category from the reference, COV is the covariate of interest, and COVi is 
assigned to 1 when the observation is within the ith category and otherwise 0. 
Continuous variables were examined with proportional linear model (Eqn i), power model 
(Eqn ii) or exponential model (Eqn iii), as shown below. 
 =  1 × [1 + 2 × (𝐶𝑂𝑉 − 𝑚𝑒𝑑𝑖𝑎𝑛(𝐶𝑂𝑉)]                   (Eqn 19) 
 =  1 × [
𝐶𝑂𝑉
𝑚𝑒𝑑𝑖𝑎𝑛(𝐶𝑂𝑉)
]2                                   (Eqn 20) 
 =  1 × 𝑒
2 ×[𝐶𝑂𝑉−𝑚𝑒𝑑𝑖𝑎𝑛(𝐶𝑂𝑉)]                                  (Eqn 21) 
Where  is the population PK parameter, 1 is the parameter of the population with the median 
COV value, and 2 is the covariate effect coefficient. Missing continuous covariates were imputed 
with the median value of observed data, and missing categorical covariates were imputed as 0. 
Model validation  
The goodness of fit of all models was evaluated by observation versus individual prediction 
(IPRED) and population prediction (PRED) plots, and normalized prediction distribution errors 
(NPDE) plots. Visual predictive checks (VPCs) were constructed with 1000 simulations using the 
final parameter estimates to examine the prediction performance of the models, using the 
prediction-corrected VPCs generated by Perl-Speaks-NONMEM (PsN)184. Bootstrap estimates 
were obtained from 500 replicates generated by repeated random sampling of the original dataset 






Outliers were determined using the residual plots from the final model. Observations 
yielding a |CWRES| > 6 were considered as outliers and were excluded.  
Pharmacogenetic Analyses and Aging-PGx Interaction 
The phenotypes of this analysis were the Bayesian post hoc PK parameter estimates obtained 
from the above final models. A candidate gene approach was used to perform this analysis. The 
candidate genes were chosen if shown to be relevant to studied drug disposition pathways. 
Variables were log-transformed to achieve normality when appropriate.  
Linear Regression without Interaction 
In the univariate analysis, the association analysis between genotypes and PK parameters 
was conducted using one-way ANOVA. Then, SNPs with a nominally significant P value were 
included in multivariate analysis, using the stepwise selection procedure in both forward and 
backward directions. Model selection was based on Akaike Information Criteria (AIC). Covariates 
of interest included chronological age, p16INK4a expression level, race, sex and BMI. Missing 
genotypes were imputed using IMPUTE2 with the 1000 Genomes Phase 3 panel185,186. For race, 
patients that were other, unknown and non-reported races were grouped as one category 
(“Others”) due to low counts. These statistical analyses were performed using R (ver 3.2, R-
project.org). A P value less than 0.05 was considered statistically significant. The significant 
associations were re-evaluated in the population PK models.  
Aging and Pharmacogenetics Interaction 
To investigate the interaction between aging and gene polymorphism, distinct linear 
regression models (R function lm(), package stats v3.4.0, www.r-project.org)187 were used to 
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determine if there is an effect on drug clearance due to the interaction between (1) chronological 
age and gene polymorphisms (SNPs), and (2) between p16INK4a expression and gene 
polymorphisms. An F-test (R function anova(), package stats v3.4.0)187 was used to compare the 
model without interaction effects to the one with interaction effects. Only significant predictors 
from the best fitting model were retained in the final model, with the cutoff for significance being 
p<0.05 for each predictor. The factors involved in each interaction effect were always included in 
the model, Multiple testing correction was performed across all drugs using the Benjamini-
Hochberg method with a false discovery rate of q < 0.1 (R function p.adjust(), package stats 
v3.4.0)187. 
In order to determine variable interactions and variable importance of all available 
variables, Random Forest ensemble method (R function randomForest (ntree=5000), package 
randomForest v4.6-12)188 was used with the PK parameter as the response, after removing all 
incomplete cases. The workflow of Random Forest ensemble method is shown is Figure 16. The 
percent increase in mean squared error (MSE) was used to determine the three most important 






Data set to grow the single 
trees 
Out-of-Bag (OOB) 
Data to estimate the error 
of the grown tree 
Factor Selection 
Random selection of predictors 
Grow Tree 
Split data using the best 
predictors 
Estimate OOB Error 












as collection of all trees 
This figure is adapted from Derek Kane, Data Science Lecture Series, Part V – Decision Tree 
and Random Forest. 
Figure 16. Workflow of Random Forest Ensemble Method. 
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Investigation of the Effects of SNPs on Protein Function 
The effects of significant SNPs on corresponding proteins were evaluated based on 
literature and database (e.g. dbSNP, PharmGKB) searching. SIFT and PolyPhen algorithms were 
used to make prediction on the influence on protein function for SNPs with no information 
currently. If still no information available, those SNPs in linkage disequilibrium with r2>0.8 were 
also investigated. Protein function prediction was conducted using SNPnexus189–191. Linked SNPs 







For EFV, sixty subjects provided data for this analysis; 54 were sparsely sampled, and 6 
provided intensive sampling. For ATV/RTV, 31 subjects provided data; 25 were sparsely sampled, 
and 6 provided intensive sampling. In addition to these drugs, all subjects also received TDF/FTC 
300/200mg by mouth once daily. Participant demographics by regimen are presented in Table 
17; demographics of the intensively sampled participants have been previously reported70. The 
median age in the EFV participants was 48 years, 18 were female, 8 demonstrated pre-frailty, 
and 2 were frail. For the ATV/RTV participants, the median age was 49 years, 12 were female, 9 





Table 17. Patient Characteristics.  
EFV: efavirenz; ATV: atazanavir; RTV: ritonavir 
Continuous data are presented as median (range); Categorical data are presented as count 
(percentage).  
Baseline Characteristics EFV Arm (n=60) ATV/RTV Arm (n=31) 
Age (years) 48 (22~73) 49 (24~61) 
Race 
Caucasian 22 (36.7%) 10 (32.3%) 
African American 34 (56.7%) 19 (61.3%) 
Others 4 (6.6%) 2 (6.4%) 
Sex 
Female 18 (30%) 12 (37.7%) 
Male 42 (70%) 19 (62.3%) 
Duration with HIV (years) 10.5 (1~31) 10 (1~24) 
Duration on Current Regimen 
(years) 
5 (1~10) 4 (1~8) 
CD4+ T-cell count (cells/mm3)  662 (10 – 1724) 629 (375~1051) 
HIV RNA <50 copies/mL 60/60 (100%) 30/31(97%) 







Model schematics for each drug are presented in Figure 17. No concentrations below the 
limits of quantification (BLQ) were measured for total drug; for unbound ATV, one sample was 
BLQ, and for unbound RTV, 9% of the samples were BLQ; half the lower limit of quantification 
was imputed as the concentration value. For EFV, one sample did not have sufficient volume for 
unbound analysis, and the same was true for five RTV samples; these concentrations were 
considered missing. The PK of unbound EFV was described using a two-compartment model with 
a first-order absorption phase. A lag time was not justified for EFV absorption, based on the 
change in objective function value (OFV). The PK of unbound ATV was described using a two-
compartment model, following first-order absorption with a lag time. For RTV, a one-compartment 
model was sufficient, and the absorption phase was described using a first-order process with lag 
time. Empirical inclusion of the effects of body weight on apparent unbound clearance (CLu/F) 
and apparent volume of distribution (Vu/F) was significant for RTV, but not for ATV or EFV. For 
ATV and RTV, due to mostly sparse sampling and a substantial variability in the absorption phase, 
the parameter estimates of the absorption rate constant (ka) and the lag time (Tlag) were less 
precise than others, with the relative standard error (RSE) >30%. Inter-occasion variability (IOV) 
was incorporated on CLu/F for the three drugs. The PK parameters of EFV were more precisely 
estimated compared to ATV and RTV given a larger sample size. All the total and unbound 
concentrations of the three drugs were included in the PK modeling analysis, with no outliers 






Xa: amount in the absorption compartment; Ka: first-order rate constant; Tlag: lag time 
in absorption; C: concentration, CL: clearance; V: volume of distribution; Q: inter-
compartmental clearance; Vp: peripheral volume of distribution; fu: unbound fraction; u: 
unbound drug. Gray shaded region represents the peripheral compartment for 
efavirenz and atazanavir. 
Figure 17. Model Structure. 
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Table 18. Atazanavir (ATV) Population Pharmacokinetic Parameter Estimates. 
CLu/F: apparent intrinsic clearance; CL/F: apparent total clearance; Vu/F: apparent unbound 
volume of distribution; V/F: apparent volume of distribution; Ka: first-order absorption rate 
constant; fu: unbound fraction; Qu/F: apparent inter-compartmental clearance of unbound drug; 
Q/F: apparent inter-compartmental clearance of total drug; Vp,u/F: apparent unbound peripheral 
volume of distribution; Vp/F: apparent peripheral volume of distribution; CI: confidence interval, 
RSE: relative standard error; CV: coefficient of variance 
a CL/F = CLu/F * fu, 
b V/F = Vu/F * fu, 
c Q/F = Qu/F * fu, 
d Vp/F = Vp,u/F * fu  
Parameter (Unit) Estimates (RSE%) 
Bootstrap Estimates 
(95% CI) 
CLu/F (L/h) 101 (2) 
105 
(79.0, 142) 
CL/F a (L/h) 5.73 - 
Vu/F (L) 1110 (3) 
1090 
(778, 1620) 
V/F b (L) 62.9 - 
Ka (h-1) 0.705 (42) 
0.623 
(0.452, 0.885) 
Lag Time (h) 0.529 (36) 
0.577 
(0.165, 1.10) 





/F (L/h) 134 (1) 
137 
(91.4, 183) 
Q/F c (L/h) 7.61 - 




d (L/h) 129 - 
Inter-Individual Variability (CV%) [Shrinkage] 
CLu/F 37.0 (1) [8%] 35.1 (26.4, 44.0) 
Vu/F  44.3 (1) [14%] 42.3 (31.0, 72.0) 
Ka 34.6 (1) [11%] 35.0 (20.0, 54.5) 
Lag Time 80.6 (8) [19%] 14.2 
(9.1, 18.5) 
fu 13.5 (4) [7%] 77.0 (58.6, 104) 
Qu/F 22.7 (14) [23%] 20.1 (3.82, 54.6) 
Vp,u/F 22.6 (13.0) [30%] 19.8 (3.84, 54.0) 
Inter-Occasion Variability (CV%) 
CLu/F 73.9 (66) 69.2 (39.4, 100) 
Residual Error (CV%) 
Total  27.6 (10) 27.8 
(23.8, 32.4) 




Table 19. Ritonavir (RTV) Population Pharmacokinetic Parameter Estimates. 
CLu/F: apparent intrinsic clearance; CL/F: apparent total clearance; Vu/F: apparent unbound 
volume of distribution; V/F: apparent volume of distribution; Ka: first-order absorption rate 
constant; fu: unbound fraction; CI: confidence interval, RSE: relative standard error; CV: 
coefficient of variance. a CL/F = CLu/F * fu, 
b V/F = Vu/F * fu,  
e fu = fu,pop * COEFBMICAT, where fu,pop represents population estimate of unbound fraction with BMI 
≥30 kg/m2, COEF is the covariate coefficient, BMICAT presents the BMI category with BMI≥30 
kg/m2 classified as 0 and BMI<30 kg/m2 as 1. 
* Population parameter estimates of subjects with body weight of 70 kg.  
Parameter (Unit) Estimates (RSE%) 
Bootstrap Estimates  
(95% CI) 
CLu/F (L/h) 772 * (3) 749 
(566, 962) 
CL/F a (L/h) 4.85 * - 
Vu/F (L) 8430 * (2) 8100 
(5380, 10900) 
V/F b (L) 52.9 * - 
Ka (h-1) 1.59 (32) 1.61 
(1.19, 2.47) 
Lag Time (h) 0.604 (51) 0.678 
(0.323, 0.873) 
fu (%) 0.628 (1) 
0.667 
(0.551, 0.782) 
Influence of BMI<30 on fu 
e 1.52 (1) 1.51 
(1.22, 2.00) 
Inter-Individual Variability (CV%) [Shrinkage] 
CLu/F 36.6 (3) [4%] 37.1 
(20.4, 54.4) 
Vu/F  75.4 (25) [2%] 80.8 
(50.8, 108) 
Ka 64 (17) [27%] 68.8 
(26.7, 137) 
Lag Time 120 (10) [24%] 128 
(68.6, 165) 
fu 26.2 (17) [14%] 23.3 
(11.2, 34.6) 
Qu/F 22.7 (14) [23%] 20.1 
(3.82, 54.6) 
Vp,u/F 22.6 (13.0) [30%] 19.8 
(3.84, 54.0) 
Inter-Occasion Variability (CV%)  
CLu/F 60.5 (55) 58.0 
(32.8, 87.1) 
Residual Error (CV%) 
Total  41.4 (20) 45.5 
(35.3, 56.0) 





Table 20. Efavirenz (EFV) Population Pharmacokinetic Parameter Estimates. 
CLu/F: apparent intrinsic clearance; CL/F: apparent total clearance; Vu/F: apparent unbound 
volume of distribution; V/F: apparent volume of distribution; Ka: first-order absorption rate 
constant; fu: unbound fraction; Qu/F: apparent inter-compartmental clearance of unbound drug; 
Q/F: apparent inter-compartmental clearance of total drug; Vp,u/F: apparent unbound peripheral 
volume of distribution; Vp/F: apparent peripheral volume of distribution; CI: confidence interval, 
RSE: relative standard error; CV: coefficient of variance 
a CL/F = CLu/F * fu, 
b V/F = Vu/F * fu, 
c Q/F = Qu/F * fu, 
d Vp/F = Vp,u/F * fu  
EFV 
Parameter (Unit) Estimates (RSE%) 
Bootstrap Estimates 
(95% CI) 
CLu/F (L/h) 1060 (1) 
1200  
(982,1410) 
CL/F a (L/h) 6.93 - 
Vu/F (L) 19900 (1) 
20700 
(14800, 29700) 
V/F b (L) 130 - 
Ka (h-1) 0.463 (5) 
0.517 
(0.382, 0.653) 





/F (L/h) 5940 (2) 
3980 
(2370, 7940) 
Q/F c (L/h) 38.8 - 




d (L/h) 159 - 
Inter-Individual Variability (CV%) [Shrinkage] 
CLu/F 29.1 (1) [19%] 33.7 
(6.91, 51.9) 
Vu/F  68.6 (1) [19%] 47.1 
(3.98, 103) 
Ka 15.9 (3) [18%] 19.0 
(3.12, 67.4) 
fu 17.5 (14) [14%] 16.2 
(9.54, 22.4) 
Qu/F 49.4 (8) [21%] 43.8 
(6.66, 143) 
Vp,u/F 31.9 (2) [19%] 17.7 
(3.47, 45.7) 
Inter-Occasion Variability (CV%) 
CLu/F 42.4 (36) 
44.0 
(22.7, 60.1) 
Residual Error (CV%) 
Total  24.2 (10) 
24.9 
(19.8, 30.8) 







The exploratory analysis of post-hoc estimates from the base models and covariates of 
interest showed relatively evident associations (P < 0.05) between sex and RTV fu, BMI and RTV 
fu, but not other parameter-covariate pairs (P > 0.05). Since the study was powered on aging-
related factors, and CLu/F and fu were the parameters of most interest, covariate-parameter pairs 
involving chronological age, p16INK4a expression, frailty phenotype and scores, CLu/F and fu were 
further tested, along with the two pairs mentioned above. Forward addition/backward elimination 
analysis supported the significant covariate effect of BMI on RTV fu, either using BMI as a 
continuous or categorical variable. Using BMI as a categorical variable gave a more stable model 
in terms of parameter estimates, and was thus retained. Sex was not significant after the 
incorporation of BMI as a covariate. No other significant covariate effects of the other parameter-
covariate pairs were found.  
Model Validation 
The diagnostic plots of ATV, RTV and EFV indicated that the model predictions correlated 
with the observations well, and there was no apparent bias in the models (Figures 18a-j, 19a-j, 
20a-j). The visual predictive checks of the three drugs (Figure 21a-c) demonstrated good 
performance of the models in predicting both total and unbound concentrations, with the predicted 
percentiles and corresponding 95% confidence intervals reasonably capturing the observed 
percentiles. Some overlap between prediction intervals near the end of the dosing interval are 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(a–c) Efavirenz (EFV), atazanavir (ATV), and ritonavir (RTV) prediction‐
corrected visual predictive checks for total (left) and unbound (right) drug. For 
each graph, time since the last dose in hours is on the x axis, with 
concentrations on the y axis. The black dots represent observed data. 
Percentiles of observations are presented in black, with solid lines for 50th 
percentiles and dotted lines for 5th and 95th percentiles. The 50th percentiles 
of predictions are presented in red solid lines, with 95% confidence intervals in 
red shaded areas. The 5th and 95th percentiles of predictions are presented in 
blue dotted lines, with 95% confidence intervals in blue shaded areas. 
Figure 21. Prediction-Corrected Visual Predictive Checks. 
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Pharmacogenetic Analyses and Aging-PGx Interaction 
Patients Consented for PGx Analyses.  
In ninety-one patients enrolled in this clinical study, seventy-four consented the genetic 
tests; 25 were in the ATV/RTV arm and 49 in the EFV arm. The median age of the 74 patients 
was 48 years. 61% of the patients were African American and 52% were male. Three patients 
demonstrated the Fried frailty phenotype. The characteristics between the two treatment arms 
were not significantly different. The studied PK parameters included apparent unbound drug 
clearance (CLu/F) of ATV, RTV and EFV. In total, twenty-two genes were selected for 
investigation. Patient demographics, PK parameters and studied genes and SNPs are 





Table 21. Overview of Demographics of Studied Population and the Pharmacokinetics and 
Pharmacogenetics of the Studied Drugs.  
ATV: atazanavir, RTV: ritonavir, EFV: efavirenz, CrCL: creatinine clearance, SNP: single 
nucleotide polymorphism, PK: pharmacokinetics, CLu/F: apparent unbound drug clearance, CL/F: 
apparent clearance, F: undetermined bioavailability. Clearance is in Liter/hour (L/h). 
* The expression of p16INK4a is presented as logarithm (base 2) of gene expression. Continuous 
variables are in median (range). Categorical variables are in count (percentage). 
 ATV RTV EFV 
No. of Subjects 25 49 
Age (years) 49 (24, 61) 48 (22, 73) 
Race 
African American 15 (60%) 30 (61%) 
Caucasian 8 (32%) 16 (33%) 
Others 2 (8%) 3 (6%) 
Sex 
Female 10 (40%) 12 (24%) 
Male 15 (60%) 37 (76%) 
CrCL (L/h) 96.6 (66.8, 228) 112 (43.3, 200) 
BMI (kg/m2) 29.8 (20.2, 40.4) 27.1 (17.6, 44.3) 
Frailty 
Status 
Non-frail 16 (64%) 37 (76%) 
pre-frail 8 (32%) 10 (20%) 
frail 1 (4%) 2 (4%) 
p16INK4a Expression* 2.20 (0.158, 3.91) 1.92 (-1.14, 2.81) 
PK Parameters and Medians 
(Ranges) 




CLu/F: 1010  
(417, 3280) 




































Linear Regression Analyses with Interaction.  
The P values for univariate analysis are shown in Table 22. In total, twenty-one SNPs 
were found to be significantly associated with the PK parameters (P <0.05). Associations between 
demographics and PK parameters were consistent with the previous population PK analysis that 
BMI was significantly associated with RTV clearance. 
In the multiple linear regression, ABCC4_c.*879T>C (rs1059751) was associated with 
increased ATV CLu/F, with no demographics being statistically significant. Decreased RTV CLu/F 
was associated with the mutation at ABCB1_c.3435 (rs1045642). BMI remained significant with 
RTV CLu/F. In addition, race was found to be predictive of RTV CLu/F; African Americans had 
significantly lower apparent clearance of RTV than the other population. Decreased EFV CLu/F 
was related to variants CYP2B6*6_15631G>T (rs3745274), ABCC4_c.3348A>G/Del (rs1751034) 
and ABCC4_c.*38T>G (rs3742106). Notably, after adjusting for the effects of these SNPs, 
p16INK4a expression was found to be significantly associated with EFV CLu/F. A doubling of 
p16INK4a expression was shown to be related to 315 L/h (31% of the median) decrease in EFV 
unbound CLu/F. Results from the multiple linear regression are summarized in Table 23. SNP 
basic information, genotype frequency, effects on phenotypes and SNP function are summarized 
in Table 24-25.  
Since the significance level was more stringent in the population model compared to the 
linear regression model, the association for ATV CLu/F was not present in the covariate analysis 
in the population model. Also, the built-in covariate effects of body weight on RTV CLu/F and Vu/F 
in the population model masked the effect of body size in the linear regression model, and also 
affected the evaluation of other factors. However, all the significant associations of EFV were 





Table 22. P Values in the Univariate Analysis. 
ATV: atazanavir, RTV: ritonavir, EFV: efavirenz, CLu/F: apparent unbound drug clearance, F: 
undetermined bioavailability, BMI: body mass index, SNP: single nucleotide polymorphism.  
* p<0.05, ** p< 0.01, *** p<0.001 
Factors ATV CLu/F RTV CLu/F EFV CLu/F 
Age 0.74 0.64 0.55 
p16INK4a 
Expression 
0.2 0.43 0.57 
Race 0.4 0.95 0.22 
BMI 0.66 0.025* 0.64 
Sex 0.1 0.75 0.07 
Frailty 
Status 


























Table 23. Stepwise Linear Regression Analysis. 
ATV: atazanavir, RTV: ritonavir, EFV: efavirenz, CLu/F: apparent unbound drug clearance, 
CL/F: apparent clearance, F: undetermined bioavailability, BMI: body mass index  
“.” p>0.05, * p<0.05, ** p<0.01, *** p<0.001,  
ǂreference race: African American; “Others” includes other races, unknown races and non-
reported races.  
Note: Only factors that are retained in the final linear regression model are showed in this table. 
Drug clearance is modeled on the log scale. The expression of p16 INK4a is presented as logarithm 




Factor P value 
Effect Size 
(L/h) 
ATV CLu/F ABCC4_c.*879T>C (MRP4) 0.040 * 151.4 
RTV CLu/F 
ABCB1_c.3435C>T (P-gp) <0.001 *** -855.6 
BMI <0.001 *** 70.21 
Caucasianǂ 0.0027 ** 603.1 
Othersǂ 0.0036 ** 756.9 
EFV CLu/F 
CYP2B6*6_15631G>T (CYP2B6) <0.001 *** -710.2 
ABCC4_c.3348A>G/Del (MRP4) 0.0020 ** -768.7 
ABCC4_c.*38T>G (MRP4) <0.001 *** -845.8 





Table 24. Summary of Significant SNPs in Univariate Analysis of Atazanavir (ATV) and 
Ritonavir (RTV). 
 CLu/F: apparent unbound drug clearance, F: undetermined bioavailability; c.: chromosome 
number. 
 
Studied Drug ATV 




c. 13 12 
Base Change 879T>C 571T>C 
Function 3'-UTR L191L 
Genotype 
Frequency 
T/T+T/C: 23 (92%) 
C/C: 2 (8%) 
T/T+T/C: 21 (84%) 
C/C: 4 (16%) 










Decreased efflux from liver to system - 
Studied Drug RTV 
dbSNP RS rs1045642 rs2069514 rs4803418 
Associated 
Gene/Protein 
ABCB1/P-gp CYP1A2/CYP1A2 CYP2B6/CYP2B6 
c. 7 15 19 
Base Change 3435C>T -3860G>A 14593C>G 
Function I1145I Promoter Intronic 
Genotype 
Frequency 
C/C: 14 (56%) 
C/T+T/T: 11 (44%) 
G/G+G/A: 22 (88%) 
A/A: 3 (12%) 
C/C: 19 (76%) 
C/G: 6 (24%) 







*1C, increased function 
Physiological 
reasonable? 
Y Y Y 
Physiological 
reason 




Table 25. Summary of Significant SNPs in Univariate Analysis of Efavirenz (EFV). 
CLu/F: apparent unbound drug clearance, F: undetermined bioavailability; c.: chromosome 
number. 
Studied Drug EFV 













c. 19 19 13 13 13 
Base Change 15631G>T 18053A>G 3348A>G/Del 311G>A 38T>G 























G/G: 3 (6%) 




































Table 26. Re-evaluation of the Effect of Aging in the Efavirenz (EFV) Population PK Model 
with Pharmacogenetic Factors. 
EFV: efavirenz, CLu/F: apparent unbound drug clearance, OFV: objective function value, IIV: 
inter-individual variability, CV: coefficient of variance. All the parameter-covariate relationships 
are coded in a linear function. The differences of OFV and IIV are based on the previous models 
where the associations with a smaller P value in the univariate analysis are included.       
EFV Model CLu/F (L/h) Coefficient △OFV △IIV(CLu) (CV%) 
Reference 1110 -- 0 0 
+ CYP2B6*6 1230 0.484 -17.17 -19.4 
+ ABCC4_c.*38T>G 1330 0.423 -10.88 -3.1 
+ ABCC4_c.3348A>G/Del 1310 0.582 -7.16 +12.9 
+ p16INK4a expression 1360 0.251 -13.02 -3.6 
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Interaction Analysis.  
To analyze interactions, two distinct linear regression models were used to determine if 
there is an interaction effect between (1) chronological age and genetic polymorphisms, and (2) 
between p16INK4a expression and genetic polymorphisms. Most of the significant SNPs in the 
previous multiple linear regression were confirmed in this analysis which was without other 
demographic variables (Table 27). Notably, we found significant evidence of the interaction 
effects of age and ABCC4_c.*879T>C (rs1059751) with ATV CLu/F. This effect was also found in 
the model with p16INK4a expression.  
In addition to the analysis with traditional statistical approaches, machine learning analysis 
was performed to evaluate the variable interactions and the overall importance of each variables 
with the PK parameters. While the Random Forest method did not find consistent interactions, 
variable importance was determined. The three most important predictors for ATV CLu/F were 
ABCC4_c.*879T>C (rs1059751), SLCO1B1_c.571T>C, (rs4149057) and sex. For RTV CLu/F, 
they were ABCB1_c.3435C>T (rs1045642), CYP1A2*1C_-3860G>A (rs2069514) and BMI. For 
EFV CLu/F, the three most important variables were CYP2B6*6_15631G>T (rs3745274), 
ABCC4_c.3348A>G/Del (rs1751034) and ABCC4_c. 311G>A (rs4148551). The three most 






Table 27. Aging-PGx Interaction-Focused Linear Regression Analysis. 
p-values, q-values and effect sizes shown from interaction models contain gene polymorphisms 
(SNPs) and age as factors or SNPs and p16INK4a expression as factors. Only factors that are 
significant after a multiple testing correction at the false discovery rate of q < 0.1 are shown. Drug 
clearance is modeled on the log scale for drug EFV. The expression of p16INK4a is presented as 





Factor p-value q-value Effect Size 
ATV CLu/F 
Age 
ABCC4_c.*879T>C 3.60E-02 4.02E-02 -1.33E+03 











Factor p-value q-value Effect Size 
RTV CLu/F 
Age 
ABCB1_c.3435C>T 3.47E-03 7.32E-03 -6.29E+02 
CYP2B6*1C_14593C>G 5.75E-03 1.03E-02 6.83E+02 
p16 INK4a 
expression 
ABCB1_c.3435C>T 1.63E-03 6.18E-03 -6.99E+02 





Factor p-value q-value Effect Size 
EFV CLu/F 
Age 
CYP2B6*6_15631G>T 3.77E-04 1.19E-03 -6.92E-01 
ABCC4_c.*38T>G 4.77E-04 1.29E-03 -8.73E-01 
ABCC4_c.3348A>G/Del 2.58E-02 3.06E-02 -4.94E-01 
p16 INK4a 
expression 
p16 INK4a expression 6.60E-03 1.27E-02 -2.41E-01 
CYP2B6*6_15631G>T 3.04E-04 1.44E-03 -6.86E-01 
ABCC4_c.*38T>G 2.48E-04 1.44E-03 -8.66E-01 






Table 28. Top Three Predictors for Drug Pharmacokinetics in the Random Forest Analysis. 
ATV: atazanavir, RTV: ritonavir, EFV: efavirenz, BMI: body mass index, CLu/F: apparent 
unbound drug clearance, F: undetermined bioavailability. 
Drug clearance is modeled on the log scale for drug EFV. The expression of p16 INK4a is 
presented as logarithm (base 2) of gene expression. Protein names related to the genes are 
presented in the parentheses.  
 



















In this study, we investigated the effects of aging and gene polymorphisms on the key PK 
parameters of three antiretrovirals in HIV‐infected subjects of a broad range of chronologic age. 
Our study shed lights on the significant effect of the cellular aging biomarker, p16INK4a, on unbound 
efavirenz disposition. In addition, the results from the interaction analysis brought to light 
interactions between genotype and aging (both chronological and cellular p16INK4a expression). 
The multiple analyses methods used reinforced several of our findings. 
Our analysis showed that increased apparent clearance of unbound ATV was associated 
with ABCC4_c.*879T>C. ATV is highly metabolized in the liver; this variant might lead to 
decreased efflux193 of ATV out of the hepatic cells, thus increased ATV metabolism due to 
accumulation. This mutation was associated with 20% increase in CLu/F compared to the 
population median value, however, the corresponding median unbound trough concentration 
calculated from the predicted median value in our studied patients (48.0 ng/mL) was still well 
beyond the unbound IC50 (~1.7 ng/mL)64,194, suggesting dose adjustment might not be needed. 
There was a nominal association with rs4149057 in SLCO1B1, the gene that also showed 
marginal significance in a GWAS study of ATV PK195. Possibly due to limited sample size, our 
study was not able to detect the UGT1A1 genotype, such as UGT1A1 *28, as a significant 
predictor of ATV PK.   
The pharmacogenetics profile of RTV was poorly studied. In our analysis, we found that 
ABCB1_c.3435C>T was significantly associated with decreased CLu/F, as previously reported196. 
RTV is a substrate of P-pg164; the presence of variant might increase the bioavailability of RTV, 
thus decrease CLu/F. In the univariate analysis, CYP1A2*1C_-3860G>A (CYP1A2 *1C, 
decreased protein function197) was associated with decreased RTV CLu/F, while 
CYP2B6_14593C>G (CYP2B6 *1C, conflicting protein function5,198) showed the opposite effect. 
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Additionally, we found that race played a role, with African Americans showing lower RTV 
clearance than other races. In our studied population, there was no association between race and 
the three SNPs mentioned above (data not shown), implying that race might predict RTV CLu/F 
independent of these three SNPs, but dependent on other genetic factors. BMI was a significant 
predictor and was associated with higher RTV CLu/F in our analysis. In the base population PK 
model selection, the effects of body weight on RTV unbound clearance and volume of distribution 
of unbound were justified according to the objective function value, whereas this was not seen in 
the co‐administrated protease inhibitor, ATV. This phenomenon was also observed on the 
unbound PK of RTV co‐administrated with lopinavir in pregnancy48. In addition, the covariate 
analysis reveals the unbound fraction of RTV is 52% higher in participants with BMI <30 kg/m2, 
or 34% lower with BMI >30 kg/m2, implying participants who are moderately obese might have 
higher RTV protein binding. In the ATV/RTV group, female participants had a higher median BMI 
than the male participants, and both participants with BMI >40 were female. In this analysis, RTV 
protein binding was shown to be sensitive to BMI, but not ATV or EFV; in the PK literature, the 
relationship between obesity and protein binding has not been clearly delineated, although it is 
postulated that alpha‐1-acid glycoprotein concentrations, to which RTV binds, are increased in 
obesity199–201. This may also be a function of sex differences, as BMI and sex are linked, and our 
sample size is moderate. Although the three frail participants had BMI values <30 kg/m2, no 
relationship between frailty and BMI was observed. Our finding suggests that the drug disposition 
of RTV is influenced by various factors in a mixed manner, which may explain the large RTV PK 
variability observed in patients. The effect sizes of the significant associations were associated 
with 30-45% increase or decrease in the median CLu/F, which may affect the magnitude of the 
inhibitory effect on ATV clearance, however, this was not able to be evaluated in the current 
analysis since the ATV-RTV interaction was not detected.  
Our study found no associations between age-related factors and the PK of ATV nor RTV. 
This is consistent with a previous analysis of associations of exposures with age, frailty 
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phenotype, and p16INK4a expression. In a noncompartmental analysis of ATV/RTV PK in Thai 
patients with HIV, age >42 years was found to be significantly associated with increased ATV and 
RTV area under the curve and peak plasma concentration (Cmax), however, the median age in this 
study was 42 years and the oldest subject was 57 years old. In the present work, 36% of ATV/RTV 
participants were 50 years of age or older, with the oldest subject 61, with no total and unbound 
clearance altered here. 
For EFV, our analyses are able to replicate the previously demonstrated effect of 
CYP2B6*6_15631G>T (rs3745274) on decreased clearance. In addition, we found 
ABCC4_c.3348A>G and ABCC4_c.*311G>A, which both contribute to decreased MRP4 
function202–204, were associated with decreased EFV CLu/F. The mechanism behind this 
relationship is not known. MRP4 is an efflux transporter distributed in the intestine, liver, kidney, 
brain, lymphocytes and other tissues, and two possible explanations may account for this. The 
first explanation could be that the MRP4 dysfunction in the intestine results in an increase in 
bioavailability, and thus the decreased CLu/F203. The second explanation could be that the 
dysfunction of MRP4 in the kidney leads to the decreased secretion of drugs to the urine, and 
thus the decrease in CLu/F. However, EFV is extensively metabolized in the liver, and nearly all 
the urine excretion component was in the form of metabolites165, suggesting that the renal 
elimination of EFV as the parent drug is limited. Thus, the first possible explanation is more likely, 
and will require further study to confirm.     
Interestingly, after accounting for these SNPs, we found that decreased EFV CLu/F was 
significantly related to higher p16INK4a expression, suggesting that elimination of EFV is associated 
with cellular aging. This result is consistent with our hypothesis that elimination ability decreases 
with aging. The underlying mechanism still needs to be elucidated, however, a previous study has 
shown that the expression of CYP2B6 was negatively regulated through a cyclin-dependent 
kinase 2 (CDK2) signaling pathway involving p16INK4a in a hepatic carcinoma cell line, HepG2205. 
Our analysis shows that EFV CLu/F decreases by 31% of the median with two-fold increase in 
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p16INK4a expression, which can increase the median maximum total EFV concentration beyond 
the upper limit of the therapeutic window (4000 ng/mL206). Therefore, dose reduction in patients 
with higher level of p16INK4a expression should be considered, especially with the present of the 
significant SNPs with even large effect sizes in decreasing EFV CLu/F. Further analysis with larger 
sample size is needed to validate this finding and inform the potential application of this biomarker 
to dosing guidance in older HIV-infected patients.  
In the interaction analyses using linear regression models, we see a significant effect of 
interaction between aging (both chronological age and p16INK4a expression) and gene 
polymorphism on ATV CLu/F. However, we only had two individuals with the ABCC4 variant in 
the ATV arm, limiting the power of the current study. The other demographic variables were not 
included in the linear regression models, due to the small sample size. Hence, we performed 
Random Forest analysis that included all the available variables. Random Forest has been shown 
to have improved power over regression approaches to detect interactions in genetic association 
studies207. However, due to the large number of predictors as compared to the limited sample 
size, the interaction effects of aging and gene polymorphism may have been suppressed by 
stronger effects of the other predictors involved in the Random Forest analysis. 
Our study has some limitations. The small sample size, especially of the ATV/RTV 
treatment arm, has limited our conclusions. We might have ruled out some important SNPs 
because of the low allele frequency. The low numbers of participants also compromise the 
statistical power of our analysis. Particularly, we lack participants with the frailty phenotype, 
limiting the conclusions regarding changes in unbound clearance and protein binding; because 
participants were asked to provide four samples over one to two dosing intervals, some selection 
bias for frail participants is inherent. Also, due to the large number of factors as compared to the 
limited sample size, we conducted the interaction analysis only involving aging (both chronological 
and cellular) and genetic factors, which may have led to the exclusion of the interaction of other 
demographic factors with the genetic factors. The interaction analyses are also limited by very 
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few individuals carrying the minor allele for the SNPs studied; however, the estimated effect sizes 
should be used to motivate well powered follow up studies to confirm genetic factors as potential 
PK predictors. Because participants were enrolled at steady state, a thorough assessment of the 
central nervous system effects of EFV and their interaction with aging, where patients may be 
more susceptible to cognitive decline, was not able to be done.  
Nevertheless, our study has several advantages. In this analysis, we take the advantage 
of both nonlinear mixed-effects modeling methods for PK data analysis and standard statistical 
methods for PGx analyses. The phenotypes are the PK parameters derived from the population 
PK models, therefore we have performed our analysis based on a set of more precise PK 
parameters, which could partially compensate the limitation of the small sample size. Using 
multiple well-established statistical analysis for subsequent analyses involving PGx, we can 
accommodate large numbers of SNPs relative to the sample size with the interaction among 
multiple factors investigated. Additionally, we explored the SNPs in a gene-wide level owing to 
the DMET array platform, which maximizes the chance to identify relevant SNPs/genes, though 
our results need to be further validated. We found the associations of several SNPs with ARVs 
PK that have not been reported before, which may point to interesting hypotheses that need to 
be investigated in future studies. Moreover, we evaluated the interaction between aging and SNPs 
in predicting ARV PK, using both the chronological and cellular aging. The significant interactions 
between aging and the genetic factors were seen for both chronological age and p16INK4a 
expression. Since we were specifically interested in the PGx-aging interactions, we performed 
targeted analyses using only those predictors in the linear regression models to evaluate their 
interactions. To overcome the exclusion of other demographic factors from the interaction 
analyses, we used the Random Forest method to determine variable importance which 
highlighted several demographic factors as important predictors of ARV PK. This attempt, though 
based on a small sample size, is able to provide directions for further investigations on gene-
based individualized therapy for the elderly in the HIV field.  
106 
 
In summary, our study provides innovative perspectives on the effect of aging on ARVs 
PK, highlighting the importance of the cellular aging biomarker, p16INK4a, in predicting the ARV 
drug disposition and the potential alterations in aging-PK relations by PGx. The investigations add 
knowledge to the current PGx of ARVs, demonstrating the importance and potential of accounting 
for pharmacogenetics in PK analysis, and facilitate further studies with focus on precision 
treatments, especially those contain drugs with similar disposition profiles with our studied ARVs, 








Chapter IV: Exploratory Analyses of Aging Effects on CD4+ T-Cell Recovery 




 Older age may be a risk factor for suboptimal CD4+ T-cell recovery in HIV-infected 
patients despite of successful viral suppression. In this chapter, we established a semi-
mechanistic model describing longitudinal CD4+ T-cell recovery at a population level, using CD4+ 
T-cell count and immune biomarker data from 122 participants from the AIDS Clinical Trials Group 
and Emory Clinic Division of Infectious Disease. CD4+ naïve and memory T-cells were described 
simultaneously. The production of naïve T-cells was parameterized using a zero-order process, 
and the conversion from naïve to memory T-cells was described using a first-order process. The 
apparent elimination of both cell types was best described by a cell density-dependent process. 
Covariate analysis in the population model showed that older age was significantly associated 
with faster apparent elimination rate of the naïve T-cells. In addition, female sex predicted slower 
apparent elimination rate of memory T-cells. Simulation showed that the median maximal CD4+ 
T-cell counts on ART treatment was 593 cells/µL (IQR 442-794) in patients aged 50 years or 
above and 738 cells/µL (IQR 548-1002) in patient aged 18-35 years. The differences in the 
percentage of subjects achieving sufficient immune reconstitution (CD4+ T-cell count>500 
cells/µL) between the two groups were 15%, 21% and 26% at year 1, 4 years and steady state, 
respectively, suggesting that advanced age may have a greater impact on long-term CD4+ T-cell 
recovery. Linear regression analysis of post hoc CD4+ T-cell dynamic parameters showed that 
immune exhaustion (defined by PD-1+/TIM-3+) was significantly associated with the rate constant 
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of naïve T-cells acquiring a memory phenotype (P = 0.022). The association between thymus 
output (defined by CD31+) and T-cell production rate was close to the margin of statistical 





Older HIV-infected patients can achieve viral suppression similar to younger ones under 
ART82. In terms of immunological response, a negative effect on CD4+ T-cell recovery in older 
patients was reported, although a few studies found similar immunological outcomes in older and 
younger HIV-infected patients. Table 29 summarizes five studies with inconsistent findings. 
These studies were selected because of their relatively large sample sizes of studied patients and 
long follow-up period208–212. 
 






The Effect of Age 
Kaufmann et al, 
JAMA, 2003 208 
2235 4 years 
Older age (>40 years) ↓ CD4+ T-cell 
change by 39 cells/µl over 48 months 
Moore et al, CID, 
2007 209 
655 6 years 
Older age (>45 years) ↓ CD4+ cell 
change by 60 cells/µl over 6 years 
Li et al, JAIDS, 2011 
210 
614 men 5 – 12 years 
Older age (≥50 years) ↓ CD4+ T-cell 
counts by 59 cells/µl over 5-12 years 
Greenbaum, AIDS, 
2008 211 
906 4 years 
Nonsignificant difference in time to 
increase by 50 cells/µL or mean 
increase in CD4+ T-cells from baseline 
between >50 years vs. <40 years 
Wright et al, HIV 
medicine, 2013 212 
3378 ≥ 5 years 
Nonsignificant difference in CD4+ T-cell 
increase rate in >50 years vs. others 
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Inconsistency in study design and data analyses exists in the above studies, such as the 
selection on the primary endpoints of CD4+ T-cell recovery and different age stratification, which 
may explain the controversial findings. As mentioned in the introduction, since aging may 
influence CD4+ T-cell recovery through different mechanisms and sometimes in an opposite 
direction, the overall effect of aging may be masked. Additionally, age-related factors present in 
chronic HIV infection, such as immune activation and immune exhaustion, could be potential 
confounders in these analyses, as they were also reported to be influential factors of impaired 
CD4+ T-cell recovery111,112,115. However, in the past studies, these factors were separately 
studied, and therefore the interactions among these factors were not evaluated.  
Mathematical modeling approaches are particularly useful in describing longitudinal data, 
relating the dynamics of CD4+ T-cells to the rates of physiological processes. Therefore, the 
evaluation of the relevant factors on the process of interest is possible. Several models have been 
proposed to describe CD4+ T-cell recovery in HIV-infected patients on ART, as summarized in 
Figure 22. Some use a simple exponential function to describe longitudinal CD4+ T-cell 
dynamics, in terms of either total CD4+ T-cells or CD4+ T-cell percentage213,214 (Figure 22a). This 
model is the most basic CD4+ T-cell recovery model, but lacks insights of various CD4+ T-cell 
subtypes. Figure 22b shows the CD4+ T-cell dynamics in a joint viral and T-cell dynamic model 
in HIV infection or PKPD of ART proposed by Perelson et al. The original model describes non-
infected and infected T-cells215. Extensions of this model can also include compartments for 
latently, persistently and defectively infected T-cells216. These models provide a mechanistic 
framework for investigations of PK-PD analysis of ARVs, however, while they perform well in 
describing the dynamic states in a short term, they do address not the long-term T-cell 
homeostasis. Also, not all the parameters of these models are able to be estimated precisely 
when fitted to the data, and they rely on values from the literatures where a different scenario or 
population was studied. Mechanistic models describe the system more physiologically and 
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therefore are easier to be extrapolated. Two types of models have been proposed to study the 
mechanisms of T-cell homeostasis during HIV infection and after ART. One type of model consists 
of two cell populations, resting cells and activated cells217,218 (Figure 22c). Resting cells can 
become activated cells where they can proliferate, die or switch back to resting cells. Cell labeling 
methods using such as deuterated glucose217 and bromodeoxyuridine218 are used to estimate 
dynamic parameters, and therefore, these values can only reflect the status of the time of 
experiment. The two cell populations in the other type of model include naïve and memory T-
cells219 (Figure 22d). This type of model is usually used to investigate the dynamics of thymus 
output and proliferation of naïve T-cells, and the parameters are estimated from thymus output 
(defined by T-cell receptor excision circles, or TRECs) and cell proliferation (defined by Ki67+) 
biomarker data in short-term HIV infection or ARV treatment109,220,221. These two types of models 
are usually complex for the purpose of parameter estimation using clinical data. They also lack a 
description of variability, therefore, the analysis of influential factors in these models are difficult.   
The measurements of CD4+ T-cell counts are highly variable. In retrospective cohort 
studies, the follow-up period also widely varies for each patient. When immune biomarkers come 
into play, the sparsity in the measurement of these markers relative to the intensive total CD4+ 
T-cell data could add to the complexity of the analysis. Nonlinear mixed-effect modeling provides 
a solution for these challenges by accommodating flexible data collection and sparse sampling8. 
It also evaluates difference sources of variability efficiently in one analysis8. In this work, we 
hypothesize that using nonlinear mixed-effect modeling approaches will allow for a better 
appreciation of the role of aging on CD4+ T-cell recovery in HIV-infected patients on effective 
ART. We aim to establish a semi-mechanistic model describing longitudinal CD4+ T-cell recovery 
at a population level and investigate the effect of aging with adjustment of multiple immunological 





a) Simple exponential model of total CD4+ T-cells. T: total T-cell measurement, int: initial CD4+ 
T-cell measurement, asy: asymptotic or long-term CD4+ T-cell measurement on treatment, c: 
cell elimination rate constant, ln(2)/c: time to achieve half asymptotic CD4+ T-cell measurement. 
b) Joint viral and T-cell dynamic model in HIV infection. T
UI
: uninfected T-cells, T*: infected T-
cells, V: infectious HIV virons, λ: production rate of uninfected T-cells, d: death rate constant of 
uninfected T-cells, k: viral infection rate constant, δ: death rate constant of infected T-cells, ρ: 
new viron production rate constant, cl: viron clearance rate constant. c) and d) Mechanistic 
models of T-cell homeostasis. R: resting T-cells, A: activated T-cells, a: activation rate constant, 
r: rate constant of reversion to resting state, π: resting cells proliferation rate constant, d: death 
rate constant, p: proliferation rate constant, N: naïve T-cells, M: memory T-cells, σ:  naïve T-cell 
production rate.  





Studied Population and Data 
The data for this analysis were obtained from two sources, the AIDS Clinical Trials Group 
Protocol 5321 (ACTG P5321) and the Bone Loss and Immune Reconstitution (BLIR) study 
conducted at Emory University.  
The ACTG P5321 is a longitudinal cohort study which investigates the differences and 
changes in HIV reservoirs over time. Participant enrollment and data collections were described 
in the original publication222. Briefly, participants in this cohort were treatment-naïve and were on 
continuous ART during follow-up. All the participants had undetectable plasma HIV-1 RNA levels 
(<50 copies/mL) at 48 weeks of ART and at all subsequent time points. T-cell HIV-1 levels, T-cell 
activation, T-cell subtype and inflammatory biomarkers were available in the paired plasma or 
peripheral blood mononuclear cell (PBMC) samples obtained before ART and at year 1, 4 and 6-
15 on treatment. Total CD4+ T-cell counts were collected every 8-16 weeks during the follow-up. 
The data usage for the current analysis was approved by both ACTG and the UNC Biomedical 
Institutional Review Board after an exempt review. Data retrieved included the following: 
1. Longitudinal total CD4+ and CD8+ T-cell counts,  
2. Immune biomarkers: CD4+ T-cell subtype (%CD45RA), CD4+ and CD8+ T-cell immune 
activation (%CD38+/HLA-DR+) before ART and at year 1, 4 and 6-15 on treatment (depending 
on the availability), 
3. Initial ART regimens: NNRTI-based (FTC/TDF/EFV, 3TC/ZDV/EFV, ABC/3TC/EFV, 
ABC/3TC/ZDV/EFV), PI-based (ABC/3TC/RTV/ATV, FTC/TDF/RTV/ATV, FTC/TDF/RTV/DRV), 
INSTI-based (FTC/TDF/RAL) or others (3TC/ZDV/EFV/NFV, EFV/RTV/LPV)  
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4. Pre-treatment characteristics: age, BMI, race/ethnicity, sex, plasma HIV-1 RNA level, 
prior smoking history (yes/no), co-infection with HBV or HCV (positive/negative). 
The BLIR study is a prospective, randomized trial aiming to investigate the association 
between ART-associated bone loss and immune reconstitution. All participants received 
ARV/RTV 300/100 mg +TDF/TFC 300/200 mg once daily for HIV treatment. Paired plasma and 
PBMC samples were collected for skeletal and immune profiling at pre-defined time points from 
week 0 to 144 on treatment. Biomarkers defining T-cell subtype, thymus output, immune 
activation and immune exhaustion were measured at week 0, 12, 36 and 48 on treatment. Total 
CD4+ T-cell counts were measured every 4-24 weeks. The original study was approved by the 
Emory University Institutional Review Board (NCT01228318). The data usage for the current 
analysis was approved by both the collaborators and the UNC Biomedical Institutional Review 
Board after an exempt review. Data retrieved included the following: 
1. Longitudinal total CD4+ T-cell counts and HIV viral load at week 0,4, 16, 24, 36, 48, 72, 
96, 120 and 144, 
2. Immune biomarkers: thymus output (%CD31+), CD4+ T-cell subtype (%CD45RA), 
CD4+ and CD8+ T-cell immune activation (%CD38+/HLA-DR+), CD4+ and CD8+ T-cell immune 
exhaustion (%PD-1+/TM-3+), 
3. Demographics: age, gender ethnicity, race, smoking status (ever smoked, prior or 
current, cigarettes per day, years smoked), weight, height, BMI  
Nonlinear Mixed-Effects Modeling 
NLME modeling of the CD4+ T-cell count data was performed using NONMEM 7.4 (ICON 
Development Solutions, Hanover, MD). Data management, graphical analysis, post-NLME 
analysis and standard statistical analysis were conducted in R (version 3.4.3, r-project.org). 
Pirana (version 2.9.2) was used for model management and NONMEM output visualization. The 
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ADVAN6 subroutine and first-order conditional estimation with interaction (FOCE-I) method were 
used for model development. 
Immune Biomarker Handling 
Naïve CD4+ T-cell count was calculated by multiplying %CD45RA+ of CD4+ T-cells and 
total CD4+ T-cell count at the corresponding time point. Memory CD4+ T-cell count was described 
as the difference between total and naïve CD4+ T-cell count. The levels of thymus output, immune 
activation and immune exhaustion were evaluated as %CD31+, %CD38+/HLA-DR+ and %PD-
1+/TIM-3+, respectively. Thymus output was measured for CD4+ T-cells. Immune activation and 
immune exhaustion were measured for CD4+ and CD8+ T-cells.    
Structural Model Establishment  
The model framework was based on the model proposed by Hanzenberg et al to describe 
the establishment of the CD4+ T-cell pool in children, both healthy and with HIV infection. The 
model consists of two cell populations, naïve and memory CD4+ T-cells. The thymus output 
contributes to the naïve T-cell production. The increase of naïve T-cell pool also depends on naïve 
T-cell proliferation. The expansion of memory T-cell pool is a result of the activation of naïve T-
cells and the proliferation of memory T-cells. Both naïve and memory T-cells undergo cell death 
which decreases the T-cell pool size. The model illustration is shown in Figure 23. 
The structural model was initially developed using the ACTG data due to its relatively 
larger sample size and longer study period. A zero-order process was used to describe the naïve 
T-cell production from thymus output. The proliferation process was tested with a first-order and 
a capability-limited process. The capability-limited rate constant was parametrized as below:  
𝒑 = 𝒑𝟎 (𝟏 + 𝒏 𝒉⁄ )⁄                   (Eqn 22) 
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where p denotes the proliferation rate constant, p0 denotes the maximum proliferation rate 
constant, n denotes the cell number and h denotes the cell number at half maximum proliferation 
rate constant. 
The cell activation and elimination was tested with a first-order and a cell density-
dependent process. The cell density-dependent elimination rate was linear associated with the 




Inter-individual variability (IIV) was assumed to be normally distributed and exponentially 
related to the population parameters. Proportional, additive and combined proportional-additive 
error models were tested for residual variability. The correlation between the residual error of total 
N: naïve T-cell pool size, M: memory T-cell pool size, σ: Thymus production of naïve T-cells, 
α: activation of naïve T-cells that acquire a memory phenotype, dN: naïve  T-cell death, dM: 
memory T-cell death, pN: naïve T-cell proliferation, p0N: maximum proliferation of naïve T-cells, 
p0M: maximum proliferation of memory T-cells, h: pool size at half maximum proliferation; r: 





















Clonal size (r) 
Thymus 
Proliferation Proliferation 
Thymus output Activation 
Figure 23. Cartoon Illustration of the Establishment of the CD4+ T-Cell Pool. 
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and naïve T-cells was explored. Model discrimination was determined by change in OFV, using 
the likelihood ratio test (α = 0.05), diagnostic plots and precision of parameter estimates.  
The structural model developed from ACTG data was used to fit the combined dataset 
from the two studies. The data fitting for the BLIR study was examined by individual fit and regular 
diagnostic plots.   
Covariate Analysis 
Covariate candidates included chronological age, gender, race, BMI, smoking status, pre-
ART viral load, initial ART class, initial ART regimes, co-infection of HBV or HCV and levels of 
immune activation. Immune activation data, presented as percent CD38+/HLA-DR+ on T-cells, 
were log-transformed to achieve normality and stabilize the covariate model. Pre-selection of 
parameter-covariate relations were based on biologic plausibility, previous reports and the 
general additive modeling (GAM) analysis performed on the model-predicted parameters. GAM 
was performed using R package Xpose4 (version 4.5.3, Sourceforge). Model discrimination of 
GAM was based on Akaike Information Criteria (AIC). Covariate analyses in the non-linear mixed-
effects model were conducted using the SCM procedure in PsN (version 4.6.0). The significant 
levels for forward addition and backward elimination were 0.05 and 0.01, respectively.  
For BLIR data, candidate covariates also included levels of thymus output and immune 
exhaustion. Due to the small portion of subjects from BLIR study in the combined data (16%), the 
covariate analysis of these two factors was performed on the post hoc estimates derived from the 
final model from the SCM analysis, using linear regression methods. The effect of age was re-
evaluated. A P < 0.05 was defined as statistical significant. 
Simulations of the Effect of Age on Immune Recovery 
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Simulations of total T-cell counts in three age groups, <35 years, 35-<50 years and ≥50 
years, were performed at year 0, 0.5, 1, 2, 4 and at steady state after ART. Reaching the CD4+ 
T-cell recovery steady state was determined as the difference between the CD4+ T-cell counts at 
two consecutive years less than 1% of the former simulated cell count. The age of 50 years was 
the documented definition of “older” patients in the field of HIV treatment, and the cut-off of 35 
years was chosen based on the equality of subjects in both groups in the studied population. For 
each age group, 100 simulated subjects aged within the corresponding intervals were created. All 
the characteristics of the simulated subjects were randomly sampled from the distribution of those 
of the studied population. Simulations were conducted 200 times. The percentages of simulated 
CD4+ T-cell counts reaching 500 cells/µL were calculated. Total CD4+ T-cell counts greater than 
500 cells/µL was chosen as an indication for sufficient immune reconstitution in HIV-infected 
patient on treatment223.     
Standard Statistical Analysis 
Comparisons of continuous and categorical demographic variables were performed 
using Wilcoxon-Mann-Whitney test and Fisher’s exact test, respectively in R (version 3.4.3, r-
project.org). 
   
Results 
Studied Participant Characteristics and Available Data 
In total, the current analysis included data from 102 participants from the ACTG study and 
20 participants in the BLIR study. The studied subjects had a median age of 39 years at treatment 
initiation, with a range of 18-64 years. 80% of the subjects were male. CD4+ T-cell baseline was 
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256 cells/µL in median. Subjects from the BLIR study had significantly lower baseline CD4+ T-
cell counts compared to those from ACTG (P < 0.0001). The BLIR study had more past/current 
smokers than ACTG (P = 0.014). Patient characteristics are summarized in Table 30. 
Table 30. Demographics of Studied Populations. 
ACTG: AIDS Clinical Trials Group, BLIR: Bone Loss and Immune Reconstitution, BMI: body mass 
index, HBV: hepatitis B virus; HCV: hepatitis C virus. Continuous variables are presented as 








Age (years) 39 (18 – 64) 37 (30 – 51) 39 (18 – 64) 
Sex 
Female 21 (21%) 3 (15%) 24 (20%) 








19 (19%) 14 (70%) 33 (27%) 
Hispanic 30 (29%) 1 (5%) 31 (25%) 
Other 2 (2%) 0 2 (2%) 




Yes 52 (51%) 16 (80%) 68 (56%) 
No 50 (49%) 4 (20%) 54 (44%) 
CD4+ T-cell Count (cells/mm³) 288 (8 – 980) 72.5 (3 – 268) 256 (3 – 980) 
Viral load (log₁₀RNA/mL) 4.61 (2.28 – 5.99) 5.3 (2.15 – 6.14) 4.67 (2.15 – 6.14) 
Regimen 
NNRTI + NRTI 42 (41%) 0 42 (34) 
PI + NRTI 39 (38%) 20 (100%) 59 (48%) 
RAL + NRTI 19 (19%) 0 19 (16%) 
Other 2 (2%) 0 2 (2) 
HBV 
Infection 
Positive  1 (1%) - - 
Negative 101 (99%) - - 
HCV 
Infection 
Positive  3 (3%) - - 
Negative 99 (97%) - - 
120 
 
The data available for the current analysis contained 2581 and 175 total CD4+ T-cell 
counts from ACTG and BLIR study, respectively. T-cell subtype biomarker, CD45RA, were 
available in 340 and 80 samples for the computation of naïve T-cell counts in ACTG and BLIR 
study, respectively. 364 CD38/HLA-DR measurements on CD4+ and CD8+ T-cells were available 
in the ACTG study. The BLIR study provided the following biomarker measurements: 81 CD31, 
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ACTG 5321 Study 























CD4+ T-cell counts versus time profiles from different participants are presented in different 
colors. Red lines represent the median CD4+ T-cell counts profiles. 
Figure 24. CD4+ T-Cell Trajectory in Participants from ACTG and BLIR Study. 
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PD-1/TIM-3 measurements on CD8+ T-cells. CD4+ T-cell counts and biomarker versus time 
profiles are presented in Figure 24 and 25, respectively.  
Basic CD4+ T-Cell Recovery Model 
The schematic of the structural model and the differential equations are shown in Figure 
26. Naïve and total T-cell counts were simultaneously analyzed in the structural model, which 
consisted of naïve and memory T-cell compartment. The total CD4+ T-cell count was the sum of 
naïve and memory CD4+ T-cell count. The production of naïve T-cells was described using a 
Different participants are presented in different colors. Immune biomarkers are presented as 
expression percentage on immune cells. Blue and red lines represent the median percentage of 
immune biomarker expression on CD4+ and CD8+ T-cells, respectively. 




zero-order process (σ). The conversion of naïve to memory T-cells was described using a first-
order process (α). The proliferation process was not able to be separated from the elimination 
process, and therefore combined to the elimination term. The cell density dependent process best 
described cell elimination (dN • N for naïve T-cell and dM • M for memory T-cell). The baselines of 
naïve (baselineN) and memory (baselineM) T-cells were estimated.  
 
 
Except for σ and IIV(dN), the parameter estimates using all the data (Model II) were 
comparable to those using the ACTG data only (Model I). The lower σ in Model I was likely due 
to the lower naïve T-cell baseline in the combined data, according to previous analysis224. The 
difference in IIV(dN) in model I and II might due to the change in the structure of variance matrix, 
where in model I, IIV(dN) was correlated with IIV(σ) and IIV(α), but not in Model II. The additive 














dN / dt = σ − α ∙ N − d
N
 ∙ N ∙ N 
dM / dt = α ∙ N − d
M
 ∙ M ∙ M 
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells that 
acquire a memory phenotype, dN: naïve T-cell death rate constant, dM: memory T-cell 
death rate constant, N: naïve T-cell number, M: memory T-cell number.  
Figure 26. Structural Model Schematic. 
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with high RSE% (>100) and didn’t improve model fit in terms of OFV, while they significantly 
improve the model fit when describing the BLIR data. Therefore, the additive residual errors were 
added in Model II for data from the BLIR study. Regardless of these differences, Model II 
described the both the ACTG and BLIR data well, as evaluated by the diagnostic plots and 
individual model fit, and thus was used for the sequential analysis. For Model II, the IIVs were on 
all parameters, with correlations between the IIVs of σ and α. All these parameters were precisely 
estimated with RSE% <30. The individual parameters were highly variable, leading to large CV% 
of IIV, however, these IIVs were precisely estimates with RSE% <15. The shrinkage of all IIVs 
was reasonably low, indicating the properness of using the current structural model for the further 
covariate analysis. The residual errors were best described by a proportional model for the ACTG 
data, and by a combined model for the BLIR data. The parameter estimates of the structural 
model, comparing the ACTG and the combined data, are summarized in Table 31. According to 
the diagnostic plots of stratified by age (Figure 27), there was no obvious bias in the model across 
different age groups. The histograms showed that the IIVs of the parameters did not significantly 




Table 31. Parameter Estimates of the Structural Model using ACTG and Combined Data. 
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells that acquire a 
memory phenotype, dN: naïve T-cell death rate constant, dM: memory T-cell death rate constant, 
baselineN: naïve T-cell count at ART initial, baselineM: memory T-cell count at ART initial, CV: 
coefficient of variance, RSE: relative standard error.  
Parameter (Units) 
Estimates (RSE%) 
Model I (ACTG Data) 
(n=102) 
Model II (Combined Data) 
(n=122) 
σ [(cell/µL)*year-1] 1050 (16) 720 (18) 
dN (year*cell/µL)-1 0.0554 (23) 0.0403 (25) 
dM (year*cell/µL)-1 0.000358 (14) 0.000365 (14) 
α (year-1) 0.885 (16) 1.08 (14) 
baselineN (cell/µL) 33 (18) 25.7 (21) 
baselineM (cell/µL) 172 (14) 150 (10) 
Inter-individual variability (CV%) [Shrinkage%]  
σ 111 (9) [24] 117 (7) [7.9] 
dN 140 (13) [26] 70.9 (14) [37] 
dM 60.8 (14) [31] 64.0 (13) [37] 
α 123 (13) [5.1] 127 (10) [5.8] 
baselineN 131 (17) [11] 150 (9) [8.9] 
baselineM 91.5 (21) [3.8] 98.9 (8) [3.1] 
Residual variability (CV%)   
Total, proportional  16.2 (4) [6.6] 16.3 (3) [6.9] 
Total, additive - 31.5 (24) [18] 
Naive, proportional  41.3 (9) [15] 42.1 (7) [15] 





Figure 27. Diagnostics of Structural Model. 
a)-d) and e)-h) are observation versus individual prediction, observation versus population 
prediction, observation (DV) vs. individual prediction (IPRED), with both an identity line (solid) 
and a Loess line (dashed); observation (DV) vs. population prediction (PRED), with an identity 
line (solid) and a Loess line (dashed); conditional weighted residual (CWRES) vs. time; 
conditional weighted residual (CWRES) vs. population prediction plots for total CD4+ T-cells 
and naïve T-cells, respectively. i)-l) are histograms of the inter-individual variability of σ, α, dN 
and dM. σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells that 
acquire a memory phenotype, dN: naïve T-cell death rate constant, dM: memory T-cell death 
rate constant. The age groups are presented as different colors. 
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Covariate Analysis in NLME Model 
The pre-selected parameter-covariate relationships for each parameter based on GAM 
analyses and investigation interest are summarized in Table 32. HBV and HCV infection were 
removed from the candidate list due to the low frequency of co-infected subjects (<3%). The SCM 
analysis found advanced age at ART initiation was a significant covariate for larger dN, suggesting 
that aging was a risk factor for CD4+ T-cell recovery. Since dN was a combination of cell 
proliferation and death (dN = rate constant of cell death – rate constant of cell proliferation), this 
relationship might indicate that aging was associated with slower cell proliferation or faster cell 
death or a combination of both. Female sex was associated with slower dM, and similar to the 
above case, it could suggest that female had faster cell proliferation or slower cell death or both. 
In addition, higher viral load at ART initiation predicted lower naïve and memory T-cell baseline. 
Higher immune CD4+ T-cell activation was associated lower memory T-cell baseline. Table 33 
summarizes the SCM analysis in the NLME model.   
Table 32. Pre-Selected Parameter-Covariate Relationships. 
σ: production rate of naïve T-cells, α: activation rate constant, dN: naïve  T-cell death rate constant 
of naïve T-cells that acquire a memory phenotype, dM: memory T-cell death rate constant, 
baselineN, baselineM : naïve or memory T-cell count at ART initiation, ART: antiretroviral therapy, 
BMI: body mass index, SCM: stepwise covariate modeling 
Parameters Covariates to be Included in SCM 
σ [(cell/µL)*year-1] Age, ART class, viral load, sex, BMI, race 
dN (year*cell/µL)-1 Age, ART class, viral load, sex, smoking status 
α (year-1) 
Age, CD4+ T-cell immune activation, CD8+ T-cell 
immune activation, smoking status, viral load 
dM (year*cell/µL)-1 
Age, ART class, CD4+ T-cell immune activation, 
CD8+ T-cell immune activation, sex, smoking status 
BaselineN (cell/µL) 
Age, CD4+ T-cell immune activation, CD8+ T-cell 
immune activation, viral load, sex 
BaselineM (cell/µL) 
Age, CD4+ T-cell immune activation, CD8+ T-cell 
immune activation, race, sex 
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Table 33. Stepwise Covariate Analysis. 
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells that acquire a 
memory phenotype, dN: naïve T-cell death rate constant, dM: memory T-cell death rate constant, 
baselineN: naïve T-cell count at ART initial, baselineM: memory T-cell count at ART initial, IIV: 
inter-individual variability. Parameter-covariate relations are described using a linear function, e.g. 
Pi = P • (1+ b * age), with Pi as the individual value, P as the population value and b as the 
covariate coefficient. Immune activation, presented as %CD38+/HLA-DR+ on the cells, are log-
transformed.   
Parameter Covariate P value Coefficient 
Forward Addition (α = 0.05) 
σ [(cell/µL) • year-1] -- -- -- 
dN (year • cell/µL)-1 Age  <0.001 0.0467 
dM (year • cell/µL)-1 
Sex (Female) 0.0039 -0.510 




Age  0.046 0.0203 
%Activated CD4+ T-cells 0.042 0.228 
baselineN (cell/µL) 
Viral load (log₁₀RNA/mL) <0.001 -0.636 
%Activated CD4+ T-cells 0.015 -0.446 
baselineM (cell/µL) 
Viral load (log₁₀RNA/mL) <0.001 -0.388 
%Activated CD4+ T-cells <0.001 -0.396 
%Activated CD8+ T-cells 0.0091 0.249 
Backward Elimination (α = 0.01) P value △IIV (%)  
σ [(cell/µL) • year-1] -- 
<0.01 
-- -- 
dN (year • cell/µL)-1 Age  -9.6 0.0389 
dM (year • cell/µL)-1 Sex (Female) -5.0 -0.597 
α (year-1) -- -- -- 
baselineN (cell/µL) Viral load (log₁₀RNA/mL) -20 -0.648 
baselineM (cell/µL) 
Viral load (log₁₀RNA/mL) -17.3 -0.422 
%Activated CD4+ T-cells -8.3 -0.378 
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Final Model Evaluation 
Parameter estimates of the final model are presented in Table 34. The model point 
estimates agreed with the bootstrap median estimates, and were precisely estimated with 
reasonably low %RSEs and narrow bootstrap 95% confidence intervals. The diagnostic plots for 
total and naïve CD4+ T-cells (Figure 28) showed that stratified by age (<35 years, 35-<50 years, 
>50 years), the observed data were well predicted, with no obvious bias in the model. The 
prediction-corrected visual predictive checks demonstrated a good performance of the model in 
predicting the overall data and also stratified by age, with the observed percentiles well captured 
by the predicted percentiles and corresponding 95% confidence intervals (Figure 29 for VPCs of 




Table 34. Final Parameter Estimates. 
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells into memory 
phenotype, dN: apparent naïve T-cell elimination rate constant, dM: apparent memory T-cell 
elimination rate constant, baselineN: naïve T-cell count at ART initial, baselineM: memory T-cell 
count at ART initial, VL: HIV viral load (log₁₀RNA/mL), IACD4: CD4+ T-cell activation, CV: 
coefficient of variance, CI: confidence interval, RSE: relative standard error. T-cell activation is 
defined by %CD38/HLA-DR, and is analyzed as log-transformed values.  
Parameter (Units) 
Estimates (RSE%) Bootstrap Estimates 
Point 
Estimates 
RSE (%)  Median 95% CI 
σ [(cell/µL) • year-1] 703 19  700 (484, 1006) 
dN (year • cell/µL)-1 0.0410 22  0.0410 (0.0255, 0.0661) 
dM (year • cell/µL)-1 0.000432 13  0.000435 (0.000314, 0.000559) 
α (year-1) 1.10 13  1.11 (0.85, 1.45) 
baselineN (cell/µL) 30.5 13  29.8 (20.3, 38.9) 
baselineM (cell/µL) 211 10  210 (173, 250) 
Covariate Effects      
VL-BaselineM -0.422 20  -0.424 (-0.552, -0.174) 
IACD4-BaselineM -0.378 18  -0.375 (-0.435, -0.138) 
VL-BaselineN -0.648 3.8  -0.645 (-0.733, -0.477) 
Age-dN 0.0389 37  0.0394 (0.0124, 0.0514) 
Sex-dM (Female) -0.48 25  -0.485 (-0.664, -0.212) 




σ 116 7.3 7.5 115 (99.7, 136) 
dN 63.7 20 41 63.4 (28.9, 82.7) 
dM 59.9 14 38 57.7 (37.3, 78.2) 
α 125 9.8 5.8 123 (97.3, 148) 
baselineN 135 8.9 9.3 137 (105, 165) 
baselineM 85.8 9.5 32 83.6 (68.5, 101) 
cor(ω2σ~ω2α) -0.802 7.2 -- -0.805 (-0.913, -0.679) 
Residual variability (CV%/SD)    
Total, proportional  16.3 3.3 6.9 16.3 (15.2, 17.3) 
Total, additive 31.2 22 18 31.7 (15.4, 44.9) 
Naive, proportional  42.1 6.6 15 41.5 (35.7, 46.7) 










































































































































































































































































































































































































Black lines represent the observation percentiles: solid line for median and dot-dash lines for 
5th and 95th percentile of observation. Black open circles represent the observation data. 
Colored shades are the 95% confidence intervals (CI) of the prediction percentile: red shades 
for 50% percentile and blue shades for 5th and 95th percentile. 





Black lines represent the observation percentiles: solid line for median and dot-dash lines 
for 5th and 95th percentile of observation. Black open circles represent the observation 
data. Colored shades are the 95% confidence intervals (CI) of the prediction percentile: 
red shades for 50% percentile and blue shades for 5th and 95th percentile. 
Figure 30. Prediction-Corrected Visual Predictive Checks Stratified by Age Group. 
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Simulations of the Effect of Age on Total CD4+ T-Cell Counts 
The simulated total CD4+ T-cell counts and the percentages of simulated subjects 
demonstrating sufficient immune reconstitution (IR) at different times after ART treatment are 
summarized in Figure 31. Twenty years after treatment were used for steady state as it was 
sufficiently long for the CD4+ T-cell recovery of all the studied patients to reach the criteria for 
steady state given the predicted individual parameters (data not shown). At the time of ART 
initiation, the simulated CD4+ T-cell counts from the established model were similar across age 
groups (around 210 cells/µL in median). At year 4 after ART treatment, median CD4+ T-cell 
counts of all age group reached 500 cells/µL. At steady state, median CD4+ T-cell counts were 
739 (IQR 548-1002), 641 (IQR 481-860) and 593 (IQR 441-794) cells/µL for simulated patients 
aged <35 years, 35-<50 years and ≥50 years, and %subjects showing sufficient IR were 81%, 
72% and 65%, respectively. Comparing the younger (<35 years) and older (≥50 years) age 
Figure 31. Simulated CD4+ T-Cell Recovery after Antiretroviral Therapy by Age Group 
CD4+ T-cell count at 5th, 25th, 50th, 75th and 95th of the simulations of each age group at time after 
treatment are presented. The median CD4+ T-cell counts are indicated for each group. Dotted 
line at 500 cells/μL is chosen as the index for sufficient CD4+ T-cell count. The percentages of 
the simulated subjects achieving sufficient immune recovery are indicated for each group on the 
top of the figure.    
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groups, the differences of median CD4+ T-cell counts between the two groups were 93, 137 and 
145 cells/μL at year 1, 4 years and steady state, suggesting that advanced age had a greater 
impact on impaired CD4+ T-cell recovery in a long run.  
Preliminary Analysis of the Effects of Thymus Output and Immune Exhaustion  
For the production rate of naïve T-cells (σ), none of the tested covariate showed statistical 
significance; however, the high level of thymus output biomarker, %CD31 on CD4+ T-cells 
showed a near-significant association with greater σ (P = 0.069). For the apparent elimination 
rate constant of naïve T-cells (dN), age and activation level on CD8+ T-cells were statistically 
significant covariates when tested separately, while age was the only significant predictor in the 
multiple linear regression model (P < 0.001). Higher level of immune exhaustion was significantly 
associated with faster activation rate constant of naïve T-cells (P = 0.022). Sex was a significant 
covariate for apparent elimination rate constant of memory T-cells (P < 0.001). When adjusted for 
these effects, age was not a significant predictor of either parameter. The covariate effect of age 
in this analysis was consistent with the finding in the NLME model. Visual relationships discussed 
above are showed in Figure 32. Linear regression analyses are summarized in Table 35. 
  
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells that acquire a 
memory phenotype, dN: naïve T-cell death rate constant, dM: memory T-cell death rate constant. 
%CD31 on CD4+ T-cells defines thymus output of CD4+ T-cells, %PD-1/TIM-3 defines immune 
exhaustion. P values from the linear regression for each relation are indicated. 
Figure 32. Post Hoc Analysis of CD4+ T-Cell Dynamic Parameters. 
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Table 35. Linear Regression Analysis of Post Hoc Parameters in the BLIR Study. 
σ: production rate of naïve T-cells, α: activation rate constant of naïve T-cells into memory 
phenotype, dN: apparent naïve T-cell elimination rate constant, dM: apparent memory T-cell 
elimination rate constant, BMI: body mass index. Thymus output is defined by CD31+. Immune 
activation is defined by CD38+/HLA-DR+. Immune exhaustion is defined by PD-1+/TIM-3+. Log-
transform of the data is applied when appropriate.  
Significant codes:  *** <0.001; ** <0.01; * <0.05; . <0.1  
 σ (cell/µL) • year-1 dN (year • cell/µL)-1 α (year-1) dM (year • cell/µL)-1 
 Univariate Adjusted Univariate Adjusted Univariate Adjusted Univariate Adjusted 
Age at ART 
initiation 
0.7  <0.001*** <0.001*** 0.62 0.89 0.97 0.57 
Sex 0.64  0.87  0.84  <0.001*** <0.001*** 
Baseline viral 
load 
0.88  0.29  0.58  0.19  
Smoking 
Status 
0.75  0.39  0.47  0.56  




0.069.  0.38  0.12  0.36  
%Activated 
CD4+ T-cells 
0.92  0.94  0.59  0.19  
%Activated 
CD8+ T-cells 
0.24  0.034* 0.11 0.24  0.36  






 In this study, we evaluated the impact of aging, in terms of chronological age, on the 
CD4+ T-cell recovery in HIV-infected patients with successful viral suppression. Using NLME 
approaches, we developed a model describing longitudinal CD4+ T-cell dynamics under ART 
treatment at a population level. Using T-cell subtype biomarker data, we divided the total T-cell 
kinetics into naïve and memory T-cell dynamics, enabling a more mechanistic evaluation of aging 
effects on CD4+ T-cell recovery. Our analysis highlights that older age may be a predictor of 
suboptimal immune recovery by influencing CD4+ naïve T-cell homeostasis. Among the three 
age groups (18-<35, 35-<50 and ≥50), the percentages of subjects achieving sufficient immune 
reconstitution were 42%, 32% and 26% at first year after ART treatment, and 81%, 72% and 65% 
at steady state, respectively. The differences of these percentages enlarged over time, indicating 
that age exhibited a greater negative impact on CD4+ T-cell recovery with longer duration of follow 
up. We also found that immune activation and immune exhaustion were associated with immune 
reconstitution, and there was a trend of the level of thymus output being associated with naïve T-
cell production. To our knowledge, this is the first analysis to use NLME methods to investigate 
the effect of aging, incorporating the evaluation of important immune biomarkers.   
The NLME model describes naïve and total CD4+ T-cell simultaneously. According to the 
current data, the naïve T-cell dynamics is described using a zero-order input and a cell density-
dependent elimination process. The memory T-cells are converted from the naïve T-cells with a 
first-order process and are eliminated following a cell density-dependent elimination process. Our 
data did not support the estimation of the proliferation process, even with different variations in 
parameterization. We chose not to fix the parameter to the literature values due to the large 
variation and uncertainty. In studies using isotope labeling methods, the proliferation rate was 
measured for total T-cells and was not differentiated for naïve and memory T-cells217,218. In studies 
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quantifying thymus output and proliferation data, instead of fitting the data, the proliferation rate 
was studied in an exploratory manner as simulating different CD4+ T-cell dynamic scenarios, 
therefore those values were theoretical and lack of validation109,220. Given this, the apparent 
elimination in our model is therefore a combination of the cell proliferation and death, with the rate 
proportional to the number of cells in the compartment.    
The NLME model was developed using data from two sources, which provide long-term 
and short term CD4+ T-cell recovery profiles respectively. The model was primarily developed 
from the ACTG model with a larger sample size (n=102), and the model was able to well describe 
the data from the BLIR study (n=20). To minimize the variability in measuring the biomarkers, the 
gating strategies from the ACTG study were shared with the BLIR study as a reference. In the 
final model, different residual error models were used for ACTG data (proportional) and BLIR data 
(proportional + additive), however, the proportional error residuals were similar between the two 
studies and therefore combined in one term for both total and naïve T-cell observations. 
The stepwise covariate analysis in the NLME model suggested that age at ART initiation 
was positively associated with the apparent naïve T-cell elimination rate constant, the parameter 
describing both naïve cell proliferation and death. The literature findings support the negative 
association between age and cell proliferation. It is possible that aging is associated with cell 
replicative senescence as a result of age-dependent DNA demethylation225. A study that directly 
measured cell proliferation rate of CD4+ T-cells in mice using a DNA labeling method showed 
that there was a two-fold drop of proliferation rates of T-cells in thymus with aging in two different 
mice strains226. On the other hand, a previous study showed a 3-fold increase in the half-life of 
naïve T-cells in aged mice compared to younger ones, suggesting an extended cell life span, or 
slower cell death, as protective mechanism for naïve T-cell pool in elderly, which is contrary to 
the positive relationship between age and cell death. Therefore, we propose that aging impairs 
CD4+ T-cell recovery by decelerating naïve T-cell proliferation. Our analysis showed that a 10-
year increase in age is associated with a 4% increase in apparent naïve T-cell elimination rate 
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constant. In terms of CD4+ total T-cell counts, simulation showed that steady state median CD4+ 
T-cell counts decrease by 13% and 20% in a patient aged 40 years and 50 years compared to a 
patient aged 30 years. However, these changes are not profound compared to the large variability 
in CD4+ T-cell counts (~30% coefficient of variance)120, and their clinical significance might be 
minimal.       
In our analysis, female sex was favorably associated with CD4+ T-cell recovery as it 
reduced the apparent memory T-cell elimination rate by 48%. As discussed above, the 
interpretation of this relationship could be multidirectional. Though the mechanism has not been 
clearly elucidated, it has been hypothesized that female hormones provide a beneficial 
environment for CD4+ T-cell homeostasis, both in the general227 and the HIV-infected 
population228. Our simulation showed that at steady state, the median change in CD4+ T-cell 
counts from baseline was 592 cells/µL (IQR 474-704) in female and 416 cells/μL (IQR 348-463) 
in male, with a ~42% increase in females compared to males. Our analysis associated higher HIV 
viral load at ART initiation with lower naïve and memory T-cells. Moreover, one logarithm increase 
in viral load had a greater impact on naïve T-cell baseline compared to on that of memory T-cells 
(decrease by 65% versus 42%). In addition, higher level of CD4+ T-cell activation was associated 
with lower memory T-cell baseline, which might be a result of increased activation-induced T-cell 
apoptosis229.       
Thymus output is the mechanism for naïve T-cell generation. The current post hoc 
analysis with the 20 subjects in the BLIR study suggested a trend between CD31 expression and 
naïve T-cell production rate, though it did not reach statistical significance. In our analysis here, 
we did not find the association between age and naïve T-cell production rate, although thymus 
involution with aging is well-delineated in the literature. However, the greatest decline in thymus 
output by age is typically demonstrated in younger ages (<20 years), after which the rate becomes 
much slower. Our studied population had a median age of 39 years at treatment initiation. In our 
analysis, the level of CD31 expression was not significantly associated with age (P = 0.28).  
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The activation level on CD4+ T-cell was nominally associated with the activation rate 
constant of the conversion from naïve to memory T-cells, however, this effect was not detected 
in the final NLME model, probably due to the adjustment for immune activation on the baseline 
memory T-cell counts. Interestingly, we found that a higher activation rate was significantly 
associated with higher immune exhaustion (Figure Y). Immune exhaustion is characterized by a 
progressive loss of T-cell functions, and commonly develops during viral-persistence in HIV 
infection as a result of chronic immune activation230. Our analysis suggested that the higher level 
of immune exhaustion was unfavorable for naïve T-cell restoration as a result of increased 
activation rate.  
Our study has several strengths. Using a semi-mechanistic NLME model, we were able 
to determine the effect of aging on naïve T-cell dynamics, and to our knowledge, this is the first 
time this relationship was observed in HIV-infected patients. Though the exact mechanism is not 
known, our study may simulate further investigations into the impact on T-cell dynamics using 
human samples. Also, we investigated multiple immune processes in relation to age, which 
provided insight into the roles of these mechanisms in CD4+ T-cell dynamics, as well as correcting 
for potential confounding effects. We performed the analysis using data from two studies with 
long-term and short-term follow-up, which effectively informed different phases of CD4+ T-cell 
recovery. The data from the ACTG study cover the CD4+ T-cell trajectory with the longest study 
period reported in the literature thus far, which provided a decent perspective of the steady-state 
CD4+ T-cell counts in HIV-infected population and support predictions of long-term trajectory with 
more confidence. The intensive biomarker data available in the BLIR study added to the 
granularity of early stage of immune recovery when CD4+ T-cell reconstitution undergoes the 
greatest changes. 
On the other hand, our analysis has some limitations. Our analysis is retrospective, and 
the unavailable information in some patients, such as thymus output and immune exhaustion 
biomarkers, prevented the evaluation of these factors in the NLME model. Also, a large portion of 
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our studied population was under 50 years old, and we did not have many patients with more 
advanced age (above 65 years) at ART initiation. The pre-specified biomarkers for division of 
naïve and memory T-cell were CD45RA+/CCR7+, however, due to technical reasons, the CCR7 
data were not available. Our study sample size was relatively small, which limited the 
generalizability of our conclusions.  
In summary, we developed a NLME model describing longitudinal CD4+ T-cell recovery 
in HIV-infected patient with successful viral suppression under ART. Our analysis revealed the 
association between older age and impaired naïve T-cell recovery and the negative effect of aging 
on long-term total CD4+ T-cell reconstitution. Our preliminary analysis shed lights on the role of 
immune exhaustion on CD4+ T-cell dynamics as well as the trend between higher thymus output 
and naïve T-cell generation. Further analysis will require more subjects in which these biomarkers 













Chapter V: Perspectives and Future Directions 
 
Quantify the Variability in Antiretroviral PK/PD at a Population Level and Inform 
Beyond: the Power of NLME Modeling Approaches    
 
The aims of this dissertation were to apply NLME modeling methods to quantify the 
association between the variability in PK/PD and the characteristics in special HIV-infected 
population receiving ART, focusing on pregnant women and older patients. Using simulation 
methods, the necessity for adjusting ART dosing and disease management in these populations 
were assessed.   
As discussed in Chapter I, pregnancy and aging could lead to physiological changes which 
could alter drug absorption, distribution, metabolism and elimination, and the key question to be 
answered is how the unbound drugs change in pregnant women and older HIV-infected patients. 
Aging is also a concerning factor in immune recovery under ART, while inconsistent findings exist 
regarding whether older patient have similar immune restoration as younger ones. NLME 
approaches are currently well-accepted for PK/PD analysis at a population level. This dissertation 
applied NMLE modeling methods to answer the above questions, taking the advantages of its 
powerfulness in describing longitudinal PK/PD, accommodating different study design, analyzing 
various sources of variability collectively and predicting new conditions. 
In Chapter II, a NLME model describing unbound and total LPV and RTV in four phases 
of pregnancy was established. The apparent clearances of unbound concentrations of both drugs 
exponentially increased up to 32 weeks of gestation. The unbound fractions of LPV and RTV were 
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similar across different stages of pregnancy. Simulations showed that the standard dosing is 
sufficient for pregnant women with susceptible virus, which is consistent with other studies 
measuring unbound LPV in pregnancy50,136. In terms of translational impact, the findings from this 
clinical study have contributed to inform the dosage recommendation for this regimen in 
pregnancy in the drug label134 and the HIV treatment guideline17. Beyond the observed 
populations, the dosing strategies for pregnant women with different viral resistance were also 
evaluated. Our simulations suggested that with low viral resistance (≤4-fold increase in viral IC50), 
standard dosing was able to provide sufficient efficacy. With moderate viral resistance (10- to 20-
fold increase in viral IC50), higher dose increased the likelihood of achieving effectiveness. With 
high viral resistance (≥20-fold increase in viral IC50), alternative regimens might need to be 
considered. These results help to fill the gap in the dosing recommendations for pregnant women 
with viral resistance. 
In Chapter III, several aging surrogates, including frailty phenotype, cytokine level and the 
expression of p16INK4a, were studied to evaluate the effect of aging on the unbound drug 
disposition of three ARVs. The NLME models describing both unbound and total concentration 
simultaneously not only accommodate the combined intensive and sparse sampling strategy, but 
also the complex study design which involved multiple PK visits for one patient. With the PK 
estimates predicted from the NLME models, our analyses associated the unbound clearance of 
the studied drugs with gene polymorphisms of relevant drug metabolic enzymes and transporters, 
and revealed the potential of aging-PGx interaction in affecting unbound drug transport for ATV. 
More importantly, after adjusting for the PGx factors, the expression of p16INK4a was showed to 
be significantly associated with slower EFV metabolism. Our analysis indicated that the median 
total EFV through concentration in patients with two-fold increase in p16INK4a expression from the 
population median was beyond the therapeutic window, implying dose reduction based on aging 
may be justified. In addition to adding new knowledge for current and generating interesting 
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hypothesis for further PGx studies of ARVs, our study opened a new perspective in investigating 
the influence of aging on ART PK.    
In Chapter IV, the first NMLE model co-analyzing the naïve and memory T-cell dynamics 
to evaluate the effect of aging was developed, using long-term and short term CD4+ T-cell 
recovery data from two studies. In addition to patient characteristics at ART initiation, the time-
varying immune activation biomarker levels were also evaluated. Our analyses revealed the 
relationship between older age and faster loss of naïve T-cells, suggesting aging is a risk factor 
of impaired CD4+ reconstitution after ART initiation. Simulation suggested that comparing older 
to younger patients, fewer subjects are able to achieve sufficient immune reconstitution over time, 
suggesting that advanced age may impair CD4+ T-cell recovery to a larger extent in the long 
term. Preliminary covariate analysis of model-predicted parameters using the currently available 
data suggested an interesting association between immune exhaustion and higher naïve T-cell 
activation rate, implying its negative impact on naïve T-cell recovery. By using a semi-mechanistic 
NMLE model incorporating multiple immune biomarkers, we were able to maximize the value of 
the available information, and quantify the intriguing relationships related to T-cell dynamics from 
a biologically relevant prospective.      
    
Future Directions   
 
While providing useful insight for optimal HIV treatment, this work had limitations. Future 
directions of this work could be laid out as below.  
For the unbound LPV/RTV study in Chapter II, one limitation was that the viral resistance 
scenarios were hypothetical, and the determination of efficacy was based on PK, not actual viral 
suppression. Further studies involving viral resistance information with a well-characterized PK-
PD relationship is needed to inform dosing strategies for pregnant women with resistant virus. 
144 
 
Other major limitation of this study was that the studied regimen, which was the first-line therapy 
at the time of the clinical trial was conducted, is no longer the preferred regimens in the guidelines 
as initial treatment for ART-naive HIV-1-infected pregnant women, although the use of LPV/RTV 
is still common. However, LPV could serve as a PK probe of CYP3A-metabolized and highly 
protein bound drugs during pregnancy to estimate the PK alterations of drugs with similar profiles. 
Furthermore, the drug efficacy given different viral resistance scenarios could also be projected. 
Approved drugs with the similar characteristics are RPV, DRV/RTV and EVG/COBI, as 
summarized in Table 1 in the introduction. The unbound drug PK of DRV/RTV has been 
studied20,21, suggesting no dose adjustment is required. The decrease in clearance of unbound 
DRV is comparable to that of LPV in 3rd trimester, and one of the two study showed nonsignificant 
unbound fraction in pregnancy compared to post-partum21. Similar alterations for other drugs 
might be expected, however, the drug disposition of these drugs are not exactly the same, 
therefore, the extrapolation among drugs should only be used as reference to help further study 
design. In addition, the modeling simulation strategies developed in this study can be applied to 
describe the unbound drug disposition of other drugs inside and outside the field of HIV treatment.  
The major limitation of the study in Chapter III was the small sample size of our studied 
populations. On one hand, it limited the generalizability of statistically significant relationships 
found in our analysis, such as the interaction between aging and ABCC4 variant in effecting ATV 
PK. On the other hand, the low frequencies of some covariate of interest compromised the 
statistical power in investigating these factors, such as the frailty phenotype and some SNPs 
shown to be relevant in previous reports. Further investigation on the effect of frailty requires the 
inclusion of more subjects with frailty evaluation. In addition to frailty itself, the interaction between 
frailty and older age in affecting ART drug disposition is also an interesting question, that is, 
whether age and frailty are additive or synergistic in their effects on drug clearance. Previous 
studies have shown an additive effect of frailty on reduced drug elimination, although the criteria 
for “frailty” vary across studies76,78. Further studies should require the criteria of frailty phenotype 
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to be uniform, especially when involving patients from different study protocols. Also, the inclusion 
of younger patients with frailty phenotype is needed for a complete evaluation the interaction 
between aging and frailty. The investigation of aging-PGx interaction could rely on the 
retrospective analyses involving data from relevant PGx studies to validate the finding in our 
analysis and to refine the estimated effect sizes to support further prospective studies.  
The association between p16INK4a expression and slower EFV metabolism found in this 
study is novel. The relationship, though further validation in large sample size is needed, may 
imply the necessity of dose adjustment in patients with higher expression of this biomarker, 
especially in those who carry genetic variants leading to increased EFV exposure, for example, 
CYP2B6*6. If the importance of this cellular biomarker in altering PK is confirmed, the next 
question would be how to apply this biomarker to dosing guidance. One direction could be 
associate it with other more accessible measurements. Chronological age is a straightforward 
one, and its relationship with p16INK4a expression is established in previous reports in both healthy 
and HIV-suppressed subjects79,81. In our study, the association between p16INK4a and 
chronological age in our studied subjects was not observed, probably due to the small sample 
size. The previous reported quantitative relationship could not be applied to the current study due 
to the discrepancy in the magnitude of p16INK4a measurement as different controlled genes have 
been used. Therefore, future study should establish a generalizable quantitative relationship 
between p16INK4a and chronological age in HIV-infected populations with suppressed virus.        
The analysis in Chapter IV is interim, and more data from additional 30 patients in the 
BLIR study will be available in the near future. Due to the lack of thymus output and immune 
exhaustion biomarker data in the ACTG study (n=102), the covariate analysis of these two factors 
were not performed in the NLME model. Further analysis may include a separate analysis 
including all the immune processes (thymus output, immune activation and immune exhaustion) 
using the complete BLIR data (n=50) to re-visit the effect of age on CD4+ T-cell recovery. The 
current simulation was performed to illustrate how older age could affect CD4+ T-cell counts in 
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the short- and long-term and to generate a general picture of the percentage of subjects achieving 
sufficient immune reconstitution in different age groups. More simulations will be conducted after 
the final model developed from the complete dataset is established. A full simulation plan is 
outlined below: 
1. CD4+ T-cell counts will be simulated for 
1) Time points: at ART initiation, 0.5, 1, 2, 4, 6 and steady state after ART 
2. Age groups: 20-80 years with 10-year increments 
3). CD4+ T-cell counts baseline: 50-550 cells/µL with 100 cells/μL increments 
2. Percentage of simulated subjects achieving sufficient immune reconstitution (CD4+ T-
cell counts ≥500 cells/µL) will be summarized   
Beyond this analysis, future studies could validate the association between aging and cell 
proliferation at the cellular level using human samples. The NLME model developed in this study 
can serve as a reference for PD analysis in other studies with similar study design, for example, 
investigation of new agents to boost CD4+ T-cell reconstitution in HIV-infected patients with 




In summary, this work applied NLME modeling methods to answer various questions in 
antiretroviral treatment which could inform optimal HIV treatment for pregnant women and older 
patients. The models developed in this work are useful references for future studies investigating 
relevant issues. Further studies are needed to validate and expand the findings to support the 





NONMEM Model Code 
LPV Individual Final Model Describing Unbound and Total Drugs (RTV model is similar) 
$PROBLEM LPV Individual Protein Binding Model 
 
$INPUT ID TIME DV AMT CMT MDV EVID II ADDL VISIT OCC WEEK VISITO VISITT VISITTH 
VISITF CD4 RNA ALBUMIN AAG WT WTCHG HGB HCT RACE RACET AGE HT BMI L2 
 
$DATA lpvpb.csv IGNORE=I 
 
$SUBROUTINES ADVAN13 TOL=9 
 

















DADT(1) = -KA*A(1) 
DADT(2) = KA*A(1)- CL/V *A(2) 
DADT(3) = DADT(2)/FU 
$ERROR 
IPRED = F 
W = F 
IF (W.EQ.0) W = 1 
IF (CMT.EQ.2) TYPE=0 
IF (CMT.EQ.3) TYPE=1 
    Y = IPRED + W*EPS(1)*(1-TYPE) + W*EPS(2)*TYPE  
IRES = DV-IPRED 
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(0,2000)  ;V 
(0,0.5) ; KA 
(0.025) ;FU 







$OMEGA BLOCK(1) 0.09 ;IOV 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
$OMEGA BLOCK(1) SAME 
 
$SIGMA BLOCK(2) 
0.1 ; SIGMA UNBOUND 
0.09 0.1 ; SIGMA TOTAL 
 
$EST METHOD=1 INTERACTION MAXEVAL=99999 NOABORT SIG=3 PRINT=1 POSTHOC 
 
LPV-RTV Interaction Model Example (linked by unbound RTV) 
$PROBLEM LPV and RTV joint model 
 
$INPUT ID TIME DV AMT RATE=DROP CMT MDV EVID II ADDL VISIT OCC WEEK VISITO 
VISITT VISITTH VISITF CD4 RNA ALBUMIN AAG WT WTCHG HGB HCT RACE RACET AGE 
HT BMI L2 
 
$DATA lpvrtvpb.csv IGNORE=I 
 
$SUBROUTINES ADVAN13 TOL=9 
 
$ABBR REPLACE ETA(OCC_CLR)=ETA(7,9,11,13) 












$OMEGA BLOCK (3) FIX 
0.0812 ; IIV CLR 
0.133 0.981;IIV VR 
-0.0701 -0.182 0.0735;IIV FUR 
$OMEGA 
0.09 ; IIV CLL 
0.1; IIV KAL 
0.1; IIV FUL 
$OMEGA BLOCK(2) 0.1 0.09 0.1; IOV 
$OMEGA BLOCK(2) SAME; 
$OMEGA BLOCK(2) SAME; 
$OMEGA BLOCK(2) SAME; 
 
$PK 
CLL= THETA(1) *EXP(ETA(4)+ ETA(OCC_CLL)) 
VL= THETA(2) 
KAL = THETA(3)*EXP(ETA(5)) 
FUL = THETA(4)*EXP(ETA(6)) 
ALAG1 = THETA(5) 
CLR = THETA(6) * (WT/70)**0.75 * EXP(THETA(12)*WEEK) * EXP(ETA(1)+ ETA(OCC_CLR)) 
VR = THETA(7)*(WT/70)*EXP(ETA(2)) 
KAR = THETA(8) 
FUR = THETA(9)*EXP(ETA(3)) 
ALAG2 = THETA(10) 
COEF = THETA(11) 







DADT(1) = -KAL*A(1) 
DADT(2) = -KAR*A(2) 
DADT(3) = KAL*A(1) - CLL*EXP(-COEF*(CRTV-0.04))/VL * A(3) 
DADT(4) = DADT(3)/FUL 
DADT(5) = KAR*A(2) – CLR/VR * A(5) 
DADT(6) = DADT(5)/FUR 
 
$ERROR 
IPRED = F 
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W = F 





IF (CMT.EQ.3) IND3=1 
IF (CMT.EQ.4) IND4=1 
IF (CMT.EQ.5) IND5=1 
IF (CMT.EQ.6) IND6=1 
    Y = IPRED + W*EPS(1)*IND3 + W*EPS(2)*IND4 + W*EPS(3)*IND5+ W*EPS(4)*IND6 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA 
(0, 200) ;CLLPV 
(0, 2000) ;VLPV 
(0, 0.5) ;KALPV 
(0.025) ;FULPV 
(0, 1) ;TLAGLPV 
(0, 137) FIX ;CLRTV 
(0, 216) FIX ;VRTV 
(0, 0.121) FIX ;KARTV 
(0, 0.143) FIX ;FURTV 
(0,1.77) FIX;TLAGRTV 




0.1 ;LPVTOTAL Pro 
0.09 0.1 ; LPVUNBOUND Pro 
0.09 0.09 0.106 ;RTVTOTAL Pro 
0.09 0.09 0.11 0.249 ;RTVUNBOUND Pro 
 
$EST METHOD=1 INTERACTION MAXEVAL=99999 NOABORT SIG=3 PRINT=1 POSTHOC 
 
EFV Individual Model Describing Unbound and Total Drugs (ATV and RTV are similar; RTV 
is 1-compartment model) 
$PROBLEM EFV protein binding model 
 
$INPUT ID TIME DV AMT CMT MDV EVID II ADDL OCC DVID AGE SEX ETHNICITY RACE 
BLACK WHITE HIVDUR REGDUR SMOKE ALCOHOL CD4 HT WT BMI FRAILTY 




$DATA efvpbnssfreeonly.csv IGNORE=I 
 
$SUBROUTINES ADVAN13 TOL=9 
 
$ABBR REPLACE ETA(OCC_CL)=ETA(7,8) 
 
$MODEL 
























IF (DVID.EQ.1) IPRED=CU 
IF (DVID.EQ.2) IPRED=CTOTAL 
W = IPRED 
IF (W.EQ.0) W = 1 
IF (DVID.EQ.1) TYPE=0 
IF (DVID.EQ.2) TYPE=1 
Y = IPRED + W*EPS(1)*(1-TYPE) + W*EPS(2)*TYPE  
IRES = DV-IPRED 














0.09 0.1  
0.09 0.09 0.1 
0.09 0.09 0.09 0.1 
0.09 0.09 0.09 0.09 0.1 
0.09 0.09 0.09 0.09 0.09 0.1 
$OMEGA BLOCK(1) 0.1 




0.09 0.1 ; Proportional error PK 
 
$EST METHOD=SAEM INTERACTION NBURN=5000 NITER=500 PRINT=50 CTYPE=3 
CITER=10 CINTERVAL=20 CALPHA=0.05 NOABORT ISAMPLE=1 
 
$EST METHOD=IMP INTERACTION EONLY=1 NITER=5 ISAMPLE=1000 PRINT=1 SIGL=12 
SEED=123334 CTYPE=3 CITER=10 CALPHA=0.05 
 
CD4+ T-Cell Recovery Final Model 
$PROBLEM CD4 Recovery combining ACTG (n=102) and BLIR data (n=20) 
 
$INPUT ID TIME DV CMT MDV CD4BASE NAIVEBASE MEMOBASE L2 SEX RACE AGE AGEC 
VL ARTCLASS ARTREG BMI SMOKE IACD4 IACD8 LIACD4 LIACD8 PID=DROP STDY 
 
$DATA ACTGBLIRCOMBINED2.csv IGNORE=I 
 







;;; OBASEMLIACD4-DEFINITION START 
OBASEMLIACD4 = ( 1 + THETA(11)*(LIACD4 - 2.02)) 




;;; CLNAGE-DEFINITION START 
CLNAGE = ( 1 + THETA(10)*(AGE - 38.5)) 
;;; CLNAGE-DEFINITION END 
 
;;; CLN-RELATION START 
CLNCOV=CLNAGE 
;;; CLN-RELATION END 
 
;;; CLMSEX-DEFINITION START 
IF(SEX.EQ.1) CLMSEX = 1  ; Most common 
IF(SEX.EQ.2) CLMSEX = ( 1 + THETA(9)) 
;;; CLMSEX-DEFINITION END 
 
;;; CLM-RELATION START 
CLMCOV=CLMSEX 
;;; CLM-RELATION END 
 
;;; OBASENVL-DEFINITION START 
OBASENVL = ( 1 + THETA(8)*(VL - 4.66)) 
;;; OBASENVL-DEFINITION END 
 
;;; OBASEN-RELATION START 
OBASENCOV=OBASENVL 
;;; OBASEN-RELATION END 
 
;;; OBASEMVL-DEFINITION START 
OBASEMVL = ( 1 + THETA(7)*(VL - 4.66)) 
;;; OBASEMVL-DEFINITION END 
 
;;; OBASEM-RELATION START 
OBASEMCOV=OBASEMVL*OBASEMLIACD4 
















TVOBASEN = OBASENCOV*TVOBASEN 
TVOBASEM=THETA(6) 
TVOBASEM = OBASEMCOV*TVOBASEM 
 
IF (TIME.EQ.0) THEN 
OBASEN = TVOBASEN*EXP(ETA(5)) 
OBASEM = TVOBASEM*EXP(ETA(6)) 
ENDIF 
 
A_0(1) = OBASEN 
A_0(2) = OBASEM 
 






IF (STDY.EQ.2) FLAG=1 
  
IF (CMT.EQ.1) THEN 
    IPRED = A(1) 
    W = IPRED 
    Y = IPRED + IPRED*EPS(1)+FLAG*EPS(3) 
ENDIF 
IF (CMT.EQ.0) THEN 
    IPRED = A(1)+A(2) 
    W = IPRED 
    Y = IPRED + IPRED*EPS(2)+FLAG*EPS(4) 
ENDIF 
IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA   
(0,650) ; KIN 
(0,0.05) ; CLN 
(0,1) ; ACT 
(0,0.0005) ; CLM 
(0,30) ; NAIVEBASE 
(0,200) ; MEMOBASE 
$THETA  (-0.4) ; OBASEMVL1 
$THETA  (-0.6) ; OBASENVL1 
$THETA  (-0.5) ; CLMSEX1 
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$THETA  (0.03) ; CLNAGE1 
$THETA  (-0.4) ; OBASEMLIACD41 
 
$OMEGA  BLOCK(2) 
 1.5  ;    IIV KIN 
 -0.09 1.5  ;    IIV ACT 
$OMEGA  0.5  ;     IIV DN 
$OMEGA  0.4  ;     IIV DM 
 2  ; IIV NAIVEBASE 
 1  ; IIV MEMOBASE 
 
$SIGMA   
0.1  ;  NAIVEPROP 
0.02  ;  TOTALPROP 
4  ;   NAIVEADD 
1000  ;   TOTALADD 
 









atvcheckf<-atvcheck[atvcheck$CMT==2 & atvcheck$DV!=0,] 






  geom_point(size=3)+ 
  geom_abline(intercept =0, slope =1)+ 
  geom_smooth(linetype=2,se=FALSE, size=1.2)+theme_bw()+ 
  theme(axis.title=element_text(size=25))+ 
  theme(axis.text=element_text(size=25))+ 
  scale_x_log10(labels=trans_format('log10',math_format(10^.x)),limits=c(3,1000))+ 
  scale_y_log10(labels=trans_format('log10',math_format(10^.x)))+ 







  geom_point(size=3)+ 
  geom_hline(yintercept =0)+ 
  geom_smooth(linetype=2,se=FALSE, size=1.2)+ 
  geom_smooth(aes(x=TIME,y=abs(CWRES)),data=atvcheckf,linetype=2,se=FALSE, 
color='red',size=1)+ 
  geom_smooth(aes(X=TIME,y=-abs(CWRES)),data=atvcheckf,linetype=2,se=FALSE, 
color='red',size=1)+ 
  theme_bw()+ 
  theme(axis.title=element_text(size=25))+ 
  theme(axis.text=element_text(size=25))+ 
  theme(legend.position='none')+ 
  scale_x_continuous(limits=c(-2,25))+ 
















simat<-sima[sima$CMT==3 & !is.na(sima$DV),] 
simaf<-sima[sima$CMT==2 & !is.na(sima$DV),] 
 
### summarise each percentile in each simulation ### 
simatbycount=ddply(simat, c("TIME","COUNT"), summarize, 
                   q5=quantile(DV,0.05,na.rm=T), 
                   q50=median(DV), 
                   q95=quantile(DV,0.95,na.rm=T)) 
simafbycount=ddply(simaf, c("TIME","COUNT"), summarize, 
                   q5=quantile(DV,0.05,na.rm=T), 
                   q50=median(DV), 




#### 95%CI of percentiles ### 
vpcat=ddply(simatbycount,c("TIME"), summarize, 
            q5low=quantile(q5,0.025), 
            q5med=median(q5), 
            q5hi=quantile(q5,0.975), 
            q50low=quantile(q50,0.025), 
            q50med=median(q50), 
            q50hi=quantile(q50,0.975), 
            q95low=quantile(q95,0.025), 
            q95med=median(q95), 
            q95hi=quantile(q95,0.975)) 
 
vpcaf=ddply(simafbycount,c("TIME"), summarize, 
            q5low=quantile(q5,0.025), 
            q5med=median(q5), 
            q5hi=quantile(q5,0.975), 
            q50low=quantile(q50,0.025), 
            q50med=median(q50), 
            q50hi=quantile(q50,0.975), 
            q95low=quantile(q95,0.025), 
            q95med=median(q95), 
            q95hi=quantile(q95,0.975)) 
 
obsa<-read.table(file.choose(),header=T,sep=',',skip=0,as.is=T) 
obsaf<-obsa[obsa$CMT==2 & obsa$DV!=0,] 
obsat<-obsa[obsa$CMT==3 & obsa$DV!=0,] 
 
### ATV TOTAL ### 
pdf('vpcat95CI.pdf') 
ggplot(data=vpcat, aes(x=TIME))+ 
  geom_line(aes(y=q50med), colour="490", linetype=1, size=1.5)+ 
  geom_line(aes(x=TIME, y=q5med), colour="deepskyblue4", linetype=5, size=1.2)+ 
  geom_line(aes(x=TIME, y=q95med), colour="deepskyblue4", linetype=5, size=1.2)+ 
  geom_ribbon(aes(ymin=q50low, ymax=q50hi), alpha=0.1, fill ="red" )+ 
  geom_ribbon(aes( ymin=q5low, ymax=q5hi), alpha=0.1, fill = "blue")+ 
  geom_ribbon(aes(ymin=q95low, ymax=q95hi), alpha=0.1, fill = "blue")+ 
  geom_point(data=obsat,aes(x=(TIME),y=DV),color="black",size=2)+ 
theme_bw()+ 
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank())+ 
  theme(axis.title=element_text(size=25))+theme(axis.text=element_text(size=25))+ 
  theme(plot.title=element_text(size=30))+ 
  ylab("Total atazanavir (ng/mL)")+ 
  xlab('Time (hr)')+ 
  theme(axis.title.y=element_text(vjust=1))+ 
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  theme(axis.title.x=element_text(vjust=-0.4))+ 
  theme(title = element_text(vjust=2))+ 
  scale_x_continuous(limits=c(-1,24.5))+ 
  scale_y_log10(labels=trans_format('log10',math_format(10^.x)),limits=c(500, 20000))+ 
  annotation_logticks(sides='lr') 
dev.off() 
 
### ATV FREE ### 
pdf('vpcaf95CI.pdf') 
ggplot(data=vpcaf, aes(x=TIME))+ 
  geom_line(aes(y=q50med), colour="490", linetype=1, size=1.5)+ 
  geom_line(aes(x=TIME, y=q5med), colour="deepskyblue4", linetype=5, size=1.2)+ 
  geom_line(aes(x=TIME, y=q95med), colour="deepskyblue4", linetype=5, size=1.2)+ 
  geom_ribbon(aes(ymin=q50low, ymax=q50hi), alpha=0.1, fill ="red" )+ 
  geom_ribbon(aes( ymin=q5low, ymax=q5hi), alpha=0.1, fill = "blue")+ 
  geom_ribbon(aes(ymin=q95low, ymax=q95hi), alpha=0.1, fill = "blue")+ 
  geom_point(data=obsaf,aes(x=(TIME),y=DV),color="black",size=2)+ 
theme_bw()+ 
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank())+ 
  theme(axis.title=element_text(size=25))+theme(axis.text=element_text(size=25))+ 
  theme(plot.title=element_text(size=30))+ 
  ylab("Unbound atazanavir (ng/mL)")+ 
  xlab('Time (hr)')+ 
  theme(axis.title.y=element_text(vjust=1))+ 
  theme(axis.title.x=element_text(vjust=-0.4))+ 
  theme(title = element_text(vjust=2))+ 
  scale_x_continuous(limits=c(-1,24.5))+ 
  scale_y_log10(labels=trans_format('log10',math_format(10^.x)),limits=c(500, 20000))+ 





Berkeley Madonna Code 




STARTTIME = 0 
STOPTIME=100 




Ka = 0.12 
VLPV = 49 






Cplasma = X2/VLPV 
Crtv = X4/VRTV 
  
d/dt(X1) = -Ka*X1+ pulse(400000, 0, 12) 
d/dt(X2) = Ka*X1  - ((CLLPV * exp(-COEF*(X4/VRTV)))/VLPV) * X2 
d/dt(X3) = -Ka2*X3 + pulse(100000,0,12) 
d/dt(X4) = Ka2*X3 - CLRTV/VRTV*X4  
  
init X1 = 0 ; Oral Dose of LPV 
init X2 = 0 ; LPV  
init X3 = 0 ; Oral Dose of RTV 
init X4 = 0 ; RTV 
 
 




STARTTIME = 0 
STOPTIME=30 







d/dt(X1) = KIN-dN*X1*X1-ACT*X1 
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